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1GENERAL INTRODUCTIONWhen invading microorganisms have passed the first hurdle represented by the 
physical barriers of the host, the innate immune system is responsible for the initial 
recognition of, and defense against pathogenic microorganisms. In past decades 
it has become clear that innate immune activation occurs through recognition of 
recurring structural patterns of microbial components, the so-called pathogen-
associated molecular patterns (PAMPs), or through recognition of host molecules 
released from the extracellular matrix or from damaged or stressed cells, the so-
called damage-associated molecular patterns (DAMPs) (1). Examples of PAMPs 
include endotoxin (lipopolysaccharide [LPS]), lipoproteins, flagellin, fimbriae, 
peptidoglycans, peptidoglycan-associated lipoproteins, lipoteichoic acid, and 
bacterial/viral DNA or RNA fragments. Examples of DAMPs include heat-shock 
proteins, hyaluronic acid, uric acid, HMGB1, and mitochondrial DNA fragments(1). 
PAMPs and DAMPs are recognized by specific pattern recognition receptors (PRRs) 
present on innate immune cells such as macrophages, monocytes, and dendritic 
cells. Binding of a PAMP/DAMP to a PRR results in activation of intracellular signaling 
cascades that subsequently leads to activation of the innate immune system. In 
case of infection, a pro-inflammatory response is mounted, which activates and 
potentiates phagocytosis and/or killing of the pathogen. In case that innate immune 
defenses do not eliminate the pathogen, a second line of defense is activated. This 
second line of defense is the adaptive immune response, which becomes prominent 
after several days and usually leads to strong immunological memory. 
Simultaneously with this pro-inflammatory response, an anti-inflammatory 
response is mounted as well. This response is generally regarded to represent a 
compensatory mechanism woth two aims: firstly, to prevent the proinflammatory 
response from derailing uncontrollably and causing extensive tissue damage, and 
secondly, to restore homeostasis (2). Depending on a number of factors, including 
pathogen load, pathogen virulence, host comorbidities, and host genetic factors, 
the magnitude of both responses varies (Figure 1). An adequate pro- and anti-
inflammatory immune response will eradicate all pathogens without causing 
serious harm to the host. However, when an inadequate immune response is 
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1suffering from opportunistic infections display a more or less impaired immune system, adjunctive immunotherapy to improve host defence is an attractive strategy to improve patient’s outcome. 
Secondary infections in sepsis patients
A recently discovered particular cause of secondary immunodeficiency is 
sepsis. Sepsis is defined as systemic inflammation caused by an infection. In 
combination with hypoperfusion or dysfunction of at least one organ system, a 
diagnosis of severe sepsis is made (6). If hypotension or signs of hypoperfusion 
occur and persists despite adequate fluid therapy, the patient is in septic shock 
(6). Conservative estimates of the incidence of sepsis are 20 million cases per year 
worldwide, accounting for more casualties than breast cancer, lung can cer, and prostate 
cancer combined (7). Especially septic shock is associated with high mortality 
rates, not only in immune compromised patients, but also in previously healthy 
patients with an adequate immune system. It was thought for decades that septic 
patients succumb to an uncontrolled pro-inflammatory immune response to 
invading microorganisms, resulting in multi-organ failure and death induced by 
hyperinflammation. However, in recent years it has become clear that the vast 
majority of septic patients do not die from the initial pro-inflammatory hit, but at 
a later time point in an immunocompromised state which reduces the patient’s 
ability to eradicate the initial infection, and/or renders them more vulnerable to 
secondary infections (8, 9). This is probably the main reason behind the fact that 
all clinical trials that investigated anti-inflammatory strategies in patients with 
sepsis have failed to achieve a significant reduction in important endpoints such as 
mortality, hospital length of stay, or occurrence of secondary infections. Therefore, 
adjunctive immunotherapy to improve host defense appears to represent a valid 
and promising strategy to improve outcome of septic patients. 
Primary infections in otherwise healthy subjects
In addition to the described opportunistic infections in immune compromised 
patients, no antimicrobial therapy is currently available for some pathogens 
(especially viruses: e.g. influenza virus), and in these patients life-threatening 
infections can develop even with an adequate immune response. For instance, 
mounted (e.g. due to a suppressed immune system) serious infections may occur. 
For example, sepsis patients were thought to succumb to an overwhelming pro-
inflammatory response. However, numerous trials have failed to improve outcome 
by dampening the pro-inflammatory immune response in these patients, and 
recently subsequent suppression of the immune system was identified to be the 
overriding immune dysfunction. In these cases, increasing the effectiveness of the 
immune response is a promising approach to prevent or combat life-threatening 
secondary infections. 
This thesis describes the effects of several immune stimulatory compounds 
on the immune response of humans following severe bacterial, fungal or viral 
infections in pre-clinical and clinical studies. In the remainder of this introduction 
the pathophysiology of infectious disease-specific immune dysfunction will be 
discussed. Furthermore, the rationale of the administered immune stimulatory 
compounds is detailed.
IMMUNE DYSFUNCTION IN INFECTIOUS DISEASES
Opportunistic infections in patients with a suppressed immune system
Some patients have genetic defects in their immune system (so-called “primary 
or inherited immunodeficiency”), but most in most cases, immunodeficiency is 
acquired and caused, among others, by administration of immunosuppressive 
agents, chemotherapy, and bone marrow diseases (so-called “secondary 
immunodeficiency’s”). Many patients with immunodeficiency’s (either primary 
or secondary) are particularly vulnerable to pathogens that usually do not cause 
infections in patients with a healthy immune system (so-called “opportunistic 
infections”) (3, 4). The incidence of opportunistic infections is steadily increasing 
due to more frequent use of invasive medical procedures and immunosuppressive 
treatment modalities. Furthermore, despite development of new classes 
of antimicrobial agents, opportunistic infections remain associated with 
unacceptable high mortality rates (5). As such, new treatment modalities to treat 
or prevent opportunistic infections are highly warranted. Because all patients 
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1influenza virus infection is a global problem which annually affects an estimated 5%–10% of adults and 20%–30% of children. The influenza epidemics are estimated to result in about 3 to 5 million cases of severe illness worldwide, and account for 
approximately 500.000 deaths annually (10). The magnitude and quality of the 
vaccination-induced antigen-specific antibody titers is considered to be the primary 
correlate of protection against influenza infection (11, 12), although protective 
antibody titers are often not reached, especially not in the elderly (13). Moreover, 
various studies suggest that cellular immunity is likely to play a significant role in 
pathogen clearance as well, directly and through indirect effects on antibody 
responses (14, 15). Also in these cases, potentiating the immune response is 
an attractive strategy to improve outcome, which could have enormous socio-
economic impact because very large patient groups could benefit.
IMMUNOMODULATORY COMPOUNDS
In spite of the clear rationale, immunostimulatory treatment in infectious diseases 
is still in its infancy. To date, only a few small studies have investigated the 
administration of immunostimulatory compounds in patients suffering from life-
threatening infectious diseases, but large randomized placebo-controlled clinical 
trials are lacking. The immunostimulatory compound that has been studied most 
extensively in the context of opportunistic infections is Interferon-gamma (IFN-γ), 
which protects against these infections in patients with chronic granulomatous 
disease (CGD) (16), Human Immunodeficiency Virus (HIV) (17), leukemia 
(18), and organ transplants (18, 19). In sepsis patients, IFN-γ and Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF) are the most extensively 
studied immunostimulatory compounds (20-22). Both of these treatments have 
been demonstrated to enhance the function of immune cells in vitro, in vivo in 
animals, and ex vivo in humans (20-22). However, effects of these compounds on 
the immune response in vivo in humans have never been studied. Nevertheless, 
IFN-γ is a registered treatment for prevention of infections in patients with CGD 
and osteopetrosis, while GM-CSF is registered for prevention of infections in 
patients with neutropenia following chemotherapy. However, the severity of 
Figure 1. Global representation of possible immunological responses in patients; Depending on a number of factors, 
including bacterial load, pathogen virulence, host comorbidities, and host genetic factors, the magnitude of this response 
may vary. Panel A. An adequate pro-inflammatory response (grey line) to eradicate all bacteria (dashed line) combined 
with an adequate non-sustained anti-inflammatory response (black line) to prevent tissue damage due to excessive pro-
inflammation (for example a healthy young adult who fully recovers from erysipelas with, except for antibiotics, no need for 
any supporting therapy); Panel B. Preexistent impaired immune functions (grey and black lines) resulting in opportunistic 
infections (for example a patient on high dose steroid therapy who develops cerebral Nocardiosis); Panel C. A normal pro-
inflammatory immune response in a healthy individual which nevertheless does not result in eradication of overwhelming 
amounts of pathogens and/or highly virulent pathogens (for example a previously healthy patient with dengue infections, 
or an infection with a highly virulent influenza strain); Panel D. An overwhelming pro-inflammatory response (grey line) in 
combination with an adequate anti-inflammatory response (black line) likely eradicates all bacteria (dashed line), but will 
also cause pronounced tissue damage and ultimately multi-organ failure (for example a previously healthy young adult with 
meningococcemia); Panel E. An appropriate pro-inflammatory response (grey line) combined with a pronounced and/or 
sustained anti-inflammatory state (black line), resulting in immunoparalysis with ongoing bacterial infection (dashed line) or 
secondary (opportunistic) infections (dotted line) (for example a patient who develops candidemia following postoperative 
abdominal sepsis). Adapted from (8).
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1AIM AND OUTLINE OF THIS THESISThe aim of this thesis was to perform translational, clinically relevant studies 
regarding immunomodulatory therapies for the adjunctive treatment of 
infectious diseases. 
In the first part of this thesis, immunotherapy for the adjunctive treatment 
of sepsis is assessed. The rationale for immunostimulatory therapy as 
adjunctive treatment for sepsis is presented in a review in chapter 2. In 
chapter 3, the effects of the immunostimulatory compounds IFN-γ and GM-
CSF on immunoparalysis are studied in a randomized, placebo-controlled 
manner using the human endotoxemia model, a model for sepsis-induced 
immunoparalysis in humans in vivo. 
The second part of this thesis focuses on the effects of immunotherapy 
for the adjunctive treatment of opportunistic infections. In chapter 4, the 
immunostimulatory effects of adjunctive IFN-γ therapy are investigated in 
patients suffering from invasive fungal infections. Chapters 5 and 6 are case 
studies describing the effects of adjunctive IFN-γ therapy in a pediatric patient with 
progressive invasive Candida infection and in an adult patient with progressive 
cerebral nocardiosis. 
In the third part of this thesis new immunomodulatory modalities are investigated. 
Chapter 7 describes the non-specific effects of live attenuated BCG vaccination on 
cellular and antibody responses induced by a subsequent influenza vaccination in 
vivo in humans. In chapter 8, the potential immunostimulatory effects of gamma-
irradiated BCG on the innate immune response in vivo in humans are studied 
using the human endotoxemia model. Chapter 9 describes the effects of orally 
administered Beta-Glucan on ex vivo innate immune responses in humans.
 
Finally this thesis is concluded with a summary in chapter 10 and a general 
discussion of the findings and future perspectives in chapter 11.
potential side-effects and the substantial costs of these compounds (e.g. one 
dose of GM-CSF costs €1500) highlights the need for development of novel 
immunostimulatory treatment modalities. Thereto, new immunomodulatory 
approaches emerge because in recent years there has been a tremendous 
progress in the understanding of immune mechanisms. 
One of these completely new immunomodulatory approaches is based on the 
recently discovered concept of “trained innate immunity”. For example, recent 
studies have shown that production of pro-inflammatory cytokines, such as 
IFN-γ, TNF-α, and IL-1β by monocytes upon ex vivo stimulation with non-
related pathogens was enhanced after vaccination with the live attenuated 
BCG vaccine, even months after vaccination. These effects were based on 
“training” of the innate immune system, as they were independent of B- and 
T-cells (23, 24). Therefore, compounds that can induce trained immunity could 
enhance human host defences against unrelated pathogens, possible with 
profound therapeutic or prophylactic implications. Next to BCG, Beta-glucan 
has also been identified as a compound that induces trained innate immunity 
(25). Beta-glucans are ubiquitous naturally occurring carbohydrates that are 
already used for centuries in alternative medicine all over the world for their 
presumed immune enhancing effects, and it is widely offered on the internet 
as a dietary supplement for humans. Due to the fact that it is inexpensive 
and well tolerated, oral Beta-glucan might represent a promising candidate 
to enhance the immune response, although its efficacy has not yet been 
established in humans.
In this thesis, we investigated whether well-known immunostimulatory 
compounds can reverse sepsis-induced immunoparalysis, and whether they are 
also able to enhance immune responses in patients with invasive opportunistic 
infections. In addition, we investigated whether the innate immune system can 
be trained in vivo in humans by live attenuated BCG, inactivated BCG and orally 
administered commercially available Beta-glucan. 
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CHAPTER 2
Immunotherapy for the 
adjunctive treatment of sepsis: 
from immunosuppression to 
immunostimulation. 
Time for a paradigm change? 
Jenneke Leentjens
Matthijs Kox
Johannes G. van der Hoeven
Mihai G. Netea
Peter Pickkers
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INTRODUCTION
Sepsis is one of the leading causes of death among hospitalized patients, 
and a frequent cause of admission to intensive care units (ICUs) (2). Despite 
advances in medical care, mortality rates of sepsis remain high. In addition, the 
incidence of sepsis in the United States has increased annually from 1975 to 
2000 by approximately 9%, to 240 cases per 100.000 persons (2). Because the 
incidence is likely to increase even further due to several reasons (increasing 
age, immunosuppressive therapies, invasive procedures), and due to the high 
mortality rate, reaching 30-40% in severe sepsis, new therapeutic perspectives 
are highly warranted. 
The classical type of therapeutical immunomodulation assessed repeatedly 
during the last decades was based on inhibition of inflammatory mediators 
such as cytokines. This approach has been investigated because of the 
beneficial effects of cytokine blockade in animal models of sepsis (3). However, 
the traditional approach of suppressing the immune system as an adjunctive 
treatment of sepsis has proven to be unsuccessful in numerous clinical trials (see 
supplementary Table 1 in the online supplement)). An important reason for this 
might be that the vast majority of septic patients do not die due to complications 
resulting from an overwhelming proinflammatory immune response, but due to 
secondary/opportunistic infections resulting from a severely suppressed immune 
response (4). In this Critical Care Perspective we will translate new insights in the 
pathophysiology of sepsis into a better understanding of the current treatment of 
septic shock, and possible future therapeutical immunomodulating approaches.
PATHOPHYSIOLOGY OF SEPSIS AND DETERMINANTS OF OUTCOME
GENERAL
A simplified overview of the innate immune response in sepsis is depicted in Figure 
1. When invading microorganisms have overtaken the first hurdle represented by 
the physical barriers of the host, the nonspecific or “innate” immune 
ABSTRACT
Sepsis is the leading cause of death in the ICU, and ranks in the top 10 causes 
of death in general worldwide. Proinflammatory mediators are related to 
symptoms observed early in sepsis patients such as fever and hemodynamic 
instability. However, in recent years it has become clear that most septic patients 
do not die from an overwhelming proinflammatory immune response, but in an 
immunosuppressive state, which can last for days or even weeks, that results 
in increased susceptibility to secondary (opportunistic) infections. Although 
infection control and supportive therapies will remain the cornerstone of 
treatment, especially in the early phase of sepsis, the identification of this so-
called “immunoparalysis” is currently causing a paradigm shift in the adjunctive 
treatment of sepsis from therapies that suppress the immune system towards 
immunostimulation. In this Critical Care Perspective we will give an overview of 
the pathophysiology of sepsis with a focus on immunosuppressive mechanisms 
that play an important role in outcome. In addition, we will present an appraisal 
of the recent advances in immunotherapy as an adjunctive treatment for sepsis. 
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receptors (TLRs), Nucleotide Oligomerization Domain-like receptors (NLRs), 
C-type lectin receptors (CLRs) and RigI-helicases (5). Binding of a PAMP to a PRR 
results in activation of intracellular signaling cascades that subsequently leads 
to activation of the innate immune system. Depending on a number of factors, 
including bacterial load, pathogen virulence, host comorbidities, and host genetic 
factors, the magnitude of this response may vary, and can ultimately lead to 
systemic inflammation and the subsequent signs and symptoms that define the 
sepsis syndrome as an entity (6).
PRO-INFLAMMATION
While highly variable between patients, the proinflammatory response often 
predominates in the early phase of an infection. This is commonly regarded as the 
hyperinflammatory phase of sepsis. The ultimate goal of this proinflammatory 
reaction is the eradication of pathogens. This phase is characterized by 
production of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and IFN-γ, 
and chemokines, including neutrophil and macrophage chemotactic factors 
such as CCL2 (MCP-1), CCL3 (MIP-1α), CCL6 (C10), and CXCL8 (IL-8) (7). The 
proinflammatory cytokines stimulate the effector functions of neutrophils, 
macrophages, and Th1-cells, exacerbating cellular immunity. These responses 
are induced in a context in which the complement system and the coagulation 
cascade are also strongly activated, and this can ultimately result in the 
typical septic shock symptoms, such as hemodynamic instability, coagulation 
abnormalities and end-organ dysfunction (7). If patients succumb to sepsis in 
the first few days, it is therefore most likely attributable to an overwhelming 
proinflammatory cytokine response. For instance, in certain forms of sepsis such 
as meningococcemia (Figure 2, panel A), circulating proinflammatory cytokine 
levels are high and correlate with (early) mortality (8). 
However, in sepsis patients in general, circulating levels of proinflammatory 
cytokines are much lower (9), and signs of immune suppression are often observed 
from very early on. For example, lymphocyte apoptosis is already observed 
upon patient admission in the hospital (10), and similar early effects have been 
observed regarding monocyte deactivation (11). In this respect it is interesting to 
Figure 1. Simplified representation of the innate immune response in sepsis. Depicted in red are 
the immunostimulatory compounds that are/have been studied to reverse immunoparalysis. 
CTLA = cytotoxic T-lymphocyte antigen; FasFP = Fas-receptor fusion protein; FLT-3L = Fms-like 
tyrosine kinase-3 ligand; GM-CSF = granulocyte macrophage-colony–stimulating factor; HLA = 
human leukocyte antigen; PAMP = pathogen associated molecular pattern; PD-L = programmed 
death-ligand; PRR = pattern recognition receptor; rhIL-7 = recombinant human IL-7; TGF = 
transforming growth factor.
system is responsible for the initial recognition of, and defense against pathogenic 
microorganisms. In past decades it has become clear that innate immune 
activation occurs through recognition of recurring structural patterns of microbial 
components, the so-called pathogen-associated molecular patterns (PAMPs). 
These PAMPs may be surface molecules of microorganisms (such as endotoxin 
(lipopolysaccharide [LPS]), lipoprotein, flagellin, fimbriae, peptidoglycans, 
peptidoglycan-associated lipoprotein and lipoteichoic acid), but also intracellular 
patterns that are released by lysis of bacteria (such as heat-shock proteins, and 
DNA or RNA fragments) (5). PAMPs are recognized by specific pattern recognition 
receptors (PRRs) present on, among others, macrophages, monocytes and 
dendritic cells. Four families of PRRs have been described to date: Toll-Like 
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cytomegalovirus, herpes simplex virus, and Candida spp. (14, 17-19). Furthermore, 
it has been reported that reduced expression of HLA-DR on monocytes (mHLA-
DR), a marker currently used to identify patients with immunoparalysis, is 
associated with reduced survival in patients with sepsis in most (20-22), though 
not all (23), studies. Likewise, attenuated TNF-α production by ex vivo LPS-
stimulated monocytes, another mean of identifying immunoparalysis, has been 
associated with impaired survival (24). Finally, the lack of positive effects of anti-
inflammatory therapies on sepsis outcome has played an important role in the 
current paradigm shift towards more attention for the immunosuppressive phase 
of sepsis (6). Hence, we can conclude that immunoparalysis is an important cause 
of the persistent adverse outcome of sepsis patient in the post-acute phase, even 
if the primary infection has been completely eradicated. As a result, secondary 
hospital acquired infections can develop despite aggressive source control, 
broad spectrum antibiotics, and the best available supportive care (Figure 2, 
panel C). Importantly, with some pro-inflammatory mediators such as HMGB-
1, sTREM-1, or C5a increasing in the subacute phase of sepsis, it has become 
clear that the pro- and antiinflammatory phase of sepsis are not distinct, but 
may occur simultaneously with a more pronounced role for anti-inflammation 
in the later phases (25).
Several mechanisms appear to be involved in the development of sepsis-induced 
immunoparalysis (see supplementary Table 2 in the online supplement for a 
schematic overview and relevant references). A number of functional defects in 
leukocytes isolated from sepsis patients have been characterized. These defects 
include impaired neutrophil (chemotactic) responses (26), diminished expression 
of important cell surface antigens like HLA-DR on monocytes causing alterations 
in antigen-presenting ability, and enhanced apoptosis, which has also been 
implicated to contribute to leukocyte deactivation by rendering specific leukocyte 
subpopulations unable to react and perform their normal cellular functions. 
Moreover, recent studies suggest that expression of inhibitory receptors like 
programmed death-1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA-4), and B 
and T lymphocyte attenuator (BTLA) play a role in the exhaustion of lymphocytes. 
Furthermore, several lymphocyte subpopulations such as CD4+CD25+ 
observe that therapies aimed to suppress proinflammatory mediators in sepsis 
failed to achieve a significant reduction in important endpoints such as mortality 
and hospital length of stay. Some interventions even led to an increased mortality 
(supplementary Table 1 in the online supplement), that could be attributed to 
increased susceptibility towards secondary infections (12). The necessity of 
adequate levels of proinflammatory mediators like TNF-α in combating infection 
has been underscored further by the finding that sepsis and other infectious 
complications are more likely to develop in patients with rheumatoid arthritis who 
are treated with TNF antagonists (13). 
ANTI-INFLAMMATION AND ASSOCIATED IMMUNOPARALYSIS
As mentioned earlier, simultaneous with the proinflammatory response upon 
infection, an anti-inflammatory reaction is mounted, presumably to curtail 
inflammation and thereby prevent collateral tissue damage (Figure 2, panel B). 
However, a too pronounced or sustained anti-inflammatory response can lead 
to generalized and long-term impairment of the host’s immune function, known 
as “immunoparalysis”(6). This profound state of immunosuppression, that can 
last days to weeks after the initial infectious hit, results in increased vulnerability 
towards secondary (opportunistic) infections (14). There is increasing evidence 
that immunoparalysis worsens outcome in the later phase of sepsis, with multiple 
studies suggesting that not the presence of immunosuppressive processes 
“per se”, but the lack of sufficient recovery of the immune response is the main 
contributor to late mortality (10, 15). To date, there is no evidence that early anti-
inflammatory immune responses in sepsis are responsible for an impaired early 
outcome. Recently, it was found that, compared with patients who died of non-
sepsis etiologies, isolated splenic and pulmonary immune cells from deceased 
sepsis patients exhibit clear signs of severe immunosuppression (4); In another 
autopsy study of patients who died from sepsis or septic shock, a continuous septic 
focus was observed in 63 of the 71 patients (88.7%) who were treated for more than 
7 days, suggesting that the “paralyzed” immune system is unable to eradicate the 
invading microorganisms (16). The clinical relevance of immunoparalysis is also 
apparent from the frequent occurrence of infections and reactivation of relatively 
less virulent bacteria, viruses or fungi, including Acinetobacter, Enterococcus, 
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T regulatory (Treg) cells, NK-T cells, and CD8+ T cells that are known to 
actively suppress the adaptive immune response may also play an important 
role in septic immune dysfunction. Others have found that a subset of mature 
human neutrophils, capable of suppressing human T cell proliferation, could be 
involved. In a murine model of sepsis, it was demonstrated that dysfunctional 
dendritic cells also play an important role in the development of sepsis-induced 
immunoparalysis (at least intrapulmonary) (27, 28). Immunoparalysis is also 
characterized by a dysregulated cytokine production, favoring the expression of 
antiinflammatory cytokines (e.g IL-10, IL-4, IL-13, transforming growth factor-β 
(TGF-β), and interleukin 1 receptor antagonist) relative to the production of 
proinflammatory cytokines.
At the intracellular level, recent studies have indicated that long-term 
cellular inhibition is due to epigenetic changes, leading to the suppression 
of proinflammatory gene transcription (extensively reviewed in (29)). In 
short, epigenetic regulation of gene transcription occurs through numerous 
mechanisms, but can be generally regarded as the regulated organization of 
gene loci into transcriptionally active or silent states. Transcriptionally active 
chromatin (euchromatin) is accessible to transcription factors and polymerases, 
while transcriptionally silent chromatin (heterochromatin) is sequestered 
form these factors. It has now become clear that TLR-induced chromatin 
modifications are responsible for transient silencing of tolerizable (T) genes 
(including those encoding proinflammatory mediators), and for priming of 
non-tolerizable (NT) genes (including those encoding antimicrobial peptides). 
The T genes are transiently inactivated to prevent pathology associated with 
excessive inflammation, while the NT genes remain inducible to provide 
continuous protection from infection and tissue repair (Figure 3). For example, 
it was demonstrated that selective histone deacetylation contributes to the 
silencing of class T genes (e.g. IL-6) in endotoxin-tolerance in macrophages (a 
LPS-induced refractory state towards a subsequent LPS challenge, bearing 
resemblance to sepsis-induced immunoparalysis). 
Figure 2. Global representation of possible immunological responses in patients with sepsis. Depending on a 
number of factors, including bacterial load, pathogen virulence, host comorbidities, and host genetic factors, 
the magnitude of this response may vary. (A) An antiinflammatory response (orange line) in combination with 
an overwhelming proinflammatory response (red line), which is likely to eradicate all bacteria (purple line) but 
will also lead to pronounced tissue damage and ultimately multiorgan failure (for example, a previously healthy 
young adult with meningococcemia). (B) An adequate proinflammatory response (red line) to eradicate all 
bacteria (purple line) combined with an adequate nonsustained antiinflammatory response (orange line) 
to prevent tissue damage due to excessive proinflammation (for example, a healthy young adult who fully 
recovers from erysipelas without the need of any supporting therapy but antibiotics). (C) A proinflammatory 
response (red line) combined with a pronounced and/or sustained antiinflammatory state (orange line) 
resulting in immunoparalysis with ongoing bacterial infection (purple line) or secondary (opportunistic) 
infections (purple dotted line) (for example, a patient who develops candidemia after postoperative abdominal 
sepsis). Adapted by permission from Reference 5.
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observed after recovery of mice from caecal ligation and puncture, when mice 
are highly susceptible to secondary infections. Recent studies have demonstrated 
that epigenetic regulation of inflammatory genes, with reciprocal changes in 
histone 3 lysine 4 (H3K4) trimethylation and H3K27 dimethylation underlies post-
sepsis immunosuppression (30, 31). In addition, it was recently demonstrated 
that negative TLR regulators such as IRAK-M and SHIP-1, might also participate 
in the development of immunoparalysis (32). For example, IRAK-M, a protein 
that negatively regulates LPS-induced inflammatory responses, is upregulated 
in monocytes isolated from septic patients (33). Moreover, chromatin remodeling 
and epigenetic gene silencing by IRAK-M has been shown to be mediated by 
reduced acetylation (AcH4) and methylation (H3K4) of specific histones in lung 
macrophages (34).
SUITABILITY OF MARKERS OF IMMUNOPARALYSIS TO GUIDE 
IMMUNOSTIMULATORY TREATMENT
The apparent detrimental effects associated with the immunoparalytic phase 
of sepsis suggests that immunostimulation may be an attractive new treatment 
strategy (discussed in the next paragraph). However, caution should be taken 
that this approach is not applied when proinflammation predominates. Although 
there is no clinical evidence to date to support this notion, immunostimulation 
during proinflammatory predominance could theoretically result in an 
augmented proinflammatory response leading to more collateral tissue damage. 
As mentioned earlier, up till now, mHLA-DR expression and the production 
of cytokines by leukocytes that are ex vivo stimulated with Toll-like receptor 
agonists, two parameters that are highly correlated (29, 35), are mostly used to 
identify immunoparalysis. It was demonstrated that sepsis patients with reduced 
expression of HLA-DR on monocytes or reduced production of TNF-α by ex vivo 
stimulated leukocytes are significantly more likely to develop secondary infections 
(22). Interestingly, recent studies indicate that, instead of a single value at a given 
time point, the slope of recovery of mHLA-DR may better reflect susceptibility 
towards secondary infections and therefore may more accurately predict 
Others have found that in endotoxin tolerance, macrophages exhibit increased 
levels of repressive histone modifications at the promoter regions of both IL-1β 
and TNF-α, mediated by dimethylation , and that DNA methylation of the TNF-α 
promoter region can silences transcription even further. These in vitro studies have 
been complemented by experimental models of immunosuppression such as that
Figure 3. Epigenetic modifications. (A) In the DNA helix, inactive DNA is wrapped around histones, so that 
genes are inaccessible for transcription. After uncoupling of the histone (A, middle), genes become accessible. 
Transcriptionally active chromatin (euchromatin) is accessible to transcription factors and polymerases, whereas 
transcriptionally silent chromatin (heterochromatin) is sequestered from these factors. Histones are proteins 
responsible for packaging and organizing the lengthy DNA strand(s) into organized chromatin. Modifications 
to the protein tails of histone core components can direct the winding or unwinding of the associated DNA. The 
activating or repressing nature of these histone tail modifications is dependent on both the chemical nature 
of the modification and the location of the modification on the histone tail. For example, as depicted in B, 
acetylation of histone tails at specific amino acid residues are believed to act as an activation histone mark. In 
contrast, methylation of histone tails can be an activation or repressing transcriptional mark, depending on both 
the type and the location of the modification. It was demonstrated that in endotoxin tolerance, toll-like receptor–
induced chromatin modifications are responsible for transient silencing of tolerizable (T) genes (including those 
encoding proinflammatory mediators) and for priming of nontolerizable (NT) genes (including those encoding 
antimicrobial peptides). The T genes are transiently inactivated to prevent pathology associated with excessive 
inflammation, whereas the NT genes remain inducible to provide continuous protection from infection (58). 
Panel A reprinted with permission from G. Almouzni, Institut Curie-CNRS; watercolor by Nicolas Bouvier.
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taken into account as immunosuppressive mechanisms can vary between these 
(41). In the meantime, the use of surrogate markers to determine whether a 
patient has passed the proinflammatory phase, such as recovery of hemodynamic 
stability indicated by decreased inotropic requirements, might be considered.
THERAPY
CURRENT APPROACH
In patients who meet the criteria for septic shock, the first approach is focused 
on careful monitoring, hemodynamic and organ function support, in addition 
to source control. The swift (if necessary surgical) removal of infected tissues in 
combination with antibiotics is the key to success in the treatment of sepsis (42). 
Prospective cohort studies showed a 4- to 8-fold higher mortality when inadequate 
initial antibiotics were administered (43, 44), and a more recent observational 
study showed that in septic shock patients, the risk of death increases by about 
8% with each hour passing without antibiotics (42). It is beyond the scope of this 
review to describe other potential supportive measures like vasopressor therapy, 
glycemic regulation, renal replacement therapy, or ventilation modes; these are 
extensively reviewed elsewhere (45).
NEW INSIGHTS
Although infection control and supportive therapies, especially in the early phase of 
sepsis, will remain the cornerstone of sepsis treatment, new adjuvant treatments 
are warranted to prevent or treat the infaust effects of the immunoparalytic phase 
of sepsis. Various immune stimulants have shown favorable results in vitro, ex vivo 
(such as effects on monocyte HLA-DR expression and/or TNF-alpha production), 
and in vivo in animals. The therapies studied and their mechanisms of action 
are depicted in Figure 1 (for a schematic overview and relevant references see 
supplementary Table 4 in the online supplement), and include the anti-apoptotic 
and immune stimulatory cytokine IL-15, the anti-apoptotic Fas-receptor 
fusion protein (FasFP) (46), caspase inhibitors, the anti-apoptotic and negative 
regulatory molecule blocking anti-PD-L1 antibody, the dendritic cell growth 
outcome (15). Nevertheless, the potential value of mHLA-DR expression and/or 
ex vivo cytokine production as indicators of a patient’s “immune status” remains 
to be demonstrated because sepsis patients often show evidence of immune 
suppression on admission, indicating that initiation of immunostimulatory 
therapy based on these markers may be questionable. Furthermore, these 
markers only reflect the status of the blood/leukocyte compartment and not the 
in vivo immune status of the patient, which is predominantly mediated by tissue-
resident macrophages. This was illustrated by a murine model of immunoparalysis 
showing that impaired bacterial clearance was largely attributable to impaired 
function of tissue-resident macrophages (36), and findings of elevated cytokine 
levels in LPS-challenged mice that lack circulating immune cells (37). Moreover, 
the difference in duration of ex vivo and in vivo endotoxin tolerance and a lack of 
correlation between ex vivo (including HLA-DR expression) and in vivo responses 
to endotoxin in humans (38-40) suggest that tissue macrophages rather than 
circulating cytokines are the main effector cells in sepsis. An important argument 
to support an immunoparalytic status of tissue macrophages has been provided 
by a recent autopsy study who demonstrated defective cytokine production 
capacity of tissue macrophages in patients deceased due to sepsis compared with 
matched control patients that died of non-septic etiologies (4).
Other potentially suitable biomarkers that have been linked to patients’ immune 
status include plasma IL-10 levels and TNF-α/IL-10 ratio, markers of anti-
inflammatory macrophages (Soluble haemoglobin scavenger receptor [sCD163]), 
markers of lymphocyte apoptosis (human soluble Fas (sFas), Fas ligand (FasL), 
and sFas/FasL ratio), and markers of T-cell exhaustion (programmed cell death 
1 [PD-1], and PD ligand 1) (see supplementary Table 4 in the online supplement 
for a schematic overview and relevant references). However, it remains to be 
determined whether these markers are truly representative of a patient’s in 
vivo immune status and thus if they are suitable to guide immunostimulatory 
treatment. With regard to the heterogeneity of the immune response in sepsis, 
combination of several biomarkers (in panels) may prove to be of additional 
value towards a more individualized, goal-directed therapy. Possibly, the type of 
underlying infection (infected tissue), or causative microorganism(s) should be 
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meta-analysis of 4 randomized, placebo-controlled clinical trials in septic patients 
(total n=195; GM-CSF treated n=75) showed an increase in clearance of infection 
(57). However, no beneficial effect of GM-CSF on 28-day mortality could be 
demonstrated. This was probably because of limited power, but one has to be 
also aware that other factors besides immunoparalysis may account for patient 
mortality. One of these randomized clinical trials used mHLA-DR expression to 
guide treatment of septic patients with GM-CSF (58). In this study, all 19 patients 
treated with GM-CSF showed normalization of mHLA-DR expression, while this 
was only the case in 3 of the 19 placebo-treated patients. Moreover, in GM-CSF-
treated patients, time-on-ventilator was reduced, as was ICU and hospital length 
of stay (58). In addition, one study has shown that immunostimulatory therapies 
can actually reverse immunoparalysis determined not only in vitro, but also in 
vivo in humans. Repeated administration of endotoxin to healthy volunteers 
(experimental human endotoxemia) was used as a model to mimic sepsis-induced 
immunoparalysis. A second endotoxin administration within a relatively short 
time-frame results in a greatly suppressed innate immune response compared 
to the response after the first endotoxin administration. Using this model it was 
demonstrated that, compared with placebo, treatment with IFN-γ in between 
endotoxin administrations (separated by one week) not only increased mHLA-DR 
expression, but also restored in vivo production of the proinflammatory cytokine 
TNF-α, while further attenuating the production of the anti-inflammatory cytokine 
IL-10 upon the second endotoxin administration. Similar, but less pronounced 
effects were found in subjects treated with GM-CSF (40). 
Recent in vitro studies have shed light on the mode of action by which IFN-γ 
reverses immunoparalysis. It was shown that IFN-γ is able to bypass the effects of 
negative regulators of the LPS signaling pathway contributing to immunoparalysis 
at the mRNA level (54). Others have found that IFN-γ does not alter proximal 
LPS signaling defects in tolerized monocytes, but reverses tolerance-associated 
epigenetic modifications that suppress TNF-α and IL-6 transcription (51). However, 
although promising, treatment with immune-stimulatory agents in sepsis is still in 
the experimental phase. New clinical trials are currently underway to confirm the 
promising results of IFN-γ (NCT01649921) and GM-CSF (NCT01653665).
factor Fms-like tyrosine kinase-3 ligand (Flt-3L), the glucocorticoid receptor 
antagonist mifepristone (RU486), the IL-10 synthesis inhibitor ammonium 
trichloro(dioxoethylene-o,o’)tellurate (AS101), the anti-regulatory T-cell and anti-
IL-10 monoclonal antibodies, the anti-transforming growth factor-β monoclonal 
antibodies, T-cell anti-CD25 antibodies, the negative regulatory molecule blocking 
anti-CTLA4, myeloid cell function augmenting Granulocyte-Colony stimulating 
factor (G-CSF), and immuno-modulating diets (such as diets containing high 
concentrations of omega-3 polyunsaturated fatty acids (PUFAs) derived from fish 
oil, or health food supplements such as the proinflammatory cytokine enhancing 
supplement Beta-glucan). However, clinical application of these therapies still 
requires extensive clinical studies to test their clinical safety and efficacy.
A promising candidate to reverse sepsis-induced immunoparalysis that is already 
available for human use and has an excellent safety profile is IL-7. IL-7 is a potent 
anti-apoptotic cytokine that enhances immune effector cell function and is essential 
for lymphocyte survival (47), and IL-7 has been shown to improve survival in murine 
models of sepsis (48). Furthermore, it was recently demonstrated that lymphocyte 
function of septic patients was restored by ex vivo stimulation with IL-7 (49). 
Interestingly, subcutaneous IL-7 administration in HIV patients reversed signs of 
immune dysfunction similar to those observed in immunoparalyzed septic patients 
(50). In these patients, IL-7 increased circulating lymphocyte numbers and restored 
their function, reflected by increased cytokine production upon ex vivo stimulation 
(50). Of note, IL-7 robustly enhances IFN-γ production, which might play an 
important role in its immunostimulatory effects (further discussed below) (49, 50). 
The two most studied therapies to reverse immunoparalysis to date are interferon-
gamma (IFN-γ) (51-56), and Granulocyte-Macrophage Colony Stimulating Factor 
(GM-CSF) (52, 53, 55, 56). These agents also represent the only two immune 
stimulants that have already been tested in clinical trials in septic patients. A one-
armed intervention study showed that subcutaneous administration of IFN-γ for 
an average of 6 days to patients with septic shock increased mHLA-DR expression 
and the production of TNF-α by leukocytes stimulated ex-vivo. Furthermore, 
8 out of the 9 patients recovered from severe sepsis (35). In case of GM-CSF, a 
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Supplementary Table 2. Potential mechanisms involved in the development of sepsis-induced 
immunoparalysis.
Mechanism Mode of action
Diminished expression of important cell surface 
antigens like HLA-DR on monocytes [7]
Alterations in antigen-presenting ability
Enhanced apoptosis of leukocytes [8] Rendering specific leukocyte subpopulations unable 
to react and perform their normal cellular functions
Expression of inhibitory receptors [9] Rendering specific leukocyte subpopulations unable 
to react and perform their normal cellular functions
Appearance of immune suppressive lymphocyte/
neutrophil subpopulations [10, 11]
Active suppression of the immune response
Dysregulated cytokine production [13] Favoring the expression of antiinflammatory 
cytokines relative to the production of 
proinflammatory cytokines
HLA, Human Leukocyte Antigen.
Supplementary Table 3. Potentially suitable biomarkers that have been linked to patients’ 
immune status.
Marker Mode of action
IL-10 levels [14-17] Marker of anti-inflammatory cytokine response
TNF-α/IL-10 ratio [18, 19] Marker of anti-inflammatory cytokine balance
sCD163 [20] Marker of anti-inflammatory macrophages
sFas, FasL, and sFas/FasL ratio) [21] Markers of lymphocyte apoptosis
PD-1, and PD ligand 1 [22, 23] Markers of T-cell exhaustion
Reduced expression of HLA-DR on monocytes 
[24-26]
Marker of reduced antigen presenting capacity of monocytes
Attenuated TNF-α production by ex vivo LPS-
stimulated monocytes [27]
Marker of reduced capacity of proinflammatory cytokine production
IL, Interleukin; TNF, tumor necrosis factor; sCD163, Soluble haemoglobin scavenger receptor; sFas, Human soluble Fas; FasL, Fas 
ligand; PD-1, Programmed cell death 1; HLA, Human Leukocyte Antigen; LPS, lipopolysaccharide.
55. Smith RP, Baltch AL, Ritz WJ, Michelsen PB, Bopp LH. IFN-gamma enhances killing of methicillin-
resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of 
daptomycin and other antibiotics. Cytokine. 2010;51(3):274-7.
56. Bundschuh DS, Barsig J, Hartung T, Randow F, Docke WD, Volk HD, et al. Granulocyte-macrophage 
colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in 
lipopolysaccharide-desensitized mice. J Immunol. 1997;158(6):2862-71.
57. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-
macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15(1):R58.
58. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage 
colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, 
placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640-8.
ONLINE SUPPLEMENT
Supplementary table 1. Overview of anti-inflammatory strategies.
Drug category Mechanisms of action Numberof RCT’s
Odds ratio survival
(95% CI)
Corticosteroids [1]
High dose
Low dose
Anti-inflammatory effects and reversal of 
relative adrenal cortical insufficiency
5
9
0.91 (0.31-1.25)
0.80 (0.40-1.37)
Mediator-specific anti- 
inflammatory [2]
Anti-TNF mAb
PAF antagonists
Soluble TNF receptors
IL-1 receptor 
antagonists
Prostaglandin 
antagonists
Bradykinin antagonists
Antibody-specific inactivation TNF-α
Receptor-specific inactivation/enzyme 
degradation of PAF
Receptor-specific inactivation circulating 
TNF
Receptor-specific inactivation IL-1
Cyclooxygenase inhibition of prostaglandin 
production
Inhibition of the kallikrein-kinin cascade
9
7
3
3
3
2
1.10 (0.97–1.25)
1.10 (0.93–1.30)
0.95 (0.78–1.16)
1.18 (0.97–1.44)
1.22 (0.78–1.58)
0.91 (0.65–1.27)
Anticoagulants
Anti-trombin III [3]
Tissue factor pathway 
inhibitor [2]
Activated protein C [4]
Anticoagulatory + anti-inflammatory 
Anticoagulatory + anti-inflammatory 
Anticoagulatory + anti-inflammatory
13
2
5
0.96 (0.89–1.03) 
1.01 (0.84–1.23)
0.97 (0.78–1.22)
Other
MD2 antagonist [5]
Immunoglobulins [6]
Inhibition of the TLR4-MD2 interaction, anti-
inflammatory
Toxin inactivation, interference with 
cytokine effects(?)
1
17
1.38 (0.75-2.53)
 1.47 (0.55-6.25)
RCT, randomized controlled trial; TNF, tumor necrosing factor; mAB, monoclonal antibodies; PAF, platelet 
activating factor; IL, interleukin; LPS, lipopolysaccharide.
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Suppression of the immune system, so-called ‘immunoparalysis’, is increasingly 
recognized as the overriding immune dysfunction in septic patients, rendering 
them vulnerable for secondary infections associated with impaired outcome. 
Trials in septic patients have demonstrated that treatment with IFN-γ or GM-CSF 
restores the cytokine response of ex vivo stimulated leukocytes, however the 
effects of IFN-γ or GM-CSF on immunoparalysis in vivo in humans have not yet 
been established. 
What this Study Adds to the Field
We report that endotoxin administration in humans results in immunoparalysis 
reflected by attenuated plasma cytokine concentrations following the second 
endotoxin challenge. Treatment with IFN-γ augments endotoxin-induced 
TNF-α and further attenuates IL-10 concentrations, indicating partial reversal of 
immunoparalysis in vivo. The effects of GM-CSF tended in the same direction as 
IFN-γ, but were not statistically significant compared with the placebo group. 
These results implicate that immunoparalysis is relevant in vivo in humans and 
that immunostimulation represents a promising treatment option to reverse 
sepsis-induced immunoparalysis in critically ill patients.
ABSTRACT
Rationale: Reversal of sepsis-induced immunoparalysis may reduce the incidence 
of secondary infections and improve outcome. While Interferon-gamma (IFN-γ) 
and Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) restore 
immune competence of ex vivo stimulated leukocytes of septic patients, effects 
on immunoparalysis in vivo are not known.
Objectives: To investigate the effects of IFN-γ and GM-CSF on immunoparalysis 
in vivo in humans.
Methods: We performed a double-blind placebo-controlled randomized study 
in 18 healthy male volunteers that received E. coli endotoxin (LPS, 2 ng/kg, 
intravenously) on days 1 and 7 (visits 1 and 2). On days 2, 4 and 6 subjects received 
subcutaneous injections of IFN-γ (100 μg/day, n=6), GM-CSF (4 μg/kg/day, n=6), or 
placebo (NaCl 0.9%, n=6).
Measurements and main results: In the placebo group, immunoparalysis 
was illustrated by a 60% [48-71] reduction of LPS-induced TNF-α plasma 
concentrations during visit 2 (p=0.03), whereas the anti-inflammatory IL-10 
response was not significantly attenuated (39% [2-65], p=0.15). In contrast, in the 
IFN-γ group, TNF-α concentrations during visit 2 were not significantly attenuated 
(28% [1-47], p=0.09), while the IL-10 response was significantly lower (reduction of 
54% [47-66], p=0.03). Compared with the placebo group, the reduction in the LPS-
induced TNF-α response during visit 2 was significantly less pronounced in the 
IFN-γ group (p=0.01). Moreover, compared with placebo, treatment with IFN-γ 
increased monocyte HLA-DR expression (p=0.02). The effects of GM-CSF tended 
in the same direction as IFN-γ, but were not statistically significant compared with 
placebo.
Conclusions: IFN-γ partially reverses immunoparalysis in vivo in humans. These 
results suggest that IFN-γ is a promising treatment option to reverse sepsis-
induced immunoparalysis.
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(19, 20). These data indicate that the in vivo response to endotoxin is mainly 
mediated by tissue-resident cells and that ex vivo measurements do not accurately 
reflect a subject or patient’s in vivo immune status. Hence, it is unknown whether 
pharmacological interventions that restore the ex vivo immune competence 
of leukocytes, such as IFN-γ and GM-CSF, are effective in restoring immune 
competence in vivo. 
As experimental human endotoxemia leads to pronounced immunosuppression, 
so-called endotoxin tolerance, both in vivo and ex vivo (20-23), it can serve as a 
model for sepsis-induced immunoparalysis. In the present proof-of-principle 
study we investigated whether treatment with IFN-γ or GM-CSF restores immune 
competence following experimental endotoxemia in humans in vivo.
METHODS
Subjects
This study was registered at ClinicalTrials.gov as NCT01374711. After approval 
from the local ethics committee of the Radboud University Nijmegen Medical 
Centre, 18 healthy, non-smoking, male volunteers gave written informed consent 
to participate in the experiments. All experiments were in accordance with the 
declaration of Helsinki. Subjects were screened before the start of the experiment 
and had a normal physical examination, electrocardiography, and routine 
laboratory values (including serology on HIV and hepatitis B). Subjects with febrile 
illness during the two weeks before the experiment were excluded. Subjects were 
not allowed to take any prescription drugs and asked to refrain from caffeine and 
alcohol intake 24 hours before the start of the experiment. Furthermore, subjects 
refrained from food 12 hours before the start of each endotoxemia experiment.
Study design 
We performed a parallel double-blind placebo-controlled randomized study. The 
study design is depicted in Figure 1. Briefly, all subjects received an intravenous 
injection of lipopolysaccharide (LPS) on two occasions (visits 1 & 2) separated 
INTRODUCTION
Sepsis is the leading cause of death in the ICU with an estimated 6 million victims 
per year worldwide (1). Although septic shock is traditionally viewed as an excessive 
systemic inflammatory reaction to invasive microbial pathogens, pharmacological 
interventions aimed at suppression of the immune response in sepsis have proved 
to be unsuccessful (2). An important reason for this might be that the vast majority 
of septic patients survive the initial pro-inflammatory hit, but die at a later time 
point from secondary/opportunistic infections in a immunosuppressed state (3-
5). This so-called sepsis-induced ‘immunoparalysis’ is increasingly recognized as 
the overriding immune dysfunction in septic patients (6), and is characterized by 
impaired innate and adaptive immune responses, including enhanced apoptosis 
and dysfunction of lymphocytes, impaired phagocyte functions, and decreased ex 
vivo cytokine production (7). A widely used marker of immunoparalysis is monocyte 
HLA-DR (mHLA-DR) surface expression, reflecting monocyte (de)activation (8). 
Prolonged downregulation of mHLA-DR expression is associated with a higher risk 
of secondary infections (9) and reduced survival in septic patients (9, 10). 
 
In light of the deleterious effects of sepsis-induced immunoparalysis on outcome, 
the sepsis research field is shifting towards novel therapies aimed at restoring 
immune competence in the later phase of sepsis (11). Recent case series and pilot 
trials indicate that long-lasting monocyte deactivation in sepsis can be reversed 
by treatment with Interferon gamma (IFN-γ) or Granulocyte Macrophage-Colony 
Stimulating Factor (GM-CSF) (12-16), reflected by restoration of TNF-α production 
by ex vivo stimulated leukocytes and increased mHLA-DR expression (17, 18). These 
compounds therefore appear promising candidates to reverse sepsis-induced 
immunoparalysis. However, as indicated above, all studies to date have analyzed 
the ‘immune status’ of the patients using ex vivo stimulation of leukocytes or flow 
cytometric analysis of HLA-DR expression on circulating monocytes. We have 
recently demonstrated that during systemic inflammation as observed during 
experimental human endotoxemia (lipopolysaccharide [LPS]) administration in 
healthy volunteers), the response of ex vivo LPS-stimulated leukocytes does not 
correlate with the in vivo LPS-induced inflammatory response in the same subject 
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intensity (MFI) within these CD14-positive cells. Lymphocyte subsets were defined 
as: T-cells (CD45+CD3+), T-helper cells (Th, CD45+CD3+CD4+), cytotoxic T-cells 
(Tc, CD45+CD3+CD8+), B-cells (CD45+CD19+), and NK-cells (CD45+CD3-CD56+). 
Subset counts were calculated by multiplying the percentage gated cells by the 
total lymphocyte count.
Calculations and statistical analysis
In view of the small sample size, normality of distribution was not assumed. 
Area under curve (AUC) during both visits 1 and 2, representing an integrated 
measure of the LPS-induced responses, was calculated using time points 0-24 
hours (cytokines) and 0-8 hours (symptom score, heart rate, mean arterial 
pressure [MAP], and temperature). Comparisons were made using Wilcoxon’s 
matched pairs (within-group comparisons, 2 groups), and Mann-Whitney U 
(between-group comparisons, 2 groups), or Kruskal-Wallis (between-group 
comparisons, 3 groups) tests as appropriate. A p-value of <0.05 was considered 
statistically significant. Data are expressed as median [interquartile range]. 
Calculations and statistical analyses were performed using Graphpad Prism 
version 5.0 (Graphpad Software, San Diego, CA, USA).
RESULTS
Demographic characteristics
Demographic characteristics of the study population are listed in Table 1. There 
were no significant differences in baseline characteristics between the three 
study groups. No serious adverse events occurred during the trial. During 
the treatment period (starting just before the first IFN-γ/GM-CSF/placebo 
administration [visit 1 t=24] until visit 2 t=0), one subject in the placebo group 
reported mild headaches and muscle pains, whereas 5 subjects in the IFN-γ 
group and 3 subjects in the GM-CSF group reported mild complaints ranging 
from headaches and muscle pains to fatigue.
by 6 days. In between, on days 2 (t=24), 4 (t=76), and 6 (t=120), subjects were 
randomized to receive subcutaneous injections of either 100 μg IFN-γ (Immukine; 
Boehringer Ingelheim Alkmaar, the Netherlands, n=6), 4 μg/kg GM-CSF (Leukine/
Sargramostim; Bayer Healthcare Pharmaceuticals, Seattle, United States, n=6), 
or placebo (NaCl 0.9%, n=6), in a double-blind fashion using the sealed envelope 
method. Endotoxemia experiments were conducted as described previously (20), a 
detailed description is provided in the online supplement. . The dosages were based 
on previous studies in septic patients (15, 17). Since GM-CSF and IFN-γ had different 
administration volumes, a double dummy was used to ensure adequate blinding.
Figure 1. Experimental design
Cytokine measurements
For plasma cytokine analysis, EDTA anticoagulated blood was centrifuged 
immediately after withdrawal at 2000g at 4˚C for 10 minutes, after which plasma 
was stored at -80˚C until analysis. Concentrations of tumor necrosis factor-alpha 
(TNF-α), Interleukin (IL)-6, IL-10, IL-1 receptor antagonist (IL-1ra), IFN-γ, and GM-
CSF were analyzed batch-wise by a Luminex assay according to the manufacturer’s 
instructions (Milliplex, Millipore, Billerica, MA, USA).
Flow cytometric analysis of mHLA-DR expression and lymphocyte subset counts
EDTA anticoagulated blood was stored at 4°C immediately after withdrawal 
and analyzed by flow cytometry (see online supplement for details). mHLA-DR 
expression was determined by calculating % HLA-DR-positive cells within CD14-
positive cells within the CD45-positive leukocytes and HLA-DR mean fluorescence 
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Figure 2. Left panel: Plasma concentration of TNF-α, IL-6, IL-10 and IL-1ra, on the first and second 
LPS-administration days (visits 1 and 2). Data are expressed as median pg/mL (n=6 per group). Right 
panel: box and whisker (Tukey) plots of area under the curve of plasma cytokine concentrations 
during visit 1 (V1) and visit 2 (V2). AU indicates arbitrary units.
Table 1. Demographic characteristics obtained during the screening visit
Placebo
(n=6)
GM-CSF
(n=6)
IFN-γ
(n=6)
Total
(n=18)
P value 
between groups
Age, yrs 21 [20-23] 22 [21-23] 20 [20-21] 21 [20-21] 0.15
Height, cm 183 [176-189] 177 [174-193] 188 [171-189] 183 [175-189] 0.97
Weight, kg 81 [89-75] 72 [67-85] 72 [68-80] 74 [70-84] 0.24
BMI, kg/m² 24 [23-26] 23 [22-23] 21 [32-26] 23 [22-24] 0.20
HR, bpm 67 [62-79] 59 [55-71] 65 [58-72] 66 [56-72] 0.50
MAP, mmHg 96 [82-104] 89 [88-98] 98 [91-99] 95 [88-99] 0.75
BMI: body mass index; HR: heart rate; MAP: mean arterial blood pressure; bpm: beats per minute. Data are 
presented as median and interquartile range.
Plasma cytokines
As expected, during visit 1 there was a typical endotoxemia-induced transient increase 
in all measured cytokines, which was similar in the three experimental groups (Figure 
2). In the LPS-placebo group, the area under the curve (AUC) of the LPS-induced 
plasma concentration of the archetypal pro-inflammatory cytokine TNF-α was 60% 
[48-71] (p=0.03) lower on visit 2 compared with visit 1, indicating immunoparalysis. 
In the IFN-γ and GM-CSF groups, this decrease in LPS-induced TNF-α release during 
the second LPS infusion was less pronounced and no longer significant (28% [1-
47] (p=0.09) and 38% [-2-63] (p=0.16) lower on visit 2, respectively). Furthermore, 
compared with placebo, the reduction in AUC for TNF-α on visit 2 compared with 
visit 1 was significantly less pronounced in the IFN-γ group (p=0.01). Similarly, in the 
placebo-treated group, plasma IL-6 levels were suppressed (74% [65-83], p=0.03) 
following the second LPS challenge, Treatment with IFN-γ (62% [42-77], p=0.03) or 
GM-CSF (70% [-27-85], p=0.09) did not prevent the attenuated response of IL-6 during 
repeated endotoxemia. In the placebo and GM-CSF groups, no significant attenuation 
of the plasma concentrations of the anti-inflammatory cytokine IL-10 between visits 
1 and 2 were observed (39% [2-65] (p=0.15) and 48% [-6-67] (p=0.21), respectively). In 
contrast, in IFN-γ-treated subjects, the IL-10 response was significantly attenuated 
upon the second LPS administration (54% [47-66], p=0.03). Finally, in the placebo 
group, the LPS-induced IL-1ra response was attenuated by 63% [52-86] (p=0.03), 
while in the IFN-γ and GM-CSF groups, IL-1ra levels were 44% [35-67] (p=0.03) and 
41% [10-76] (p=0.06) lower on visit 2 compared with visit 1, respectively. This reduction 
was not significantly different compared with placebo-treated subjects.
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(p<0.01 compared with t=0 for all three groups, Figure 4). In the placebo group, the 
total leukocyte count tended to decrease during the treatment period (a reduction 
of 24% [6-31], p=0.06, whereas in the IFN-γ group, the effects were highly variable 
between subjects (median reduction of 32% [-22-54], p=0.25). In the GM-CSF 
treated group, there was a clear increase in leukocyte counts during the treatment 
period (increase of 21% [3-36], p=0.22; p=0.009 compared with placebo). This 
effect was almost completely attributable to an increase of neutrophils (p=0.02 
compared with placebo). In the placebo and GM-CSF groups, the LPS-induced 
leucopenia 1 hour after the first LPS-administration was less pronounced and 
no longer significant after the second LPS-administration (p=0.19 and p=0.44, 
respectively), while in the IFN-γ group, no attenuation of the LPS-induced effects 
occurred and again a distinct trend towards leucopenia was observed following 
the second LPS-administration (p=0.06). The subsequent leukocytosis was 
similar between the three experimental groups during visit 2, with a comparable 
distribution of leukocyte subpopulations, except for eosinophils which showed a 
pronounced rise in the GM-CSF treated group during visit 2 (p=0.03). Lymphocyte 
subset analysis of T-cell (including T-helper and cytotoxic T-cells), B-cell, and 
NK cell counts by flow cytometry revealed no differences between groups 
(Supplementary Table 2 and Supplementary Figure 2 in the online supplement).
Figure 4. Leukocyte count and differentiation
Data are expressed as median values of 6 subjects per group.
mHLA-DR expression
In the placebo-group, the percentage HLA-DR positive monocytes (%mHLA-DR+) 
decreased from 73% [68-84] at t=0 to 61% [54-71] (p=0.03) during the first LPS 
challenge (Figure 3). A similar reduction was observed in the IFN-γ and GM-CSF 
groups during visit 1 (prior to the administration of study medication). Throughout 
the treatment period %mHLA-DR+ remained stable in the placebo and GM-CSF 
groups (from 80% [74-84] to 76% [72-80], p=0.30 and from 85% [80-92] to 94% [82-
95] (p=0.40), respectively). Conversely, in the IFN-γ group, mHLA-DR expression 
tended to increase during the treatment period, from 83% [79-92] to 98% [94-
99] (p=0.06). Histograms of a representative subject from the IFN-γ group are 
shown in Supplementary Figure 1 in the online supplement. The effects of IFN-γ on 
%mHLA-DR+ during the treatment period were significantly different compared 
with placebo (p=0.02). Moreover, %mHLA-DR+ in the IFN-γ group remained above 
85% in the acute phase (8 hours) following the second LPS administration, while 
it dropped to 65-70% in the other two experimental groups (Supplementary Table 
1 in the online supplement). MFI data showed a similar pattern as %mHLA-DR+ 
(Supplementary Table 1 in the online supplement).
Figure 3. %HLA-DR positive monocytes (%mHLA-DR+)
Data are ex-pressed as median values of 6 subjects per group.
Hematological parameters
Following the first LPS administration, total leukocyte counts showed the 
characteristic biphasic pattern in all three experimental groups, a leukopenic phase 
at t=1 (p<0.01 compared with t=0 for all three groups) followed by leukocytosis 
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DISCUSSION
Immunoparalysis is increasingly recognized as the overriding immune response 
observed in sepsis patients and the interest in pharmacological interventions 
aimed at the prevention and treatment of immunoparalysis is growing. This is 
the first study showing that IFN-γ partially restores in vivo production of the pro-
inflammatory cytokine TNF-α, while this is accompanied by further dampening 
of the anti-inflammatory IL-10 response following a second LPS administration. 
The more pro-inflammatory spectrum during the second LPS challenge indicates 
that IFN-γ partially reverses LPS-induced immunoparalysis in vivo in humans. 
In accordance, IFN-γ prevented the reduction in symptom score and heart rate 
response to a second LPS administration and significantly increased mHLA-DR 
cell-surface expression, reflecting monocyte function improvement. The effects 
of GM-CSF tended in the same direction as IFN-γ, but were not statistically 
significant compared with the placebo group.
In sepsis patients, the term immunoparalysis is commonly used to indicate 
reduced responsiveness of leukocytes upon ex vivo stimulation with LPS. Data 
on the ‘immune status’ of tissue-resident cells, which play a more important role 
in host defense compared with leukocytes, is limited due to the lack of access to 
these cells/tissues in patients. However, there is a strong relation between ex vivo 
responsiveness and susceptibility towards secondary infections and outcome 
in sepsis patients (24, 25). Furthermore, a very recent study demonstrated that 
immunosuppression was also found in splenocytes and lung tissue of sepsis 
patients (6). We (20-22), and others (26, 27) have demonstrated that endotoxin 
administration in healthy volunteers leads to a profound suppression of 
cytokine production, both in ex vivo LPS-stimulated leukocytes and in vivo. This 
indicates that the human endotoxemia model and the associated development 
of endotoxin tolerance (20, 21) represents a suitable model for sepsis-induced 
immunoparalysis. To the best of our knowledge, we are the first to investigate 
reversal of immunoparalysis in vivo, and the result of this study suggest that 
repeated LPS administration with an interval of one week is a suitable model to 
investigate possible interventions to reverse sepsis-induced immunoparalysis. 
Clinical parameters
The first LPS administration expectedly elicited transient flu-like symptoms, which 
were comparable between all three experimental groups. (Figure 5, upper panel). 
Symptoms were significantly less pronounced in the placebo and GM-CSF groups 
following the second LPS administration (reduction in AUC symptom score of 72% 
[48-87] (p=0.03) and 50% [29-75] (p=0.03), respectively). In the IFN-γ group however, 
the symptom score did not significantly differ between visit 1 and visit 2 (reduction 
AUC of 9% [-21-49, p= 0.48]), an effect that was significantly different compared 
with the placebo group (p=0.02). In both the placebo and GM-CSF groups, the LPS-
induced increase in heart rate was significantly attenuated after the second LPS 
administration (reduction in AUC heart rate of 10% [7-14] (p=0.03) and 4% [1-13] 
(p=0.03), respectively, Figure 5, lower panel). In the IFN-γ group, heart rate response 
was not significantly attenuated during the second LPS challenge (7% [-1-11,p=0.15]). 
In all three groups, there was a significant LPS-induced rise in temperature and a 
decrease in MAP during both visits (p<0.01 in all three groups for visits 1 and 2, data 
not shown). No differences in temperature and MAP (based on AUC) between visits 1 
and 2 were observed in any of the experimental groups.
Figure 5. Left panel: Symptom score and heart rate after LPS administration during visits 1 and 2. 
Data are expressed as median values of 6 subjects per group. Right panel: box and whisker (Tukey) 
plots of AUC of symptom score and heart rate after LPS administration during visit 1 (V1) and visit 
2 (V2). AU indicates arbitrary units. 
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in septic patients (total n=195), treatment with GM-CSF was associated with 
a significantly increased rate of reversal from infection (16). Not surprisingly, 
no beneficial effect of GM-CSF on 28-day mortality could be demonstrated 
because of limited power. Recently, a double-blind, randomized, placebo-
controlled trial used mHLA-DR expression to guide treatment of septic patients 
with GM-CSF (15). In a selected patient population with very low mHLA-DR 
expression, GM-CSF restored mHLA-DR expression and TNF-α production of ex 
vivo LPS-stimulated monocytes. Moreover, the results suggested that GM-CSF 
may shorten the time on mechanical ventilation and hospital/intensive care unit 
length of stay. In our study, GM-CSF tended to increase mHLA-DR expression, 
although to a much lesser extent than IFN-γ. Furthermore, GM-CSF prevented 
the attenuation in TNF-α, IL-6, and IL-1ra plasma levels following the second 
LPS-administration observed in the placebo group, but, unlike IFN-γ, this 
difference was not statistically significant compared with the placebo group for 
any of the studied cytokines. The small sample size in our study is a possible 
explanation for this lack of significance. An alternative explanation is that the 
immunoparalysis evoked by repeated LPS administrations is relatively mild, 
thereby limiting possible beneficial effects of GM-CSF. This is illustrated by the 
fact that in the aforementioned studies in septic patients, treatment was started 
when mHLA-DR expression was below 50% (15) or even 30% (17), while mHLA-
DR expression in our subjects never dropped below 61%. 
The promising results of IFN-γ in this study as well as previous case series warrant a 
larger trial in septic patients. However, care should be taken with regard to the timing 
of this intervention in the clinical setting. The more pronounced pro-inflammatory 
response in the early phase of sepsis might be amplified by IFN-γ, thereby possibly 
enhancing shock/tissue damage (42). Although no evidence of detrimental effects 
of IFN-γ are available, there is a clear need for suitable biomarkers to identify a 
patient’s ‘immune status’. Currently, mHLA-DR expression and the production 
of cytokines by ex vivo stimulated leukocytes, two parameters that are highly 
correlated (15, 17), are used to this end. Decreased expression of mHLA-DR has 
been reported to be associated with reduced survival in septic patients (10, 43-
46) by some, but not all (47, 48). Recent studies indicate that, instead of a single 
IFN-γ is a well-known activator of monocytes. It increases monocyte antigen-
presenting capacity by upregulating costimulatory and HLA molecules (28). 
Furthermore, previous studies have demonstrated that IFN-γ reverses LPS-tolerance; 
it restores inflammatory cytokine production in vitro, and in vivo in mice (29-31). 
In contrast, IFN-γ failed to restore TNF-α production by ex vivo LPS-stimulated 
leukocytes obtained four hours after LPS administration in vivo, possibly related 
to the short IFN-γ incubation time (32). Interestingly, a case series report revealed 
that, when administered to septic patients with low mHLA-DR expression, IFN-γ 
treatment resulted in restoration of mHLA-DR expression and ex vivo LPS-induced 
TNF-α production by monocytes. Moreover, the recovery of monocyte function 
resulted in resolution of sepsis in eight of nine patients (17). More recently, two case 
reports showed similar results (9). It is clear that more studies are needed to confirm 
these observations. Our data expand on these studies by showing for the first time 
that IFN-γ can indeed restore immune competence in vivo.
 We found differential effects of IFN-γ on the various cytokines studied. In 
agreement with our results, earlier work has demonstrated that IFN-γ enhances 
TNF-α production (31, 33, 34) and suppresses IL-10 release by primary human 
monocytes in vitro (33). In contrast to our data, it was recently shown that IFN-γ 
prevents LPS-induced tolerization for IL-6 in primary human monocytes in vitro (31). 
We do not have a clear explanation for the lack of an effect of IFN-γ on IL-6 in our study, 
although in vitro/in vivo differences may play a role. It should be noted, however, that 
the absence of restoration of the IL-6 response does not necessarily reflect a less pro-
inflammatory spectrum in IFN-γ-treated subjects, because IL-6 has been shown to 
possess both pro- and anti-inflammatory properties (35, 36). No effects of IFN-γ on 
IL-1ra levels were observed in our study. Reports regarding the direct effects of IFN-γ 
on IL-1RA production are conflicting (37-39). Moreover, while generally regarded as 
an anti-inflammatory cytokine, IL-1ra production is induced by both TNF-α and IL-6 
(40, 41). Therefore, the lack of an effect of IFN-γ on IL-6 levels in our study might 
have diluted its effects on IL-1ra production through enhanced TNF-α release. In this 
respect, it is of note that we did observe a trend towards restoration of IL-1ra.
Similar to IFN-γ, GM-CSF is known for its potent immunostimulatory effects. In 
a recent meta-analysis of four placebo-controlled randomized controlled trials 
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study illustrate the extent of the effects of IFN-γ. Second, experimental human 
endotoxemia remains a model of sepsis-induced immunoparalysis, rather than 
completely mimicking the complex pathologic clinical condition of sepsis, and our 
study population is distinctively different from ICU patients suffering from sepsis. 
Furthermore, inherent to the administration of purified LPS, this model is limited 
to activation of the immune system by the Toll-like receptor 4 pathway, whereas 
in the pathophysiology of sepsis, a combination of recognition pathways can be 
engaged by a large variety of microorganisms.
In conclusion, we demonstrate that IFN-γ partially reverses immunoparalysis in 
vivo in humans. These results implicate that IFN-γ-mediated immunostimulation 
could represent a promising treatment option to reverse sepsis-induced 
immunoparalysis in critically ill patients.
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value at a given time point, the slope of recovery of mHLA-DR may better reflect 
susceptibility towards secondary infections and therefore may more accurately 
predict outcome (9, 49, 50). Likewise, attenuated TNF-α production by ex vivo LPS-
stimulated monocytes is associated with a higher incidence of clinical infection (24). 
Moreover, in a recent study in trauma patients suffering from sepsis, attenuated 
TNF-α production by ex vivo LPS-stimulated monocytes was shown to be an earlier 
predictor of clinical outcome than mHLA-DR expression (25). However, the potential 
value of mHLA-DR expression and/or ex vivo cytokine production as predictors of a 
patient’s immune status remains questionable because they only reflect the status 
of the blood/leukocyte compartment. Recent studies of our group indicate that this 
compartment barely contributes to the in vivo immune response to LPS (19, 20). 
In accordance, in the present study HLA-DR expression of circulating monocytes 
returned to normal levels within 24 hours, while the in vivo immune response was 
still severely blunted 6 days later. These results indicate that tissue-resident immune 
cells, such as macrophages, are the predominant mediators of the in vivo immune 
response. In this respect, the slow turnover rate of tissue-resident macrophages, 
as opposed to that of circulating cells, is a plausible explanation for the lengthy in 
vivo refractory state towards a second LPS challenge. The fact that the function of 
tissue-resident immune cells, like their counterparts in the blood compartment, is 
severely compromised in septic patients was recently confirmed (5). It was shown 
that postmortem obtained tissue-resident cells of patients who die of sepsis exhibit a 
distinct immunosuppressed phenotype compared with cells obtained from patients 
who die of etiologies not related to sepsis. Taken together, novel markers to assess 
a patient’s in vivo immune status are highly warranted, but their identification and 
applicability is hampered by the lack of access to tissue-resident immune cells. In the 
meantime and with regard to the timing of immunostimulatory therapy, the use of 
surrogate markers to determine whether a patient is out of the initial overwhelming 
pro-inflammatory phase, such as recovery of hemodynamic stability indicated by 
decreased inotropic requirements, might be considered.
Our study has several limitations. First, because of the small sample size, some 
of the trends described did not reach statistical significance, likely due to a type 
2 error. Despite the small sample size, the significant primary end-points of our 
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and lymphocytes were identified in a 8-color immunophenotyping (NAVIOS flow 
cytometer, Beckman Coulter, Miami). Monocytes and lymphocytes were identified 
by forward and side scatter and by cell-specific binding. The following monoclonal 
antibodies were used for monocyte HLA-DR analysis: HLA-DR-PE  (Immu-357), 
CD14-ECD (RMO52), CD45-KO (J33). Lymphocyte subpopulations were identified 
by gating on the lymphocyte population in the CD45/SS plot followed by a gating 
on CD3-APC (UCHT1), CD4-PECy5.5 (13B8.2), CD8-APCAlexa700 (B9.11), CD19-
APCAlexa750 (HD37) and CD56-PECy7 (N901) to determine the helper T cells, 
cytotoxic T cells, B cells and NK cells within the lymphocyte gate (all MoAbs were 
obtained from Beckman Coulter, Marseille, France).
ONLINE SUPPLEMENT
METHODS
Endotoxemia experiments
After admission to the research intensive care unit of the Radboud University 
Nijmegen Medical Centre, purified LPS (US Standard Reference Endotoxin 
Escherichia Coli O:113) obtained from the Pharmaceutical Development Section 
of the National Institutes of Health (Bethesda, MD) was administered at a dose 
of 2 ng/kg body weight. In all subjects, heart rate (5-lead electrocardiogram) and 
blood pressure (20-gauge radial artery catheter) were monitored starting 2 hours 
before administration of LPS until discharge 8 hours after LPS administration. A 
cannula was placed in an antecubital vein to permit infusion of prehydration fluid 
(1.5 L 2.5% glucose/0.45% saline 1 hour before LPS administration), endotoxin, and 
continuous infusion of 2.5% glucose/0.45% saline (150 mL/hour during 8 hours after 
LPS administration) to ensure optimal hydration status. Body temperature was 
measured using an infrared tympanic thermometer (FirstTemp Genius, Sherwood 
Medical, Crawley/Sussex, UK). The course of endotoxin-induced flu-like symptoms 
(headache, nausea, shivering, and muscle and back pain) was scored every 30 
minutes on a 6-point Likert scale (0=no symptoms, 5=very severe symptoms), 
resulting in a total score of 0 to 25.
Flow cytometric analysis of mHLA-DR expression and lymphocyte subset counts
To ascertain that expression levels did not change due to a delay between withdrawal 
and analysis, we performed separate experiments on 5 different blood samples. 
Expression was determined immediately after withdrawal and after 24 hours 
storage at 4°C. When samples were immediately stored at 4°C after withdrawal 
and analyzed within 24 hours, we did not observe significant differences in % or 
MFI compared with samples that were immediately analyzed after withdrawal. 
Therefore, analysis was performed within 24 hours after immediate storage at 4°C. 
After withdrawal, 100 μl blood was incubated with the following fluorochrome-
conjugated monoclonal antibodies, for 15 minutes protected from light at 4°C. 
After erythrocyte lysis (NH4CL: 180 mL + 20 mL lysis stock dilution [BD Pharm-
Lyse, BectonDickinson]), cells were washed three times in PBS and monocytes 
76 77
3
SUPPLEMENTARY FIGURES
Supplementary Figure 1 (1/2). mHLA-DR expression histograms of a representative subject from 
the IFN-γ group. 
SUPPLEMENTARY TABLES
Supplementary Table 1. Monocyte HLA-DR expression.
Placebo IFN-γ GM-CSF
% MFI % MFI % MFI
Visit 1 t=0 73 [68-84] 7.6 [6.5-10.2] 79 [67-88] 9.6 [6.3-11.2] 85 [77-91] 9.4 [7.0-11.0]
Visit 1 t=4 61 [57-78] 5.2 [4.4-7.6] 74 [50-78] 5.3 [4.1-7.3] 72 [66-76] 6.0 [4.7-7.4]
Visit 1 t=8 68 [63-78] 6.6[5.8-8.4] 58 [58-82] 6.6 [5.5-7.0] 68 [58-89] 6.0 [5.0-13.7]
Visit 1 t=24 80 [74-84] 13.0[10.0-15.1] 83 [79-92] 12.3 [11.5-14.4] 85 [80-92] 11.8 [9.6-26.8]
t=72 80 [74-83] 9.4[7.1-10.5] 83 [77-93] 9.7 [7.4-10.7] 81 [65-85] 9.1[5.9-10.5]
t=120 80 [79-85] 7.4[6.4-10.3] 85 [80-91] 12.0 [9.6-13.2] 83 [71-87] 8.1 [7.5-8.9]
Visit 2 t=0 76 [72-80] 6.5[5.7-7.8] 98 [95-100] 13.1 [10.6-17.4] 94 [82-95] 12.2 [10.2-14.5]
Visit 2 t=4 62 [51-66] 4.7[3.5-5.3] 91 [74-92] 7.8 [5.1-9.4] 71 [46-94] 7.5 [5.4-12.9]
Visit 2 t=8 71 [67-81] 7.3[6.5-8.7] 87 [81-93] 10.0 [8.8-11.8] 70 [65-79] 8.5 [6.7-12.4]
Visit 2 t=24 84 [81-87] 12.4[10.9-13.6] 82 [77-96] 14.5 [13.1-24.0] 73 [66-88] 12.9 [8.2-17.8]
% indicates % HLA-DR-positive monocytes, MFI indicates monocyte HLA-DR mean fluorescent intensity. Values are 
presented as median [interquartile range] of 6 subjects per group.
Supplementary Table 2. Lymphocyte subset counts.
Timepoints
Placebo IFN-γ GM-CSF
T-cells Th-cells Tc-cells T-cells Th-cells Tc-cells T-cells Th-cells Tc-cells
Visit 1 t=0 1,06 [1,00-1,52] 0,43 [0,42-0,79] 0,35 [0,29-0,46] 0,97 [0,94-1,42] 0,44 [0,40-0,64] 0,28 [0,21-0,41] 1,07 [0,84-1,53] 0,48 [0,43-0,59] 0,28 [0,21-0,41]
Visit 1 t=4 0,27 [0,21-0,41] 0,11 [0,08-0,18] 0,08 [0,05-0,12] 0,25 [0,14-0,40] 0,09 [0,04-0,17] 0,06 [0,03-0,12] 0,21 [0,17-0,37] 0,08 [0,06-0,13] 0,06 [0,03-0,12]
Visit 1 t=8 0,43 [0,35-10,4] 0,20 [0,15-0,42] 0,10 [0,00-0,20] 0,34 [0,24-0,45] 0,13 [0,09-0,17] 0,01 [0,06-0,12] 0,49 [0,31-0,77] 0,19 [0,13-0,30] 0,01 [0,06-0,12]
Visit 1 t=24 1,16 [1,07-1,64] 0,54 [0,43-0,76] 0,36 [0,30-0,47] 1,27 [0,98-1,62] 0,51 [0,41-0,75] 0,35 [0,22-0,52] 1,21 [1,08-1,89] 0,53 [0,49-0,78] 0,35 [0,22-0,52]
t=72 1,38 [1,26-2,12] 0,64 [0,51-0,89] 0,43 [0,34-0,66] 1,20 [1,10-2,43] 0,49 [0,42-1,08] 0,35 [0,25-0,73] 1,22 [1,09-2,28] 0,56 [0,48-0,85] 0,35 [0,25-0,73]
t=120 1,64 [1,26-2,48] 0,63 [0,50-1,26] 0,49 [0,38-0,69] 1,22 [0,94-1,85] 0,49 [0,35-0,72] 0,35 [0,21-0,54] 1,26 [0,93-2,44] 0,48 [0,43-0,80] 0,35 [0,21-0,54]
Visit 2 t=0 1,32 [1,15-2,02] 0,55 [0,49-1,02] 0,42 [0,37-0,66] 0,89 [0,72-1,46] 0,38 [0,33-0,72] 0,23 [0,17-0,51] 1,31 [1,03-1,76] 0,58 [0,54-0,69] 0,23 [0,17-0,51]
Visit 2 t=4 0,44 [0,36-0,75] 0,20 [0,16-0,30] 0,14 [0,08-0,21] 0,27 [0,20-0,44] 0,12 [0,07-0,19] 0,06 [0,05-0,14] 0,27 [0,25-0,54] 0,15 [0,11-0,21] 0,06 [0,05-0,14]
Visit 2 t=8 0,83 [0,64-1,11] 0,30 [0,27-0,47] 0,24 [0,17-0,32] 0,60 [0,51-1,00] 0,26 [0,19-0,41] 0,16 [0,10-0,32] 0,61 [0,55-1,06] 0,29 [0,26-0,39] 0,16 [0,10-0,32]
Visit 2 t=24 1,42 [1,26-1,95] 0,57 [0,45-0,79] 0,40 [0,30-0,52] 1,08 [0,98-1,78] 0,42 [0,38-0,67] 0,32 [0,22-0,46] 1,42 [1,21-1,93] 0,60 [0,48-0,68] 0,32 [0,22-0,46]
Timepoints
Placebo IFN-γ GM-CSF
B-cells NK-cells B-cells NK-cells B-cells NK-cells
Visit 1 t=0 0,15 [0,13-0,18] 0,13 [0,11-0,19] 0,20 [0,12-0,29] 0,10 [0,09-0,16] 0,18 [0,09-0,30] 0,10 [0,09-0,16]
Visit 1 t=4 0,08 [0,07-0,10] 0,04 [0,02-0,05] 0,09 [0,07-0,16] 0,04 [0,02-0,07] 0,08 [0,03-0,13] 0,04 [0,02-0,07]
Visit 1 t=8 0,11 [0,07-0,15] 0,02 [0,01-0,07] 0,12 [0,06-0,25] 0,01 [0,01-0,04] 0,14 [0,06-0,21] 0,01 [0,01-0,04]
Visit 1 t=24 0,17 [0,13-0,21] 0,19 [0,17-0,27] 0,23 [0,12-0,32] 0,25 [0,16-0,26] 0,12 [0,10-0,28] 0,25 [0,16-0,26]
t=72 0,18 [0,14-0,23] 0,23 [0,20-0,26] 0,21 [0,15-0,35] 0,21 [0,18-0,28] 0,19 [0,10-0,37] 0,21 [0,18-0,28]
t=120 0,19 [0,13-0,24] 0,26 [0,23-0,32] 0,22 [0,16-0,44] 0,23 [0,16-0,30] 0,16 [0,11-0,39] 0,23 [0,16-0,30]
Visit 2 t=0 0,22 [0,16-0,24] 0,12 [0,11-0,18] 0,20 [0,10-0,24] 0,12 [0,07-0,14] 0,22 [0,12-0,33] 0,12 [0,07-0,14]
Visit 2 t=4 0,14 [0,08-0,15] 0,03 [0,02-0,07] 0,08 [0,05-0,12] 0,03 [0,02-0,05] 0,08 [0,03-0,14] 0,03 [0,02-0,05]
Visit 2 t=8 0,21 [0,14-0,22] 0,06 [0,04-0,08] 0,15 [0,07-0,26] 0,04 [0,04-0,06] 0,19 [0,08-0,24] 0,04 [0,04-0,06]
Visit 2 t=24 0,24 [0,16-0,30] 0,27 [0,23-0,34] 0,29 [0,12-0,32] 0,23 [0,19-0,28] 0,18 [0,12-0,35] 0,23 [0,19-0,28]
Lymphocyte counts determined by flow cytometry. T-cells (CD45+CD3+); T-helper cells (Th, CD45+CD3+CD4+); 
cytotoxic T-cells (Tc, CD45+CD3+CD8+); B-cells (CD45+CD19+); NK-cells (CD45+CD3-CD56+). Values are presented 
as median [interquartile range] of 6 subjects per group.
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Supplementary Figure 2. lymphocyte subset counts determined by flow cytometry. T-cells 
(CD45+CD3+); T-helper cells (Th, CD45+CD3+CD4+); cytotoxic T-cells (Tc, CD45+CD3+CD8+); B-cells 
(CD45+CD19+); NK-cells (CD45+CD3-CD56+). Values are presented as median of 6 subjects per 
group.
Supplementary Figure 1 (2/2). mHLA-DR expression histograms of a representative subject from the 
IFN-γ group. 
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INTRODUCTION
The incidence of fungal infections is steadily increasing in the last years due to 
invasive medical diagnosis and immunosuppressive treatment modalities. 
Despite development of new classes of antifungal agents (1), the invasive fungal 
infections remain associated with unacceptable high mortality rates and represent 
a major cause of death worldwide (2-7). The emergence of significant resistance 
to the currently available antifungal therapies emphasizes the need for novel 
approaches to treat invasive fungal infections (8, 9). Invasive fungal infection are 
most commonly observed in individuals with immune defects or a compromised 
immune system, and the number of these patients is steadily increasing (10).
Therefore, adjunctive immunotherapy to improve host defence is an attractive 
strategy to improve the outcome of patients with disseminated fungal infections.
In the past decade, major progress in the understanding of anti-fungal host 
responses has enabled the development of a number of novel molecular and cell-
based immunotherapeutic approaches for invasive fungal infections (11). Although 
invasive candidiasis and aspergillosis are rather different in their pathogenesis, 
the major protective host response against both fungi is the effective induction 
of Th1 and IFN-γ responses (12-16). The Th1 cytokine response activates effector 
phagocytic cells that kill the fungus (17). Interestingly, Th1 immunity against A. 
fumigatus was demonstrated to be cross-protective against C. albicans (18). 
Interferon-gamma (IFN-γ), the prototype Th1 cytokine, promotes Th1 
differentiation and skews the immune response towards a protective Th1 
phenotype (19). As such, it has been implicated as a treatment option in (invasive) 
fungal infections (20, 21). Moreover, limited evidence suggests that recombinant 
IFN-γ (rIFN-γ) has a beneficial effect on the outcome of fungal infections in 
patients with chronic granulomatous disease (CGD) (22), HIV (23-25) , leukemia 
(26, 27), and in patients receiving organ transplants (28). However, it has not been 
investigated whether rIFN-γ actually enhances the immune response in these 
patients to explain these beneficial clinical effects.
ABSTRACT
Background: Invasive fungal infections are very severe infections associated with 
high mortality rates, despite the availability of new classes of antifungal agents. 
Based on pathophysiological mechanisms and limited pre-clinical and clinical 
data, adjunctive immune-stimulatory therapy with interferon-gamma (IFN-γ) 
may represent a promising candidate to improve outcome of invasive fungal 
infections by enhancing host defence mechanisms. 
Methods: In this open-label, prospective case series, we describe eight patients 
with invasive Candida and/or Aspergillus infections who were treated with 
recombinant IFN-γ (rIFN-γ, 100 μg s.c., thrice a week) for 2 weeks in addition to 
standard antifungal therapy. 
Results: Recombinant IFN-γ treatment in patients with invasive Candida and/or 
Aspergillus infections partially restored immune function, as characterized by an 
increased HLA-DR expression in those patients with a baseline expression below 
50%, and an enhanced capacity of leukocytes from treated patients to produce 
proinflammatory cytokines involved in antifungal defence. 
Conclusions: The present study provides evidence that adjunctive immunotherapy 
with IFN-γ can restore immune function in fungal sepsis patients, warranting 
future clinical studies to assess its potential clinical benefit.
Trial registration: ClinicalTrials.gov - NCT01270490
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Blood sampling
Plasma, serum and whole blood specimens were collected at baseline (BL) and 
serially after the start of antifungal therapy (days 1, 2, 3, 7, 14 and 28). Blood 
cultures were performed as part of routine care.
Leukocyte populations and surface HLA-DR expression 
Heparin anticoagulated blood was stored at 4°C immediately after withdrawal 
and analyzed by flow cytometry. To determine the extent of immune 
suppression, HLA-DR expression was determined by calculating % HLA-DR-
positive cells and HLA-DR mean fluorescence intensity (MFI) within CD14+ 
cells and various lymphocyte subsets within CD45+ leukocytes+ (see online 
supplement and supplemental figure 1 for details and a representative flow 
diagram). Lymphocyte subsets were defined as: T-cells (CD45+CD3+),
Figure 1. Screening, Randomization, and Follow-up of the Study Patients. The principal investigator 
was immediately notified when Candida spp. were cultured in blood. With at least one systemic 
inflammatory response syndrome (SIRS) symptom present in the 24 hours prior to blood culture 
withdrawal, and administration of systemic antifungal therapy < 72 hours, patients were deemed 
eligible for the ‘IFN-γ as an adjunctive treatment for candidemia’ pilot-study. In addition, 5 patients 
not meeting inclusion criteria but who were also treated with rIFN-γ as a therapy of last resort, were 
included in analysis.
In this report we describe a series of patients with invasive Candida and/or Aspergillus 
infections in whom we investigated the effects of treatment with rIFN-γ on the host 
innate and adaptive immune responses. 
MATERIALS AND METHODS
Patients and treatment
To assess the feasibility and preliminary efficacy of IFN-γ in combination with 
anidulafungin for the treatment of candidemia, a single-centre, prospective, 
randomized open-label pilot (Phase IIIb) study was conducted. This study was 
registered at ClinicalTrials.gov (NCT01270490) and approved by the local ethics 
committee of the Radboud University Medical Center. Due to slower than 
anticipated enrollment rates (from August 2010 until March 2013, only 12 patients 
could be screened, of which 6 were eligible and provided informed consent 
[Figure 1]), the study was terminated early. However, during this period, several 
other patients presented with invasive fungal infections which had an insufficient 
response to standard antifungal therapy. Although these patients did not meet 
the inclusion criteria (i.e. presenting with one or more positive cultures of blood or 
normally sterile tissue growing Candida spp.), they were deemed to benefit from 
adjunctive immunotherapy as “therapy of last resort” as decided by the attending 
physician. Within the parameters of standard clinical care these patients were 
treated according to the same protocol as the patients enrolled in the study, and 
were therefore included in the present case series. All patients with a history of 
documented epileptic seizures, pre-existent severe renal impairment (creatinine 
clearance <30/mL/min) or severe liver failure (defined as a spontaneously increased 
prothrombin time) were excluded. After obtaining informed consent, eight patients 
(3 study patients, 5 last resort patients) were treated with rIFN-γ (Immukine, 
Boehringer Ingelheim, 50 μg/m2 body surface, subcutaneously, three times a 
week) in addition to standard antifungal therapy as recommended by national and 
international treatment guidelines (29, 30). Three patients who were included in 
the Phase IIIb Candida pilot-study were assigned to the control group and did not 
receive rIFN-γ.
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Statistical analysis
In view of the small sample size, normality of distribution was not assumed. 
Comparisons of baseline with follow up time points were made using Wilcoxons 
signed rank test (within-group comparisons, 2 groups). A p-value of <0.05 was 
considered statistically significant. Data are expressed as means and standard 
error of the mean. Calculations and statistical analyses were performed using 
GraphPad Prism v 5.0 (GraphPad Software, San Diego, CA, USA).
RESULTS
Patient characteristics
The patients treated with rIFN-γ (5 men, 3 women) had a median age of 49.5 [IQR 
28.5-68.8] years. The three female patients in the control group were 36, 51 and 
73 years old. Clinical characteristics of the participants are listed in Table 1. Of the 
6 patients included in the pilot study, three patients had a positive blood culture 
for C. albicans, two patients for C. glabrata, and one patient for C. tropicalis. During 
randomization, the three patients with C. albicans cultures were assigned to rIFN-γ 
treatment, whereas the two patients with C. glabrata and one with C. tropicalis 
cultures were assigned to the control group. However, no pathophysiological 
evidence currently exists to suggest that rIFN-γ therapy would have a different 
effect on the immune system in case of albicans vs. non-albicans Candida 
infections. Of the other 5 patients treated with rIFN-γ as therapy of last resort, one 
patient had proven acute aspergillosis, one had probable acute aspergillosis, and 
one probable chronic aspergillosis according to the EORTC/MSG criteria (34).One 
patient had a positive blood culture for C. tropicalis associated with osteomyelitis. 
This patient developed new suspected lesions on positron emission tomography-
computed tomography (PET-CT) while receiving antifungal treatment. In 
another patient, CT-scan revealed progression of suspected hepatic Candida 
lesions during antifungal treatment. All patients included suffered some degree 
of immunosuppression: the 6 patients with positive blood cultures for Candida 
spp. had impaired physical barriers due to the presence of indwelling venous 
catheters (for the need of recurrent blood sampling or total parental nutrition), 
T-helper cells (Th, CD45+CD3+CD4+), cytotoxic T-cells (Tc, CD45+CD3+CD8+), B-cells 
(CD45+CD19+), and NK-cells (CD45+CD3-CD56+). Subset counts were calculated by 
multiplying the percentage of gated cells by the total lymphocyte count. Patients 
with <50% HLA-DR positive monocytes at baseline were considered to exhibit 
immune paralysis. This threshold of 50% is well below the lower bound of the 99% 
confidence interval obtained in healthy volunteers in an earlier study of our group 
using the same methodology in the same laboratory (31). Therefore mHLA-DR 
expression levels below 50% are likely to represent immunoparalysis.
Cytokine assays
Venous blood was drawn into 10 mL EDTA tubes, after which peripheral blood 
mononuclear cells (PBMCs) were isolated as described previously (32). In short, blood 
was diluted in phosphate buffered saline (PBS) (1:1) and fractions were separated 
by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) density gradient 
centrifugation. Cells were washed twice with PBS and resuspended in RPMI-1640+ 
(RPMI-1640 Dutch modification supplemented with 10µg/mL gentamicin, 10mM 
L-glutamine, and 10mM pyruvate) (Gibco, Invitrogen, Breda, The Netherlands). 
The PBMCs were counted using a particle counter (Beckmann Coulter, Woerden, 
The Netherlands) and were plated in 96 well round-bottom plates (Corning, NY, 
USA) at a final concentration of 2,5x106/mL, in a total volume of 200 µL. The PBMCs 
were stimulated for 24 hours, 48 hours, and 7 days with medium alone, or medium 
containing E. coli lipopolysaccharide (LPS; 10 ng/mL), phytohaemaglutinnin 
(PHA; 10μg/ml), heat-inactivated Candida albicans blastoconidia (1x106/ml) or 
heat-inactivated Candida albicans hyphae (derived from 1x106/m conidia). After 
stimulation, cell culture supernatant was collected and stored at -20°C. When all 
samples were collected, cytokines were measured using commercially available 
ELISAs (R&D Systems, MN, USA and Sanquin, Amsterdam, The Netherlands) 
according to the protocols supplied by the manufacturer. Ex-vivo production of 
cytokines was assessed at timepoints at which their production has been shown 
to peak (33).Monocyte derived cytokines such as Interleukin (IL)-1β and tumour 
necrosis factor (TNF)-α were measured in culture supernatants of 24 hour cultures, 
IL-10 was measured in culture supernatants of 48 hour cultures. T-cell derived 
cytokines IL-17 and IL-22 were measured in culture supernatants of 7 day cultures.
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We monitored the fold change in cytokine production compared with baseline 
(before start of treatment). IL-1β and TNF-α are pro-inflammatory cytokines of 
the innate immune system crucial in the induction and maintenance of the anti-
fungal immune response (35-40). Before IFN-γ treatment, inter-patient variability 
in cytokine production was high (e.g. TNF-α median [IQR] concentration after 
stimulation with LPS was 792 pg/mL [314-2005]). Nevertheless, in all patients an 
increase in the capacity to induce different cytokines was observed in the first 
two days after initiation of IFN-γ treatment, independent of their baseline values 
(group data shown in figure 2), at subsequent time points only a trend towards 
increased could be observed. In contrast, the placebo-treated patients IL-1β and 
TNF-α responses over time remained similar to baseline. The response against 
hyphae of C. albicans was highly variable between patients. Some rIFN-γ-treated 
patients demonstrated a profound increase of TNF-α production after treatment 
(up to 70 fold), whereas other patients showed no relevant change in TNF-α 
production. Cytokine production remained similar in patients in the control group.
Effect of rIFN-γ on ex-vivo IL-17 and IL-22 production
Both IL-17 and IL-22 are cytokines that are thought to be protective in the host 
defence against invasive fungal infections (35, 41-45). PHA-induced IL-17 and IL-
22 production was increased 1 day after initiation of rIFN-γ treatment (figure 3). 
However, at subsequent time points a trend towards increased IL-17 and IL-22 
production was observed, which reverted to baseline levels at day 28. Production 
of IL-17 and IL-22 upon stimulation with Candida blastoconidia was elevated after 
rIFN-γ treatment in 6 of 8 patients. Hyphae induced IL-17 and IL-22 production was 
increased in 4 of 8 and 5 of 8 patients respectively. Patients who received placebo 
therapy did not display a trend towards increased IL-17 or IL-22 production during 
the course of treatment (group data shown in figure 3).
or an implantable cardioverter-defribillator (ICD) lead. The patient with progression 
of suspected hepatic Candida lesions on the CT-scan, and one patient with proven 
acute aspergillosis (diagnosed by isolation of A. fumigatus from lung tissue biopsies) 
were immunocompromised because of (therapy for) acute myeloid leukaemia. 
Another patient with acute invasive aspergillosis (A. fumigatus isolated from 
BAL fluid) received immunosuppressive therapy (prednisone and azathioprine) 
for sarcoidosis and suffered from a co-infection with Mycobacterium genavense 
localized in the bone marrow. A third patient developed chronic pulmonary 
aspergillosis (diagnosed by consistent CT abnormalities with cavitation and culture 
of A. fumigatus from BAL fluid) after radiotherapy for lung carcinoma. Only two 
patients, both with acute aspergillosis, were admitted to the Intensive Care Unit 
to receive organ supportive therapy (mechanical ventilation and hemodynamic 
support).
Clinical outcome 
The three patients in the control group and five out of eight patients treated with 
rIFN-γ recovered uneventfully from the fungal infection. Two patients with invasive 
aspergillosis that were already admitted to the ICU at the time of treatment died 
due to infectious complications of severe pulmonary aspergillosis, despite rIFN-γ 
treatment. The patient with a Candida endocarditis, who despite rIFN-γ treatment 
developed intracerebral mycotic aneurysm, could be discharged from the hospital 
93 days after onset of invasive candidiasis. 
In all patients treated, rIFN-γ was well tolerated. Five patients reported moderate 
fever upon administration of rIFN-γ, which responded well to acetaminophen. Two 
patients developed liver enzyme abnormalities for which tuberculostatic antibiotics 
and voriconazole were temporarily discontinued, resulting in recovery of the liver 
enzyme abnormalities while rIFN-γ treatment was continued. No other significant 
adverse events were observed.
Effect of rIFN-γ on ex-vivo IL-1β and TNF-α production
To assess the effect of rIFN-γ on the capacity of PBMCs to produce pro-inflammatory 
cytokines, cells were isolated and stimulated before, during, and after treatment. 
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Figure 3. Effect of rIFN-γ on ex-vivo IL-17 and IL-22 production 
PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after rIFN-γ administration. 
Isolated PBMCs were stimulated for 7 days with PHA, C. albicans blastoconidia, or C. albicans 
hyphae. IL-17(a) and IL-22(b) concentrations were measured in culture supernatants. Baseline 
concentrations were used as control and set at 1; subsequent measurements are plotted as the 
mean relative fold change ±SEM. Significant change from baseline was determined by subjecting 
the data to Wilcoxons signed rank test. (*=p<0,05).
Figure 2. Effect of rIFN-γ on ex-vivo IL-1β and TNF-α production 
PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after rIFN-γ administration. 
Isolated PBMCs were stimulated for 24 hours with LPS, PHA, C. albicans blastoconidia, or C. albicans 
hyphae. IL-1β(a) and TNF-α(b) concentrations were measured in culture supernatants. Baseline 
concentrations were used as control and set at 1; subsequent measurements are plotted as the 
mean relative fold change ±SEM. Significant change from baseline was determined by subjecting 
the data to Wilcoxons signed rank test. (*=p<0,05; **=p<0,01).
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out of eight IFN-γ treated patients exhibited HLA-DR positive monocyte levels 
below the “immunoparalysis threshold” of 50% and in these patients, an increase 
of HLA-DR-positive monocytes after IFN-γ treatment between 10% and 44% 
was observed which persisted throughout the study period (Figure 5). Patients 
with a baseline HLA-DR expression higher than 50% did not show a change 
in expression. The patient with a HLA-DR-expression <50% who did not show 
increased levels of HLA-DR positive monocyte numbers at any time point, was 
one of the two patients who died due to infectious complications. No correlation 
was found between the level of mHLA-DR expression and TNF-α production of 
LPS-stimulated PBMCs. An inverse correlation of baseline mHLA-DR levels with 
severity of underlying illness and tissue involvement was found (with higher 
mHLA-DR levels in patients with only impaired physical barriers, e.g. due to 
indwelling catheters, compared to patients with impaired immune responses, e.g. 
due to chemotherapy, immune suppressive agents, bone marrow disease,; data 
not shown because this compromises patients anonymity).
Figure 5. mHLA-DR expression
Panel A. mHLA-DR expression in rIFN-γ treated patients (solid dots) and in patients in the control 
group (open squares). Panel B. mHLA-DR expression in rIFN-γ treated patients, divided into 
immunoparalyzed patients with baseline HLA-DR expression below 50 % (solid dots), and without 
HLA-DR defined immunoparalysis (open dots). Data are expressed as median[IQR].
Cell populations
There were no significant changes in the total leukocyte and granulocyte numbers 
in rIFN-γ-treated patients (supplemental Figure 2A). Monocyte counts significantly 
Immunoparalyzed IFN-treated patients
Immunocompetent IFN-treated patients
Effect of rIFN-γ on ex-vivo IL-10 production
In addition to pro-inflammatory cytokines, the capacity to produce anti-
inflammatory cytokines can also influence disease outcome. In particular the 
anti-inflammatory cytokine IL-10 has been associated with protection against 
immunopathology during severe infections. IL-10 production in response to 
stimulation with LPS, PHA and Candida was highly variable between patients and 
did not show a distinct pattern following rIFN-γ treatment (figure 4). No relevant 
differences compared to the placebo-treated patients were observed. 
HLA-DR expression
The numbers of HLA-DR-positive monocytes, a marker of immunosuppression, 
varied substantially between patients at baseline (39.05 % [27.5-61.6] vs. 90.6 [88.7-
92.5] in IFN-γ-treated patients and placebo-treated patients, respectively). Five 
Figure 4. Effect of rIFN-γ on ex-vivo IL-10 production 
PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after rIFN-γ administration. 
Isolated PBMCs were stimulated for 48 hours with LPS, PHA, C. albicans blastoconidia, or C. albicans 
hyphae. IL-10 concentrations were measured in culture supernatants. Baseline concentrations 
were used as control and set at 1; subsequent measurements are plotted as the mean relative fold 
change ±SEM. 
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circulating granulocyte numbers. It is not known whether this reduction is due 
to activation and migration into the infected tissue, or whether a true decrease 
in granulocyte generation was induced by the treatment. Although the decrease 
in granulocyte numbers was slight, the fact that granulocytes, and especially 
neutrophils, are crucial in the antifungal host defence warrant careful monitoring 
of granulocyte numbers during IFN-γ treatment. 
Several clinical studies and case reports have previously demonstrated beneficial 
effects of rIFN-γ in combination with antifungal therapy on outcome of fungal 
infections (for example in patients with CGD (n=130) (22, 46, 47), HIV (n=173) (23-
25), leukaemia (n=5) (26, 27), and transplant patients (n=7) (28), in a patient with 
S. aureus liver abscess and invasive C. albicans infection (48), in a patient with 
intracerebral aspergillosis (49), in two patients with progressive chronic pulmonary 
aspergillosis (50), and in two patients with idiopathic CD4 lymphopenia and 
cryptococcal meningitis (51)). However, in contrast to our study, ex-vivo immune 
responses in these patients were not investigated. Due to the limited number 
of patients and the very heterogeneous population, we could not assess clinical 
endpoints, although a mean mortality of 25% in the IFN-γ treated patients lies 
below the mean 40% estimated in patients with invasive fungal infections (10, 52). 
To the best of our knowledge, we are the first to describe mHLA-DR expression, a 
widely used marker of immunosuppression in (bacterial) sepsis patients ((53)), in 
patients with invasive fungal infections. In all IFN-γ treated patients who showed 
baseline mHLA-DR levels below the immunoparalysis threshold of 50% and 
survived, IFN-γ mediated upregulation of mHLA-DR expression was observed. In 
agreement with the data presented in this case series, rIFN-γ has been shown to 
significantly increase numbers of HLA-DR-positive monocytes both in a human 
preclinical bacterial sepsis model and in septic patients (31, 54). Reduced production 
of TNF-α by leukocytes ex-vivo stimulated with LPS has also been shown to be 
marker of immunoparalysis in sepsis patients. In contrast to our study, mHLA-
DR expression and ex-vivo TNF-α production were found to be highly correlated 
in bacterial sepsis patients (54, 55). A possible explanation for this discrepancy 
is that, in contrast with the emerging consensus that immunoparalysis renders 
increased one week after initiation of rIFN-γ therapy (supplemental Figure 2C) and 
lymphocyte numbers significantly increased at 2 and 7 days after initiation of rIFN-γ 
therapy (supplemental Figure 2D), which could be attributed to slight changes in 
CD4 lymphocytes (supplemental Figure 2E), B-lymphocyte (supplemental Figure 
2F) and NK-cell numbers (supplemental Figure 2G) and a significant increase of 
CD8 lymphocytes (supplemental Figure 2H). No clear changes in leukocyte (subset) 
counts were observed in placebo-treated patients.
DISCUSSION
While several small clinical trials illustrated the beneficial clinical effects of adjuvant 
treatment with IFN-y, the proposed immunostimulating effect of IFN-γ as the 
mechanism of action has not been investigated. In this case series we demonstrate 
for the first time that adjunctive immunotherapy with rIFN-γ improves the leukocyte 
immune responses in patients with severe invasive fungal infections. This was 
primarily reflected by increased ex-vivo pro-inflammatory cytokine responses of the 
innate immune system such as IL-1β or TNF-α, as well as an increased production of 
the T-cell cytokines IL-17 and IL-22, which are known to play an important role in the 
anti-fungal host defence (35, 41-45), and by an increase in HLA-DR expression in 
mHLA-DR expression in those patients with a low cellular expression as a measure 
of their immune suppression.
In addition to enhanced ex-vivo responses, subtle changes in the leukocyte 
differentiation were observed following IFN-γ treatment. Although there were 
no significant differences in total leukocyte numbers after treatment with rIFN-γ, 
shifts in leukocyte subpopulations such as increased monocyte and lymphocyte 
counts were apparent. While lymphocyte numbers increased after rIFN-γ therapy, it 
could not directly be attributed to a specific subset as all of them showed increased 
values. The most significant increase was that of CD8 cells one week after initiation 
of rIFN-γ therapy. Monocytes and lymphocytes are known to be crucial cells in 
the host defence against fungal infections. However, the increase of monocytes 
and lymphocytes during rIFN-γ therapy was accompanied by slightly decreased 
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study is the limited number of patients studied. Because the control group 
consisted of only three patients, no statistical analysis between the treatment 
and control groups could be performed. However, despite the small sample size, 
the increase in HLA-DR expression in patients with mHLA-DR expression levels 
below 50% and the increased ex-vivo response of several cytokines that are crucial 
in antifungal host defence is a promising observation that underlines the potential 
of immunotherapy. The slow enrolment of patients presenting with candidemia 
was the main factor contributing to the decision to terminate the phase IIIb 
Candida pilot-study early. With a reported incidence of 2.5-11 per 100.000 persons 
in Europe (60), and based on previous epidemiological data in our hospital this 
low enrollment was not expected at the time of the initiation of the study. The 
much lower incidence of candidemia in the last two years in our hospital is most 
likely due to a new antibiotic stewardship introduced recently in our hospital, 
which has reduced the incidence of opportunistic infections. The cut-off value of 
mHLA-DR expression levels of 50% to distinguish between immunoparalyzed 
and immunocompetent patients is another limitation of this study, as this is an 
arbitrary value chosen. We chose this value because it is well below the 99% CI of 
mHLA-DR values in healthy volunteers (31). Therefore, patients with mHLA-DR 
below 50% do have an impaired antigen presenting capacity of their monocytes 
which we show to be enhanced by IFN-γ therapy. Whether this cut-off value truly 
represents immunoparalysis, reflected by enhanced susceptibility to secondary 
infections or reduced capacity to clear opportunistic infections, remains to be 
investigated. Furthermore, the use of a standardized analysis technique to quantify 
mHLA-DR, such as the Quantibrite method, is preferable, because it facilitates an 
objective comparison of mHLA-DR expression levels between studies and aids 
in the definitive establishment of a cut-off value to identify immunoparalyzed 
patients. Larger studies are required to confirm the data obtained here. To do so, 
multicentre studies should be facilitated in order to fully explore the potential of 
IFN-γ immunotherapy. 
Our data indicate that adjunctive immunotherapy with rIFN-γ in patients with 
invasive fungal infections partially restores cell-mediated immunity. This suggests 
that IFN-γ treatment enhances anti-fungal immunity and larger studies are 
patients more vulnerable to opportunistic infections in general (53), different 
defects in immune defences may be responsible for enhanced susceptibility 
towards different pathogens. 
Based on the apparent inverse correlation of baseline mHLA-DR levels with 
severity of underlying illness and tissue involvement, mHLA-DR levels seem to 
reflect disease severity and general immune status, and not specific immune 
defects per se. Hence, patients with invasive fungal infections and associated 
impaired anti-fungal immune responses will probably benefit more from 
immunostimulatory treatment compared to patients with only impaired physical 
barriers, e.g. due to indwelling catheters and apparent intact anti-fungal immune 
responses. Biomarkers reflecting the capacity of specific anti-fungal immune 
defences are required to identify patients who suffer from invasive fungal 
infections due to impaired cell-mediated immunity. It is important to identify 
such patients and attempt a tailored immunotherapeutic approach guided by the 
actual level and type of immunoparalysis of that specific patient. A blood based 
assay has been described that demonstrates a failure to induce IFN-γ expression 
in renal transplant patients and differences in IL-10 and TNF-α expression (56), 
which could be promising biomarkers to identify patients who could benefit from 
adjunctive immunotherapy.
The intracellular mechanism(s) through which the beneficial effects of IFN-γ are 
mediated remain to be elucidated. Recently it was proposed that IFN-γ exerts 
its effects at the transcription level (57), while others have demonstrated that 
IFN-γ reverses tolerance-associated epigenetic modifications (58). Another 
possible mechanism involved in the IFN-γ mediated reversal of immunoparalysis 
is the downregulation of negative TLR regulators such as IRAK-M, a protein that 
negatively regulates LPS-induced inflammatory responses and contributes to the 
development of immunoparalysis (59). 
Administration of rIFN-γ was tolerated well. Several patients developed a mild 
fever upon administration, which responded well to acetaminophen treatment. 
No other side effects were observed. The most important limitation of the present 
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the following fluorochrome-conjugated monoclonal antibodies, for 15 minutes 
protected from light at 4°C. After erythrocyte lysis (NH4CL: 180 mL + 20 mL 
lysis stock dilution [BD Pharm-Lyse, BectonDickinson]), cells were washed 
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Supplementary Figure 2. Changes in immune cell populations. Total leukocyte numbers (a) and 
numbers of granulocytes (b), monocytes (c) and lymphocytes (d) measured in peripheral blood. 
Numbers of CD4 lymphocytes (e), B-lymphocytes (f), CD8 lymphocytes (g) and NK cells (h) within 
the lymphocyte population were quantified using flowcytytometry.
SUPPLEMENTARY FIGURES
Supplementary Figure 1. Representative flow diagram of monocyte HLA-DR measurements. 
Heparin blood was first analysed on forward- and side scatter to exclude cell debris and erythrocytes 
(A). Subsequently, CD45+ cells were selected (B) and within the CD45+ fraction was gated for CD14+ 
cells(C). The CD45+ CD14+ cells (D) were analysed for the percentage of HLA-DR positivity (E).
J Ped Infect Dis. 2015; Epub 2015/09/15
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INTRODUCTION
Patients suffering from leukemia are prone to invasive fungal infections because of 
the presence of indwelling catheters in combination with an immunocompromised 
immune status due to prolonged periods of neutropenia and mucosal breakdown 
associated with intensive chemotherapeutic regimens (1-3). Candida spp. are the 
most frequent fungal opportunistic pathogen in such patients (4), with 30 day 
mortality rates reaching 40% in adult patients (5, 6). In the pediatric population 
prognosis of invasive candida infections is slightly better, but particularly in cases 
with poor response to antifungal therapy, mortality remains unacceptably high (7-9). 
Adjuvant interferon-gamma (IFN-γ), an immunostimulatory cytokine, may 
improve outcome of fungal infections in adult patients with immune paralysis 
(10-12). This was recently substantiated in a small case-series which showed that 
IFN-γ partially restored anti-fungal immune function in patients with invasive 
fungal infections (13). Therefore, in adult patients who deteriorate despite optimal 
antifungal treatment, adjuvant IFN-γ immunotherapy could be considered as 
adjuvant salvage therapy (12). Here we report the clinical case of a three-year old 
patient with severe systemic C. dubliniensis infection and poor clinical response 
to standard antifungal therapy. Adjuvant therapy with IFN-γ restored immune 
function and likely contributed to clinical improvement.
CASE REPORT
A previously healthy three-year-old boy was diagnosed in June 2014 with common 
acute lymphoblastic leukaemia (cALL), with CNS status CNS-2 and the favourable 
t(12;21) translocation. He started induction chemotherapy the day after his diagnosis 
according to protocol ALL-11 (Dutch Childhood Oncology Group study for children with 
ALL; https://www.skion.nl/workspace/uploads/Onderzoeksprotocol-ALL11-version-4-3-
september-2014.pdf). On day 15 after start of chemotherapy he developed neutropenic 
fever, for which empirical antibiotics were started (ceftazidim and vancomycin). 
Despite antibiotic treatment, fever persisted, and a blood culture drawn on day 28 
ABSTRACT
Despite advances in supportive care and novel antifungal agents, mortality due to 
invasive Candida infection remains high. A three-year-old boy with disseminated 
C. dubliniensis infection during induction chemotherapy for acute lymphoblastic 
leukemia deteriorated, despite resolution of neutropenia and optimal antifungal 
treatment. Monocyte HLA-DR-expression was extremely low, suggesting 
immunoparalysis. Adjuvant immunotherapy with IFN-γ restored the immune 
response, accompanied by clinical and radiographic recovery.
112 113
5
B on day 134 and micafungin on day 143. Nine months after the leukaemia 
diagnosis, reinduction chemotherapy was started. Bone marrow biopsies were 
regularly performed, which showed that the leukemia remained in remission. As 
a precautionary measure, voriconazole was continued and micafungin restarted. 
Figure 1.  A, magnetic resonance imaging of the brain (T1 weighted image with fat suppression following 
intravenous infusion of gaudolinium) on day 51 shows multiple brain abcsesses (arrows). B, liver biopsy 
on day 51 shows yeast cells (Grocott-Gomori’s methenamine silver stain’s stain, 400x maginification). 
PCR of the tissue was positive for Candida spp. C, summary of the clinical course, antimycotic and 
immunomodulatory treatment of the patient. C-reactive protein levels are shown in grey and on the 
left y-axis; Percentage of monocytes positive for HLA-DR are shown in black and on the right y-axis.
was positive for Candida dubliniensis, with good in vitro sensitivity to micafungin, 
amphotericin B and voriconazole. Micafungin and G-CSF were started on day 30 and 
the central venous catheter (CVC) was removed on day 36. Ultrasound investigations 
of the abdomen, retinal inspection by the ophthalmologist and magnetic resonance 
imaging (MRI) of the brain did not show any evidence for disseminated candida 
infection. Neutrophil counts recovered and G-CSF was stopped on day 39.
Because of progressive fever and a further increase in serum C-reactive protein, 
antifungal therapy was switched to liposomal amphotericin B and voriconazole 
on day 39. The following days the patient continued to deteriorate and was 
transferred to the intensive care unit for respiratory support. Imaging of the 
abdomen and brain now showed multiple nodular lesions in the brain, kidneys, 
liver and spleen, with a radiological appearance suggestive of disseminated 
Candida infection (Figure 1A). Ultrasound guided biopsy of the liver (histology 
and PCR) confirmed the presence of Candida spp. in the nodular hepatic lesions 
(Figure 1B). Flucytosine was added to the antimycotic regimen for better central 
nervous system penetration. The patient continued to deteriorate and on day 66, 
micafungin was re-added to the treatment. HLA-DR expression on monocytes 
was extremely low at that time, demonstrating immunoparalysis. Granulocyte 
oxidative burst, phagocytosis and chemotaxis were normal.
Because of the immunoparalysis, IFN-γ (Immukine, Boehringer Ingelheim, 50 
μg/m2 body surface, subcutaneously, three times/week) was started as salvage 
therapy on day 74. Initially, the clinical condition and appearance of nodular lesions 
on imaging analysis did not improve, after which it was decided to increase the 
dose to daily injections. After five days of daily IFN-γ administration, pericardial 
effusion developed. IFN-γ administration was reverted to three times per week, 
with spontaneous disappearance of pericardial effusion. Finally, monocyte HLA-
DR expression increased and the clinical condition of the patient improved. 
Imaging of the brain revealed complete resolution of lesions and abdominal 
ultrasound showed markedly diminished kidney, liver and spleen lesions. Despite 
IFN-γ treatment, the patient suffered from several episodes of CVC-associated 
bacterial sepsis. IFN-γ treatment was stopped on day 115, liposomal amphotericin 
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DISCUSSION
Here we describe a child with proven progressive disseminated invasive 
candidiasis. Despite receiving multiple antifungal agents with low minimal 
inhibitory concentrations to the cultured C. dubliniensis, the patient deteriorated. 
Last resort adjunctive immunotherapy with IFN-γ resulted in normalization of 
mHLA-DR expression, and cytokine responses were also partly restored. This 
restoration of innate immune functions paralleled and likely contributed to 
clinical recovery.
 
To adequately eradicate Candida spp., innate immunity has to be intact (15, 
16). In our patient chemotherapy-induced neutropenia resolved, but innate 
immune function was severely impaired as demonstrated by very low levels 
of mHLA-DR expression (reflecting diminished antigen presenting capacity). 
In adult patients, mHLA-DR expression is currently the most widely used 
marker of impaired innate immunity, but its accuracy still lacks solid evidence 
(12). Although reference values are not available for the pediatric population, 
we observed an extremely low level of mHLA-DR (both MFI and % positivity), 
which increased dramatically during IFN-γ treatment. This implies that mHLA-
DR expression is likely to be a useful biomarker for innate immune function in 
children as well, but further studies in pediatric patients are highly warranted. 
Our assessment of ex vivo cytokine responses to Candida revealed multiple 
effects of IFN-γ therapy on the capacity of PBMCs to mount adequate cytokine 
responses. After initiation of IFN-γ therapy, we observed enhanced production 
of TNF-α of PBMCs ex vivo stimulated with both Candida yeast and hyphae, 
which is similar to what we have previously observed in a case series of patients 
with invasive fungal infections treated with adjunctive IFN-γ immunotherapy 
(13). In addition, IFN-γ treatment resulted in a slight restoration of the IL-17 
response to Candida hyphae (of which we assume that it reflects the response to 
Candida spp. in the infected tissues). Because IL-17 is of primordial importance 
in the anti-fungal immune defense (17), it is tempting to speculate that long-
term IFN-γ treatment could lead to a full recovery of IL-17 responses, although 
Immunological analysis
Blood samples were collected during routine blood withdrawals, and immune 
responses before and during IFN-γ treatment were evaluated. HLA-DR expression 
on monocytes (mHLA-DR) was determined as a percentage of HLA-DR positive 
monocytes (a detailed description is provided in the Online Supplement) and as 
mean fluorescence intensity (MFI) levels as described earlier (14). Before IFN-γ 
treatment, almost all monocytes lacked HLA-DR expression (2%, normal range 
above 90% positivity) and concurrently MFI mHLA-DR expression level was very 
low (MFI of 4.2 in the patient, compared with 9.2 [5.1-14.8] (median [min-max]) in 
healthy controls (14)). During IFN-γ treatment mHLA-DR positivity increased to 
50%, with supranormal levels of expression with a MFI of 18.4 (Figure 1C).
In addition we investigated ex-vivo cytokine responses of peripheral blood 
mononuclear cells (PBMCs) stimulated with various morphological forms of 
Candida albicans (hyphae and yeast) and Escherichia coli lipopolysaccharide 
(LPS) for 24 hours (TNF-α), 48 hours (IFN-γ), and 7 days (IL-17) as described 
earlier (13), before IFN-γ treatment, and 8 days later. Before initiation of IFN-γ 
treatment the patient demonstrated normal TNF-α production of PBMCs upon 
ex vivo stimulation with Candida yeast and hyphae, whereas responses to ex vivo 
stimulation with LPS were lower than those of one healthy volunteer aged 28 
years (Supplementary Figure S1 A-C). Of interest, the IL-17 response to ex vivo 
stimulation with Candida hyphae was not detectable (Supplementary Figure 
S1 B), and no Th1 (IFN-γ) response was mounted upon ex vivo stimulation with 
Candida yeast (Supplementary Figure S1 C). After initiation of IFN-γ treatment, 
TNF-α responses upon ex vivo stimulation with Candida hyphae and yeast were 
boosted when compared with responses before treatment, yet the response 
against LPS was unchanged (Supplementary Figure S1 A). The IL-17 response 
against Candida hyphae which was absent before the initiation of IFN-γ therapy 
was slightly restored, although the IL-17 response against Candida yeast was 
reduced (Supplementary Figure S1 B). IFN-γ responses against Candida yeast 
remained unchanged, but IFN-γ response against Candida hyphae was reduced 
after initiation of IFN-γ treatment (Supplementary Figure S1 C). 
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this has to be determined in future studies. However, one must be cautious in 
interpreting the effects of IFN-γ adjunctive therapy on cytokine production 
capacity, as these have been done in only one patient with only one (not age-
matched) control, which may explain that some of the results are not fully 
consistent (e.g. increased of IL-17 production capacity upon stimulation with 
Candida hyphae, but not for yeasts). More studies are therefore needed to fully 
decipher the immunologic effects of IFN-γ adjunctive therapy.
Experience with IFN-γ treatment in children is limited (18), but it is well tolerated 
in children with chronic granulomatous disease, a rare inherited disorder of 
leukocyte function (19). Life-threatening side-effects are rare, although in early 
clinical trials deterioration of pre-existing heart disease was observed in patients 
who were treated with doses of 250µg/m2 or higher, which spontaneously 
reverted when treatment was discontinued. In our patient, pericardial effusion 
occurred during daily injections, which resolved after reverting to the usual 
three times per week. and therefore very likely could be attributed to the IFN-γ 
therapy. Hence, this case underscores that close monitoring is warranted when 
IFN-γ dose is increased, or when heart disease is already present, because side 
effects can be potentially life-threatening.
CONCLUSION
Treatment of a leukemic child with refractory disseminated candidiasis with 
adjuvant IFN-γ increased innate immune activation and altered cytokine 
responses. These improvements paralleled clinical improvement, indicating 
this immunotherapeutic approach may have contributed to the favorable 
clinical outcome. This observation warrants further study in pediatric patients 
with invasive fungal infections who deteriorate despite optimal antifungal 
treatment, in which immunotherapy with IFN-γ may be considered as adjuvant 
salvage therapy. 
118 119
5
ONLINE SUPPLEMENT
Flow cytometric analysis of mHLA-DR expression
We used to methods to determine mHLA-DR expression. First, we determined 
Mean Fluorescence Intensities as described earlier (1). Briefly, EDTA anticoagulated 
blood was stored at 4°C immediately after withdrawal and analyzed by flow 
cytometry. After withdrawal, 100 μl blood was incubated with the following 
fluorochrome-conjugated monoclonal antibodies, for 15 minutes protected from 
light at 4°C. After erythrocyte lysis (NH4CL: 180 mL + 20 mL lysis stock dilution 
[BD Pharm-Lyse, BectonDickinson]), cells were washed three times in PBS and 
monocytes and lymphocytes were identified in an 8-color immunophenotyping 
(NAVIOS flow cytometer, Beckman Coulter, Miami). Monocytes and lymphocytes 
were identified by forward and side scatter and by cell-specific binding. The 
following monoclonal antibodies were used for monocyte HLA-DR analysis: 
HLA-DR-PE (Immu-357), CD14-ECD (RMO52), CD45-KO (J33). Lymphocyte 
subpopulations were identified by gating on the lymphocyte population in the 
CD45/SS plot followed by a gating on CD3-APC (UCHT1), CD4-PECy5.5 (13B8.2), 
CD8-APCAlexa700 (B9.11), CD19-APCAlexa750 (HD37) and CD56-PECy7 (N901) 
to determine the helper T cells, cytotoxic T cells, B cells and NK cells within the 
lymphocyte gate (all MoAbs were obtained from Beckman Coulter, Marseille, 
France). mHLA-DR expression was determined by calculating HLA-DR mean 
fluorescence intensity (MFI) within CD14-positive cells. Second, we determined 
which percentage of CD14-positive monocytes was HLA-DR positive, using HLA-
DR positive B-cells as an internal positive control.
Cytokine assays
Ex-vivo cytokine production was determined as described earlier (2). In short, 
blood was diluted in phosphate buffered saline (PBS) (1:1) and fractions were 
separated by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) 
density gradient centrifugation. Cells were washed twice with PBS and 
resuspended in RPMI-1640+ (RPMI-1640 Dutch modification supplemented 
with 10µg/mL gentamicin, 10mM L-glutamine, and 10mM pyruvate) (Gibco, 
Invitrogen, Breda, The Netherlands). The PBMCs were counted using a particle 
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Supplementary Figure 1. Effect of IFN-γ on ex-vivo cytokine responses
PBMCs of the patient were isolated before initiation of IFN-γ treatment and 8 days later. Panel A. 
TNF-α production of PBMCs ex-vivo stimulated with LPS, C. albicans yeast, or C. albicans hyphae for 
24 hours. Panel B. IL-17 production of PBMCs ex-vivo stimulated with C. albicans yeast, or C. albicans 
hyphae for 7 days. Panel C: IFN-γ production of PBMCs ex-vivo stimulated with C. albicans yeast, or 
C. albicans hyphae for 48 hours. 
counter (Beckmann Coulter, Woerden, the Netherlands) and were plated in 96 
well round-bottom plates (Corning, NY, USA) at a final concentration of 2,5x106/
mL, in a total volume of 200 L. The PBMCs were stimulated for 24 hours, 48 hours, 
and 7 days with medium alone, or medium containing E. coli lipopolysaccharide 
(LPS; 10 ng/mL), phytohaemaglutinin (PHA; 10μg/ml), heat-inactivated Candida 
albicans yeast (1x106/ml) or heat-inactivated Candida albicans hyphae (derived 
from 1x106/m yeast). After stimulation, cell culture supernatant was collected and 
stored at -20°C. When all samples were collected, cytokines were measured using 
commercially available ELISAs (R&D Systems, MN, USA and Sanquin, Amsterdam, 
The Netherlands) according to the protocols supplied by the manufacturer. Ex-
vivo production of cytokines was assessed at time points at which their production 
has been shown to peak (3). Monocyte derived cytokines such as tumour necrosis 
factor (TNF)-α were measured in culture supernatants of 24 hour cultures, IFN-γ 
was measured in culture supernatants of 48 hour cultures. T-cell derived cytokine 
IL-17was measured in culture supernatants of 7 day cultures.
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INTRODUCTION
Nocardiosis is a rare Gram-positive bacterial infection caused by aerobic 
actinomycetes of the genus Nocardia. Nocardia species (spp.) can cause both localized 
and disseminated infection (1), and they are responsible for approximately 2% of all 
brain abcesses (2). Mortality rates up to 66% have been reported in patients with 
multiple lesions (3). Because nocardiosis is most commonly observed in individuals 
with immune defects (1), adjunctive immunotherapy is a potentially attractive 
strategy to improve host defense and the outcome of patients with disseminated 
nocardiosis. Interferon-gamma (IFN-γ), a well-known immunostimulatory cytokine 
(4), has shown promising results in the adjunctive treatment of other opportunistic 
infections (5-7). Moreover, IFN-γ is used as prophylactic treatment for prevention 
of Nocardia infection in patients with chronic granulomatous disease (CGD) (8). 
Therefore, IFN-γ represents a promising candidate to improve the outcome of 
invasive Nocardia infections. However, to date, no reports of adjunctive treatment 
with IFN-γ for patients with Nocardia infections have been reported.
CASE REPORT
A 50-yr-old male patient with multiple Nocardia cerebral abscesses was referred to our 
university hospital because of clinical deterioration despite adequate antimicrobial 
treatment. Six months earlier, the patient was referred to a pulmonologist because 
of recurrent pneumonia, and unidentified interstitial pneumonitis was diagnosed 
per exclusionem. Corticosteroid treatment was initiated and administrated in a 
dose varying between 5 to 30 mg per day. Two months prior to admission at our 
centre, he had been admitted to a non-university hospital with a one-month history 
of fever, behavioral changes, progressive unilateral muscle weakness, nausea and 
headache. At this admission, cerebral magnetic resonance imaging (MRI) showed 
two annular contrast enhancements in the left gyrus frontalis intermedius and in the 
right centrum semiovale, with both lesions showing pronounced vasogenic edema 
(MRI of the largest lesion is depicted in Figure 1, Panel A). At day 7 of admission, 
stereotactic aspiration of the largest lesion yielded 3 ml purulent discharge with 
ABSTRACT
Despite advances in medical care, mortality due to cerebral Nocardia abscesses 
remains unacceptably high. In this report we present a typical immunocompromised 
patient, who deteriorated clinically despite optimal antimicrobial treatment. 
Adjuvant immunotherapy with IFN-γ resulted in partial restoration of the immune 
response, and paralleled clinical and radiographic recovery. 
What was known on this topic?
Nocardiosis is a rare opportunistic Gram-positive bacterial infection. Despite 
optimal antimicrobial treatment, the mortality rate remains very high, especially 
in patients with multiple brain abcesses. 
What does this add?
In patients with intracerebral Nocardia abscesses who deteriorate despite optimal 
antimicrobial treatment, immunotherapy with IFN-γ could be considered as 
adjuvant salvage therapy.
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The patient was deemed to benefit from adjunctive immunotherapy as “last resort 
therapy”. Therefore, after referral to our centre and obtaining informed consent, 
IFN-γ (Boehringer-Ingelheim, Arnhem, The Netherlands) treatment was initiated 
at day 55 of admission (50 μg/m2 subcutaneously, thrice weekly). In addition, 
two days after initiation of IFN-γ therapy, ceftriaxone was started next to TMP-
SMX and meropenem because of persistent fever. Four days later, meropenem 
was stopped, as recent cultures were negative for multi-resistant bacteria, and 
there were no clear effects on the clinical course despite treatment for 14 days. 
Compared with the MRI performed one week before initiation of IFN-γ treatment, 
the MRI performed 14 days later showed no new lesions and a decrease of the 
right paraventricular lesion (Figure 1, Panel E). Fever disappeared 12 days after 
initiation of IFN-γ treatment. However, despite combination antimicrobial 
therapy (TMP-SMX and ceftriaxone), disappearance of fever, and ameliorating 
radiography, cerebrospinal fluid (CSF) remained purulent and amikacin was 
added, administered intrathecally through an Ommaya catheter. Within two 
weeks, the headache subsided and CSF became normal, and amikacin could be 
discontinued. Nausea persisted slightly longer, but one week later only trunk 
balance impairment and vertigo with a tendency to fall remained. Combination 
antimicrobial therapy and adjunctive IFN-γ treatment were well tolerated and 
were continued. The condition of the patient further improved and 3 and a half 
months after initiation of IFN-γ treatment he was discharged, being also able to 
walk. MRI showed further improvement (Figure 1, Panel F). He was discharged on 
TMP-SMX and with IFN-γ treatment. 
However, 4 days after discharge patient was readmitted because of a Non-ST-
Elevation myocardial infarction. Coronary angiography showed no stenosis 
eligible for intervention and medication was optimalized. The same day chest 
X-ray followed by a CT-scan showed free subdiaphragmal air with pneumatosis 
intestinalis, a rare complication of high dose corticosteroid administration. 
Abdominal surgery showed no additional cause for free air. The patient was 
admitted at the Intensive Care Unit in need of ventilator support and inotropic 
medication. He died seventeen days later due to cardiovascular causes that were 
not directly related to the Nocardia infection, which was confirmed on autopsy.
cultures of the discharge revealing Nocardia asteroides. Initial treatment consisted 
of cefotaxime, ceftazidime, and metronidazole intravenously, which was changed 
to high dose cotrimoxazole (TMP-SMX, 1920 mg t.i.d. intravenously) as soon as the 
culture results became available. Additional susceptibility testing revealed the strain 
to be susceptible for the prescribed antibiotics. Despite this treatment, the patient’s 
headache worsened and after two weeks of admission he developed neck stiffness 
related to the exudation of the left abscess into the left ventricle. In addition, after 
an initial decrease in size (Figure 1, Panel B), subsequent sequential MRI’s showed no 
further reduction in size of the lesions and surrounding edema (Figure 1, Panel C and 
D). Meropenem treatment was added at day 47 of admission after urine cultures 
became positive for multi-resistant Escherichia coli.
Figure 1. Studies of the largest right paraventricular brainlesion by magnetic resonance 
imaging (MRI). Panel A shows a T1-weighted contrast enhanced hyperintense MRI image of the 
right brain lesion at admission on January 12th 2012 (sized 25x22x20 mm, with extensive surrounding 
edema). Culture guided inital treatment with cotrimoxazol resulted in an initial decrease in size and 
reduction of edema (Panel B; size of lesion: 17x15x17 mm). However, subsequent imaging showed 
little to no further reduction of the abscess (Panel C; size of lesion: 15x13x19 mm, and D; size of 
lesion: 16x13x19 mm). Therefore, adjunctive immunotherapy with IFN-γ treatment was initiated at 
March 6th. MRI performed 12 days later showed a decrease of the right paraventricular lesion (Panel 
E: 12x13x17mm). Further ameliorating of MRI images was observered three weeks later (Panel F; 
size of lesion:12x9x12 mm). All images are published with permission of legal representative.
128 129
6
blood withdrawal, additional blood was collected to analyze immune responses 
before and during IFN-γ treatment (see online supplement for methods of blood 
sampling and cytokine assays). Before IFN-γ treatment, the capacity of peripheral 
blood mononuclear cells (PBMCs) to produce cytokines upon ex vivo stimulation 
with Candida albicans, lipopolysaccharide (LPS), and phytohaemagglutinin (PHA) 
was severely blunted (Figure 2, Panel A to F). IFN-γ treatment was associated with 
an increased production of Interleukin (IL)-1β, Tumor Necrosis Factor (TNF)-α, IL-
6, and IL-10 by PBMCs stimulated with all three stimuli (Figure 2, Panel A to D). C. 
albicans–induced ex-vivo production of the T-helper 17 (Th17) cytokines IL-17 and 
IL-22, was also increased, although to a lesser extent (Figure 2, Panel E and F).
DISCUSSION
In this case report we describe that adjunctive immunotherapy with IFN-γ can 
result in augmentation of the innate immune response in a patient with progressive 
Nocardia abscesses, and very likely contributed to clinical recovery. 
Patients with impaired cell-mediated immunity (including hematopoietic stem cell 
transplant patients and patients receiving long-term treatment with steroids) have 
a particularly high risk to develop opportunistic infections, including nocardiosis 
(1). Immunotherapy to improve cell-mediated immunity is therefore a promising 
therapy to improve outcome in these patients. It has previously been demonstrated 
that IFN-γ has favorable effects on outcome of sepsis patients who exhibit clear signs 
of suppression of cellular immune responses, which renders them more vulnerable 
to opportunistic infections (4). In addition, IFN-γ restored the suppressed cytokine 
production in vivo in humans in an experimental sepsis model (4), and in patients 
with severe invasive fungal infections (7). Furthermore, IFN-γ has a beneficial effect 
on the outcome of opportunistic infections in immunocompromised patients with 
HIV (5), or leukemia (6). However, whether IFN-γ restored the impaired cellular 
immune responses in these patients was not investigated. In the present study, 
we demonstrate that IFN-γ improved cellular immune responses in a patient with 
cerebral nocardiosis, and this correlated with improvement of the clinical outcome. 
Immunological analysis
Besides corticosteroid use, personal and family history was negative for immune 
deficiencies. However, additional testing revealed a CD4 lymphopenia (140 cells/
mm3) in the absence of HIV infection. This may be related to the steroid treatment, 
but a primary cause cannot be excluded. Together with routine clinical 
Figure 2. Cytokine production by PBMC’s ex vivo stimulated with different stimuli before and 
during IFN-γ treatment. IL, interleukin; TNF, tumor necrosis factor; LPS, lipopolysaccharide; PHA, 
Phytohaemagglutinin; IFN, Interferon. 
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CONCLUSION
Optimal antimicrobial treatment in patients with nocardiosis should be 
individualized according to species identification, resistance profile, and CNS 
penetration capacity of the antimicrobial agent used. In patients with intracerebral 
Nocardia abscesses who deteriorate despite optimal antimicrobial treatment, 
immunotherapy with IFN-γ could be considered as adjuvant salvage therapy. 
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Taking into account all available human data, consisting of retrospective studies 
and small case series, but not of randomized clinical trials, the most appropriate 
therapeutic agent and treatment duration for Nocardia infections remains to be 
established. Therapeutic recommendations are therefore based on the results of basic 
research, animal models, and clinical expert opinions (2, 9). In patients with central 
nervous system (CNS) involvement, treatment options include antimicrobial therapy 
alone, freehand or stereotactic aspiration, or craniotomy plus enucleation, in addition 
to antimicrobial therapy. With different Nocardia spp. having different resistance 
profiles, species identification is crucial to determine the most suitable antibiotic 
treatment (10). Obviously, in case of CNS involvement, therapy should include drugs 
with favorable penetration into the CNS (e.g., TMP-SMX and ceftriaxone). 
In our patient, meropenem instead of ceftriaxon was started next to TMP-
SMX, because of additional presence of multiresistant E. coli in urine cultures. 
Meropenem is also active against most Nocardia spp., and can pass the blood-
brain barrier. Despite appropriate combination therapy against Nocardia spp., 
his condition deteriorated. The compromised status of the immune response 
reflected by the impaired ex-vivo cytokine responses may at least in part explain his 
deterioration, and may also be responsible for the high mortality among patients 
with nocardiosis. The immunocompromised status may have thus represented 
an important compromising factor, which was improved by IFN-γ treatment. 
However, in the current case, the purulent ventricular involvement could also 
account for the lack of clinical recovery. Based on the course of the symptoms, 
the intraventricular administration of amikacin was probably also an important 
contributing factor in the clinical recovery. Unfortunately, three weeks after the 
patient recovered and was discharged, he died of complications of end-stage 
interstitial pneumonitis not related to Nocardia infection. 
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ONLINE SUPPLEMENT 
METHODS
Blood sampling
Together with routine blood sampling, additional blood was drawn to analyse 
immune responses. Specimens were collected at baseline (day 0) and at several 
timepoints after start IFN-γ immunotherapy (days 1, 2, 7 and 14). 
Cytokine assays
Venous blood was drawn into 10 mL EDTA tubes, after which peripheral blood 
mononuclear cells (PBMCs) were isolated. In short, blood was diluted in phosphate 
buffered saline (PBS) (1:1) and fractions were separated by Ficoll (Ficoll-Paque 
Plus, GE healthcare, Zeist, The Netherlands) density gradient centrifugation. Cells 
were washed twice with PBS and resuspended in RPMI-1640+ (RPMI-1640 dutch 
modification supplemented with 10µg/mL gentamicin, 10mM L-glutamine, and 
10mM pyruvate) (Gibco, Invitrogen, Breda, The Netherlands). The PBMCs were 
counted using a particle counter (Beckmann Coulter, Woerden, The Netherlands) 
and were plated in 96 well round-bottom plates (Corning, NY, USA) at a final con-
centration of 2,5x106/mL, in a total volume of 200 µL. The PBMCs were stimulated 
for 24 hours, 48 hours, and 7 days with medium alone, or medium containing E. 
coli lipopolysaccharide (LPS; 10 ng/mL), phytohaemaglutinnin (PHA; 10μg/ml), or 
heat-inactivated Candida albicans blastoconidia (1x106/ml). After stimulation, cell 
culture supernatant was collected and stored at -20°C. 7 day cultures were sup-
plemented with 10% human pooled serum.
After all samples were collected, cytokines were measured using commercially 
available ELISAs (R&D Systems, MN, USA and Sanquin, Amsterdam, The 
Netherlands) according to the protocols supplied by the manufacturer. Interleukin 
(IL)-1β, Tumor Necrosis Factor (TNF)-α, and IL-6 were measured in culture 
supernatants of 24 hour cultures, IFN-γ and IL-10 were measured in culture 
supernatants of 48 hour cultures, and IL-17 and IL-22 were measured in culture 
supernatants of 7 day cultures.
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INTRODUCTION
Sepsis is a clinical condition that represents a major medical challenge due to its 
high mortality rate. Related to this, it is a major clinical challenge also because it 
may be difficult to diagnose in due time, and difficult to treat. Previous adjunctive 
therapeutic strategies, aiming to treat sepsis by inhibition of pro-inflammatory 
mediators have failed, likely related to the recent insight that the majority of septic 
patients do not succumb to the initial pro-inflammatory “hit”, but die at a later 
time-point in a pronounced immunosuppressive state [1-3]. This so-called ‘sepsis-
induced immunoparalysis’ results from counter-regulatory anti-inflammatory 
pathways that are activated simultaneously with pro-inflammatory mechanisms 
[2-4]. This renders patients unable to clear the initial infection and increased 
vulnerable to secondary infections [2, 3, 5]. As a consequence, reconstitution of 
immunocompetence is emerging as a new and promising therapeutic target to 
improve outcome in sepsis patients [2, 3, 6, 7].
Bacille Calmette-Guérin (BCG) is the most widely used vaccine worldwide. 
In addition to protection against tuberculosis [8], both observational studies 
and randomized clinical trials have shown that BCG vaccination is associated 
with beneficial effects on other infectious diseases as well. In this regard, early 
administration of BCG vaccination leads to strongly reduced infant mortality, 
mainly as a result of lower incidence of neonatal sepsis, respiratory infection, and 
fever [9-15]. These non-specific effects of BCG are suggested to be mediated by 
two mechanisms: potentiation of adaptive immune responses against unrelated 
pathogens, so-called ‘heterologous immunity’[16], and epigenetic functional 
reprogramming of innate immune cells to an enhanced phenotype, a process 
described as ‘trained immunity’ [17-20]. The latter process is characterized by 
enhanced production of pro-inflammatory cytokines by monocytes that have 
been previously primed by BCG, and is apparent upon stimulation with either 
specific or unrelated pathogens [17, 21]. In line with this, mononuclear cells 
isolated from healthy volunteers and stimulated with unrelated pathogens show 
enhanced innate immune responses after BCG-vaccination [17], and some of 
these effects even persist for up to one year [21]. These effects largely rely on 
ABSTRACT
Bacille Calmette-Guérin (BCG) vaccine exerts non-specific immunostimulatory 
effects, and may therefore represent a novel therapeutic option to treat sepsis-
induced immunoparalysis. We investigated whether BCG vaccination modulates 
the systemic innate immune response in humans in vivo during experimental 
endotoxemia. We used inactivated gamma-irradiated BCG vaccine because of the 
potential risk of disseminated disease with the live vaccine in immunoparalyzed 
patients. In a randomized double blind placebo-controlled study, healthy male 
volunteers were vaccinated with gamma-irradiated BCG (n=10) or placebo 
(n=10) and received 1 ng/kg lipopolysaccharide (LPS) intravenously on day 5 after 
vaccination to assess the in-vivo immune response. Peripheral blood mononuclear 
cells were stimulated with various related and unrelated pathogens 5, 8 to 10, 
and 25 to 35 days after vaccination to assess ex-vivo immune responses. BCG 
vaccination resulted in a scar in 90% of vaccinated subjects. LPS administration 
elicited a profound systemic immune response, characterized by increased levels 
of pro-and anti-inflammatory cytokines, hemodynamic changes, and flu-like 
symptoms. However, BCG neither modulated this in-vivo immune response, 
nor ex-vivo leukocyte responses at any time-point. In conclusion, gamma-
irradiated BCG is unlikely to represent an effective treatment option to restore 
immunocompetence in patients with sepsis-induced immunoparalysis.
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criteria were febrile illness during the 2 weeks before start of the study, prior 
BCG-vaccination, any vaccination other than BCG within 3 months before start 
of the study, and a tuberculin skin test within 1 year prior to the start of the study. 
Throughout the study period, subjects were not allowed to take any drugs, 
including acetaminophen, and were asked to refrain from alcohol and caffeine 24 
hours, and from food 12 hours before the start of the endotoxemia experiment. All 
study procedures were conducted in accordance with the declaration of Helsinki 
including current revisions and Good Clinical Practice guidelines. 
Study design and procedures
We performed a randomized double-blind placebo-controlled study. The 
study design is schematically depicted in Figure 1. For reasons detailed in the 
introduction, gamma-irradiated (and therefore inactivated) BCG vaccine was used 
in this study. Irradiated BCG was cultured for 6 weeks using Mycobacteria Growth 
Indicator Tubes according to Dutch national guidelines to confirm inactivation, 
and no growth was observed. Subjects were randomly assigned to receive either 
0.075 mg (0.1 ml) gamma-irradiated BCG-vaccine intracutaneously (BCG-vaccine 
SSI; Statens Serum Institut, gamma-irradiation [25-30 kGy] performed by Synergy 
Health Ede, The Netherlands; n = 10) or 0.1 ml placebo (BCG-reconstitution fluid: 
diluted Sauton 1+3; Statens Serum Institut; n = 10) in a double-blind fashion. 
Five days after vaccination, all subjects received an intravenous injection of 
LPS (lipopolysaccharide derived from Escherichia coli O:113, Clinical Center 
Reference Endotoxin, National Institutes of Health [NIH], Bethesda, MD), 1 ng/
kg. Endotoxemia experiments were conducted as described previously [24]. Heart 
rate (three-lead electrocardiogram), blood pressure, respiratory rate, and oxygen 
saturation (pulse oximetry) data were recorded from a Philips MP50 patient monitor 
every 30 seconds by a custom in-house–developed data recording system. LPS-
induced flu-like symptoms (headache, nausea, shivering, muscle and back pain) 
were scored every 30 min on a six-point Likert scale (0 = no symptoms, 5 = worst 
ever experienced), resulting in a total score of 0–25 points. After the endotoxemia 
experiment, additional blood samples were drawn on days 8-10 and days 25-30 
after vaccination. During the last visit, BCG scar formation was measured by an 
independent research nurse (to maintain blinding) using a centimeter ruler. 
innate immune cells, as BCG vaccination enhances resistance against Candida 
infection and increased lipopolysaccharide (LPS)-induced cytokine production in 
splenocytes of mice lacking T- and B-cells [17].
Considering its potentiating effects on host defense, BCG could represent 
a therapeutic option to prevent or treat sepsis-induced immunoparalysis. 
Nevertheless, as patients with sepsis have an increased susceptibility to secondary 
infections, vaccination with live BCG may be associated with unwarranted 
risks for dissemination [22]. As recent data showed that gamma-irradiated 
BCG has similar potentiating effects on trained immunity in vitro (Arts et al, 
submitted), but does not present any risk for infection, this inactivated form of 
BCG represents a clinically relevant alternative in these patients. However, the 
effects of BCG vaccination on the immune response in humans have hitherto only 
been shown ex vivo [17, 21]. It has yet to be established whether these findings 
can be extrapolated to the human in-vivo situation, because ex-vivo data might 
not always reflect in-vivo responses [23, 24]. The human endotoxemia model, in 
which healthy volunteers are administered a low dose of LPS, represents a unique 
model to study modulation of the systemic inflammation in humans in vivo in a 
safe, highly standardized, and reproducible manner [25].
The aim of the present study was to investigate the effects of vaccination with 
gamma-irradiated BCG on the systemic innate immune response in adult males in 
vivo during experimental endotoxemia. 
METHODS
Subjects
After approval from the Arnhem-Nijmegen Ethics Committee, 20 healthy 
non-smoking male volunteers gave written informed consent to participate in 
this study that was registered at ClinicalTrials.gov as NCT02085590. Subjects 
were screened before the start of the experiment and had a normal physical 
examination, electrocardiography, and routine laboratory values. Exclusion 
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Mycobacterium tuberculosis (MTB) (1 μg/ml end protein concentration, strain H37Rv), 
Escherichia coli lipopolysaccharide (LPS; 1 ng/ml; Sigma-Aldrich, St. Louis, Mo., USA), 
heat-killed Staphylococcus aureus (1 x 106 microorganisms/ml, clinical isolate), or 
heat-killed Candida albicans (1 x 106 microorganisms/ml, strain UC820). After 24h (for 
determination of TNF-α, IL-1β, and IL-6) or 48h (for determination of IFN-γ and IL-10) 
of incubation, plates were centrifuged and supernatants were stored at -20°C until 
analysis. Cytokines were measured batch-wise using commercially available ELISAs 
(R&D Systems, MN, USA and Sanquin, Amsterdam, The Netherlands) according to 
the protocols supplied by the manufacturers. 
Calculations and Statistical Analysis
Data are represented as median and interquartile range or mean and SEM, based 
on their distribution (calculated by the Shapiro–Wilk test). The area under the 
curve (AUC) of cytokine levels during experimental endotoxemia, representing 
an integrated measure of the cytokine response, was calculated using time 
points 0-8 hours post-LPS. Comparisons were made using Mann-Whitney U 
tests (non-normally distributed data, between-group comparisons) or repeated 
measures two-way ANOVA (normally distributed data, where the time factor 
represents differences across both groups over time and the interaction factor 
represents between-group differences over time). Ex-vivo cytokine data were 
log-transformed to obtain a normal distribution. A P-value < 0.05 was considered 
statistically significant. Calculations and statistical analyses were performed using 
Graphpad Prism version 5.0 (Graphpad Software, San Diego, CA, USA).
RESULTS
Baseline characteristics
No differences in baseline characteristics between both groups were present 
(Table 1). Gamma-irradiated BCG vaccination resulted in a scar at the vaccination 
site in 9 out 10 subjects (median [range] size of 6 [1-9] mm). In the placebo group, 
1 subject developed a small scar (1 mm). BCG vaccination did not result in fever or 
other clinical symptoms and no serious adverse events occurred during the trial.
Figure 1. Experimental design. BCG: Bacille Calmette-Guérin; LPS: lipopolysaccharide
Cytokine Measurements
To analyze plasma cytokines, ethylenediaminetetraacetic acid (EDTA) 
anticoagulated blood was centrifuged at 2,000 x g at 4°C for 10 minutes immediately 
after withdrawal, and plasma was stored at -80°C until analysis. Concentrations of 
TNF-α, IL-6, IL-8, IL-10, IL-1β, IL-1 receptor antagonist (IL-1ra), MCP-1, and IFN-γ 
were measured in plasma batch-wise using a Luminex assay according to the 
manufacturer’s instructions (Milliplex; Millpore, Billerica, MA, USA). 
Leukocyte counts and differentiation
Analysis of leukocyte counts and differentiation was performed in EDTA 
anticoagulated blood using routine analysis methods also used for patient samples 
(flow cytometric analysis on a Sysmex XE-5000).
Peripheral mononuclear cell stimulation assays
The mononuclear cell fraction was isolated by density centrifugation of EDTA 
anticoagulated blood, diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia 
Biotech, Uppsala, Sweden). Isolated cells were washed twice in saline and resuspended 
in culture medium (RPMI, Invitrogen, Carlsbad, California, USA) supplemented with 
10 μg/ml gentamicin, 10 mM L-glutamine and 10 mM pyruvate. Cell counts were 
performed in a Coulter counter (Coulter Electronics). A total of 5 x 105 mononuclear cells 
in 100 μl were added to round-bottomed 96-well plates (Greiner) with RPMI, sonicated 
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very low levels (approximately 10 pg/mL) were found, but no clear patterns over 
time or differences between groups were observed.
As described earlier, scar size differed substantially between BCG-vaccinated 
subjects, which might represent vaccination efficacy, and is associated with non-
specific beneficial effects of BCG [27, 28]. Therefore, we stratified the BCG-vaccinated 
group according to scar size (≤5 mm, n=5; >5 mm, n=5). These stratified analyses did 
not reveal notable differences in cytokine responses either (supplementary Figure 1). 
 After LPS administration, transient leukocytosis developed, reaching maximum 
levels at T=8 hours, with no differences between groups (mean ± SEM of BCG and 
placebo groups, respectively: 10.2 ± 0.7 vs. 9.7 ± 0.7 X 109/L, p=0.62). At the first visit after 
the endotoxemia day (day 8-10), leukocyte numbers were normalized in both groups 
(5.2 ± 0.4 vs. 5.7 ± 0.6 X 109/L in the BCG and placebo groups, respectively, p=0.50). 
Cytokine production by peripheral blood mononuclear cells 
Five days after vaccination with BCG or placebo, but before LPS administration 
in vivo, there were no differences between groups in ex-vivo cytokine responses 
induced by specific (Mycobacterium tuberculosis) or unrelated (LPS, Staphylococcus 
aureus, and Candica albicans) pathogens or stimuli (fold change data [compared 
with baseline] of IFN-γ, TNF-α, and IL-1β are depicted in Figure 4, and fold change 
data of IL-6 and IL-10 in supplementary Figure 2. Absolute values of all cytokines are 
depicted in supplementary Figure 3). Similar to previous endotoxemia experiments 
[24, 29], four hours after LPS administration, an overall profound decrease in 
ex-vivo cytokine production was observed, indicative of immunoparalysis. BCG 
vaccination did not influence the development or magnitude of immunoparalysis. 
Likewise, no differences between groups in ex-vivo cytokine responses to any of 
the pathogens or stimuli were found on days 8-10 and 25-35 after vaccination. 
Of note, LPS-induced production of IFN-γ, as well as LPS- and Mycobacterium 
tuberculosis-induced production of IL-10, was absent in many subjects and very 
low in others. Therefore, the endotoxemia-induced decrease in ex-vivo cytokine 
production was less noticeable and did not always reach statistical significance 
for these combinations. Staphylococcus aureus- and Candica albicans-induced IL-
10 production was absent in virtually all subjects and was therefore not analyzed. 
Table 1. Baseline characteristics
Placebo (n=10) Gamma-irradiated BCG (n=10) P-value
Age, y 20.0 (19.0-24.3) 20.5 (19.8-22.0) 0.82 
Height , cm 183.0 (178.3-193.0) 183.5 (178.8-189.8) 0.91 
Weight, kg 80.8 (70.3-83.5) 78.9 (76.4-93.4) 0.58 
BMI, kg/m2 22.7 (21.5-24.7) 24.2 (23.1-25.8) 0.09 
Heart rate, bpm 66.0 (59.0-76.3) 70.0 (64.8-82.0) 0.30 
MAP, mmHg 97.0 (95.0—103.8) 93.0 (89.5-99.3) 0.14 
BCG: Bacille Calmette-Guérin; BMI: Body Mass Index; MAP: Mean Arterial Pressure 
Data are represented as median (interquartile range). P-values calculated using Mann-Whitney U tests. 
Hemodynamic parameters and symptoms
LPS administration resulted in a typical increase in heart rate and flu-like 
symptoms, and a decrease in mean arterial blood pressure (MAP) in all subjects, 
with no differences between groups (Figure 2). 
Figure 2. Blood pressure, heart rate, and symptoms during experimental endotoxemia in subjects 
vaccinated with gamma-irradiated BCG or placebo. Data are expressed as mean±SEM (n=10 per 
group). P values calculated using repeated measures two-way analysis of variance (ANOVA, time 
and interaction terms). MAP: mean arterial pressure; HR: heart rate; bpm: beats/min. 
Plasma cytokines and circulating leukocyte counts
BCG-vaccination did not result in increased plasma levels of any of the measured 
cytokines in the days following vaccination (Figure 3). As expected, administration 
of LPS resulted in a sharp increase in plasma levels of the pro-inflammatory 
cytokines TNF-α, IL-6, IL-8 and MCP-1, as well as the anti-inflammatory cytokines 
IL-10 and IL-1RA (Figure 3). However, no differences were observed between the 
BCG and placebo groups. Similar to previous human endotoxemia studies [26], 
plasma levels of IL-1β and IFN-γ were below the lower detection limits in the 
majority of the subjects at most time points. In some subjects and/or time-points, 
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Figure 3. Plasma cytokine concentrations in subjects vaccinated with gamma-irradiated BCG or 
placebo. In the panels A-D, median values of pro-inflammatory cytokines TNF-α, IL-6, IL-8, and MCP-
1 are depicted while in panels E and F median values of anti-inflammatory cytokines IL-10 and IL-1RA 
are shown (n=10 per group). Panels G-L depict median ± interquartile range of area under curve (AUC) 
the respective cytokines (n=10 per group). P values calculated using Mann-Whitney U-tests.
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or abrogated the “training capacity” of BCG. While live vaccines can replicate and/or 
disseminate in the host’s body and thereby trigger the immune response to a greater 
extent, inactivated vaccines only activate immune responses locally [30]. Although 
the scar formation in gamma-irradiated BCG-vaccinated subjects indicates a local 
immune response, it could be envisioned that possible training effects of gamma-
irradiated BCG are much less sustained and widespread, and thus less pronounced. 
Along these lines, it was demonstrated that two and four weeks after vaccination 
with live BCG, 83 and 50% of individuals still displayed viable BCG at the vaccination 
site [31], respectively, indicative of a relatively long-lasting “active infectious pool” of 
bacteria (or their products) and/or cytokines that trigger a variety of responses. This 
is likely not relevant for the in-vitro situation, where cells are continuously exposed to 
bacteria and/or their products irrespective of whether they are alive or inactivated. 
Also, others have shown that viable bacteria elicit more potent immune responses 
compared to killed bacteria, due to recognition of so called ‘vita-PAMPs’ such as 
prokaryotic mRNA by innate immune cells [32]. The absent effects of gamma-
irradiated BCG on ex-vivo cytokine responses to stimulation with M. tuberculosis 
further substantiate the hypothesis that gamma-irradiation results in functional 
inactivation of BCG, resulting not only in abrogation of trained immunity but also of 
“classic” specific protection against M. tuberculosis.
 Secondly, the timing of the interventions in our study might have precluded 
effects of gamma-irradiated BCG. We chose to assess in-vivo and ex-vivo responses 
already five days after vaccination, in order to assess potential short-term effects 
that may be most relevant during sepsis. We hypothesized that this period would 
be sufficient to induce trained immunity based on the fact that in-vitro training by 
BCG only takes one day and that non-specific beneficial effects of BCG-vaccination 
in neonates were already apparent within 3 days [15]. Nevertheless, in previous 
studies enhancing effects of BCG on leukocytes were found 2 weeks, 3 months, 
and one year after vaccination [17, 21]. No earlier time-points were assessed in 
these earlier studies. 
 Thirdly, we only included young male volunteers in this study. There are 
considerable differences in the cytokine response to LPS between males and 
females [33]. This is likely influenced by menstrual cycle-related hormonal 
variations that can affect the immune response. Because we wanted our study 
DISCUSSION
In the present study, we demonstrate that gamma-irradiated BCG vaccination 
does not influence the LPS-induced innate immune response in adult males 
in vivo five days later. Furthermore, no effects of BCG vaccination on cytokine 
production of leukocytes stimulated ex vivo with specific and unrelated 
pathogens were observed. 
As all measured parameters were similar between groups, we can conclude that 
five days after vaccination, gamma-irradiated BCG has no effect on the innate 
immune system and therefore does not induce trained immunity. This is evident 
from both the lack of an effect on LPS-induced plasma cytokine levels in vivo, as 
well as from the similar ex-vivo innate cytokine responses (TNF-α, IL-1β, IL-6, and 
IL-10) against unrelated pathogens five days after vaccination in both groups. 
Previous epidemiological studies have shown that scar formation after vaccinia or 
BCG vaccination is associated with improved survival, possibly related to improved 
resistance against infections [27, 28]. Therefore, we stratified subjects based on 
scar size, but no effects were found in these analyses either. Furthermore, no 
effects indicative of trained immunity induction were found at later time-points, 
ranging from 8-10 days to 25-35 days after vaccination. 
Our results are different from previous studies that used the live attenuated BCG 
vaccine [17, 21] instead of the gamma-irradiated BCG. There are several reasons 
and/or limitations of the present study that might explain these differences. First 
and foremost, we used gamma-irradiated BCG in the present study because our 
target treatment population consists of immunoparalyzed septic patients who 
may be at risk for disseminated mycobacterial infection [22]. We hypothesized that 
gamma-irradiated BCG would be effective in inducing trained immunity in vivo 
because recent unpublished data of our group showed that gamma-irradiated BCG 
exerts monocyte training in vitro. Furthermore, previous in-vitro studies showed that 
monocytes could be trained with live BCG, as well as with the inert NOD2 ligand 
MDP [17], highlighting that live BCG persistence is not mandatory for inducing 
trained immunity in vitro. Nevertheless, inactivating the vaccine could have reduced 
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CONCLUSIONS
Gamma -irradiated BCG does not modulate the in-vivo innate immune response 
in adult male volunteers five days after vaccination. Furthermore, vaccination did 
not induce trained immunity ex vivo. Therefore, gamma-irradiated BCG is unlikely 
to represent a viable treatment option to restore immunocompetence in patients 
with sepsis-induced immunoparalysis. 
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population to be as homogenous as possible, we therefore included only males, 
analogous to virtually all of our previous endotoxemia studies. This might have 
biased our results, because the majority of the studies on non-specific effect of the 
BCG vaccine point to important sex-differential non-specific effects, and often the 
most pronounced effects were observed among females [12, 34, 35]. Non-specific 
effects may also vary with age, nevertheless, live BCG exerted profound effects in 
a similarly aged study population [17, 21].
 Fourthly, possible training effects of gamma-irradiated BCG on monocytes 
in the long-term might have been obscured by the LPS administration five days 
after vaccination. BCG-induced trained immunity has been shown to be mediated 
through epigenetic reprogramming of monocytes [17]. Interestingly, exposure to 
LPS results in opposite epigenetic changes in monocytes and/or macrophages 
[20]. Therefore, possible training effects induced by gamma-irradiated BCG might 
have been nullified by the LPS administration. 
 Fifthly, the human endotoxemia model employed in this study is relatively 
mild and does not replicate the severe sepsis-induced immunoparalysis 
observed in actual patients. Therefore, although unlikely based on the complete 
absence of effects in the present study, we cannot exclude the possibility that 
gamma-irradiated BCG exerts immunomodulatory effects in a true model of 
immunoparalysis or in immunoparalyzed septic patients.
 Finally, our study is limited by the fact that, apart from medical history, we did 
not screen for previous exposure to Mycobacterium tuberculosis. We chose not to 
perform a tuberculin skin test since this could trigger trained immunity effects on 
its own which would confound our study results. However, the infectious pressure 
of tuberculosis in the Netherlands is very low [36], and this possibility is unlikely to 
explain the absent effects of gamma-irradiated BCG.
In view of the points raised above, a study using live BCG and possibly other 
timing of the interventions could be considered. While such as study would 
be warranted to elucidate the mechanisms behind the important nonspecific 
beneficial effects of BCG vaccination in neonates [9-15], it may be less relevant 
with regard to sepsis patients, in which the use of live BCG vaccine would be 
associated with too high risks.
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Supplementary Figure 3. Production of IFN-gamma, TNF-α, IL-1β, IL-6, and IL-10 by peripheral 
blood mononuclear cells stimulated ex vivo with Mycobacterium tuberculosis (MTB), LPS, 
Staphylococcus aureus (SA), and Candica albicans (CA) of subjects vaccinated with gamma-irradiated 
BCG or placebo. Data expressed as median and interquartile range (n=10 per group). Day 6 was the 
endotoxemia experiment day. For statistical analyses, see Figures 4 and supplementary Figure 2, 
which depict the same data expressed as fold change compared with day 1.
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INTRODUCTION
Annually, influenza virus infection leads to millions of cases of severe illness 
worldwide and up to an estimated 500.000 deaths (1). The potential for the sudden 
emergence of pandemic influenza strains represents an incessant threat on even a 
larger scale: it is estimated that if a strain with similar virulence to the 1918 ‘Spanish 
flu’ emerged today, it could kill between 50 and 80 million people (2). With very few 
therapeutic options available, seasonal vaccination is the backbone of influenza 
management. High-affinity antibodies play a key-role in the protective immune 
response against influenza virus infection (3). However, antibodies generated by 
vaccination most often do not effectively neutralize emergent strains due to the 
high mutation rate of the influenza viral genome (4). In addition, vaccination is not 
always effective, as 85% of healthy adults and only 40-60% of elderly people mount 
a protective antibody response, due to original antigenic sin (5), and an age-related 
decline in immune function (a process called immunoscenescence) (6). As a result, 
particularly in high-risk groups, the protective effects of influenza vaccination are 
limited, and strategies to improve host immune defences against influenza virus 
infection and the response to influenza vaccination are highly warranted (7).
In addition to protection against tuberculosis (TB), vaccination with Bacille Calmette-
Guérin (BCG) provides protection against other infectious diseases (8). Murine 
studies have shown that vaccination with BCG results in protection not only against 
secondary infections with Candida albicans (9), Schistosoma mansoni (10), but 
also against influenza virus (11). Moreover, non-specific beneficial effects of BCG-
vaccination on mortality of young children were demonstrated in observational 
studies (12), and several randomized studies demonstrated reduced overall mortality 
in BCG-vaccinated neonates, which could not be explained by TB prevention (13, 
14). The underlying immunologic mechanisms responsible for the non-specific 
effects of BCG are currently being unravelled, and they may be mediated by both 
induction of trained innate immunity and heterologous adaptive immune responses. 
Assessment of trained immunity in BCG-vaccinated individuals has recently shown 
that monocytes undergo epigenetic reprogramming towards an enhanced pro-
inflammatory phenotype (15, 16). This results in increased production of pro-
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Study design 
The design of this placebo-controlled randomized trial is depicted in Figure 
1. Briefly, subjects were randomized using the sealed envelope method to 
receive intradermal injections of either 0.1 ml of live attenuated BCG vaccine 
(BCG-vaccin SSI/Danish strain 1331; Bilthoven Biologicals, Bilthoven, the 
Netherlands; n=20) or placebo (NaCl 0.9%; n=20), in a double-blinded fashion. 
Fourteen days later all subjects received an intra-muscular injection of 0.5 ml 
trivalent influenza vaccine season 2013-2014 (containing A/California/7/2009 
(pandemic H1N1, H1N1pdm09) derived strain, Victoria/361/2011 related strain 
derived from A/Texas/50/2012 (A/H3N2/2012), and B/Massachusets/2/2012 
(B/2012) derived strain surface antigens, and no adjuvants; Batrevac; Abbot 
biologicals B.V., Weesp, the Netherlands). Adverse effects were recorded after 
day 0, and antibody titres and cytokine production capacity were assessed 
before BCG vaccination (day -14), before influenza vaccination (day 0) and 
7, 14, and 28 days after influenza vaccination. The primary study endpoint 
was the difference in HI antibody titres over time after influenza vaccination. 
Secondary endpoints were the proportion of participants in each group who 
achieve seroconversion (defined by a ≥4-fold rise in antibody titre) over time 
after influenza vaccination, and cytokine responses of leukocytes ex-vivo 
stimulated with various influenza-related and unrelated stimuli over time after 
BCG vaccination. 
Hemagglutination inhibition (HI) assay
HI assays were performed according to standard procedures which are detailed 
in the Online Supplement. Every sample was run in duplicate and Geometric 
Mean Titres were determined by calculating the mean of the log-transformed 
duplicate titres followed by back-transformation (10x, where x equals mean 
log-transformed titre). Seroconversion was defined as ≥ 4-fold titre increase 
compared with baseline. Antibody titres were similar between day -14,(before 
BCG/placebo-vaccination) and day 0 (before influenza vaccination) within 
groups for all three vaccine strains in the placebo group, and for two vaccine 
strains in the BCG-group (a significant difference in the A/H3N2/2012 strain was 
found, see Supplementary Table S1). This variability could due to assay variation 
inflammatory cytokines, such as IFN-γ, TNF-α, and IL-1β upon ex vivo stimulation 
with unrelated pathogens, even up to one year after BCG vaccination (15, 16). 
As the nonspecific immunomodulatory effects of BCG vaccination increase 
the function of myeloid immune cells with antigen-presenting properties, 
we hypothesized that BCG vaccination could enhance immune responses 
to other vaccines in general, and to influenza vaccination in particular. In the 
present randomized trial, we investigated the effects of BCG-vaccination on the 
immunogenicity of a trivalent influenza vaccine in healthy volunteers.
MATERIALS AND METHODS
Subjects
This study was registered at ClinicalTrials.gov as NCT02114255. After approval 
from the Arnhem-Nijmegen Ethics Committee, 40 healthy, non-smoking, male 
volunteers gave written informed consent to participate in the study, which took 
place from May to July 2014. All experiments were conducted in accordance 
with the declaration of Helsinki. Subjects were screened before the start of the 
experiment and had a normal physical examination. Subjects who were vaccinated 
with BCG before, received influenza vaccination in the previous year, or had febrile 
illness during the two weeks before the experiment were excluded. Subjects were 
not allowed to use any prescription drugs.
BCG/Placebo 
vaccination
Influenza 
vaccination
HI antibody titers
Ex vivo stimulations
Screening
Demographics
Recording side-effects
X
Figure 1. A schematic representation of the study design. BCG, Bacille Calmette-Guérin; HI: 
Hemaglutination inhibition.
162 163
8
Table 1. Demographic characteristics
Placebo (n=20) BCG (n=20) P-value
Age (years) 20.5 [20.3-25] 21 [20-24] 0.35
Height (cm) 178 [175-188] 183 [180-190] 0.13
Weight (kg) 74.4 [66.2-82.8] 80.2 [72.3-93.4] 0.06
BMI (kg/m²) 22.3 [21.1-24.7] 24.5 [22.2-27.0] 0.08
Data are presented as median and interquartile range. P-values were calculated using Mann-Whitney U-tests. 
Table 2. Baseline (day 0) antibody titres
Placebo (n=20) BCG (n=20) P-value
A/H1N1/2009 132.7 [68.71-257.04] 42.31 [22.5-103.3] 0.13
A/H3N2/2012 66.4 [32.1-137.4] 115.9 [57.9-231.2] 0.33
B/2012 39.0 [20.5-74.3] 40.9 [20.9.78.0] 0.78
Data are presented as Geometric Mean Titres [95%CI]. P-values were calculated using Mann-Whitney U-tests.
RESULTS
Demographic characteristics and side effects
Baseline characteristics were similar in both groups (Table 1). No serious adverse 
events occurred during the study. None of the subjects in the placebo group and 10 
subjects in the BCG group reported a local inflammatory reaction at the injection 
site, which resolved in all cases within four weeks after injection. After influenza 
vaccination, six placebo-vaccinated subjects and six BCG-vaccinated subjects 
reported mild complaints (including fatigue, headache, malaise and muscle pain 
at the injection site), which resolved within two days after vaccination in all cases.
or from a non-specific boosting effect of BCG on plasma cells. We calculated 
relative increases in antibody titres compared to titres at day 0, just before 
influenza vaccination. 
Peripheral blood mononuclear cell stimulation and cytokine measurements
Venous blood was drawn into EDTA tubes, after which peripheral blood 
mononuclear cells (PBMCs) were isolated and stimulated with various stimuli, 
after which cytokines were determined in supernatants. A detailed description is 
provided in the Online Supplement. 
Statistical analyses
All data were not normally distributed (determined using Kolmogorov-Smirnov 
tests). Demographic data were analyzed using Mann-Whitney U tests. Differences 
between the two groups over time were calculated using Mann-Whitney U tests 
of Area Under the Curve (AUC) calculated from the fold-change data (to correct 
for baseline differences). Within-group differences in cytokine production over 
time were calculated using Friedman tests. Within-group differences in cytokine 
production between day 0 and day 14, and antibody titres between day -14 and 
day 0 were calculated using Wilcoxon matched-pairs tests. Stratified HI assay 
analysis according to baseline titers was based on routine dilutions used to 
assess HI titers. Finally, differences in seroconversion rate between groups over 
time were calculated using log-rank tests. A p-value of <0.05 was considered 
statistically significant. We calculated that, in order to be able to detect a two-
fold difference in H1N1 titre increase between the BCG and placebo groups with 
a power of 80%, an SD of 113% (17), and a two-sided alpha of 0.05, 20 subjects per 
group were needed. Calculations and statistical analyses were performed using 
Graphpad Prism version 5.0 (Graphpad Software, San Diego, CA, USA).
164 165
8
antibody titres revealed similar patterns compared with the overall analysis 
presented in Figure 2 (Supplementary Figures S1-S3). As expected, HI antibody 
responses induced by influenza vaccination were much more pronounced in 
subjects with low baseline antibody titres. Accordingly, subjects with high baseline 
antibody titres in both groups barely attained seroconversion defined by ≥4-fold 
increase from baseline. These data indicate that differences between groups were 
mainly based on responses of subjects with low baseline antibody titres. When 
subjects with high baseline antibody titres (set as the titre for which ≤ 25% of 
subjects in both groups attained seroconversion) were excluded, the potentiating 
effect of BCG vaccination on antibody responses against the H1N1pdm09 strain 
becamemore apparent (Supplementary Figure S4, panel A). In addition, atrend 
towards enhanced antibody responses against the influenza B strain in the BCG 
group also emerged when groups were stratified (Supplementary Figure S4, panel 
C), while antibody responses against the A/H3N2 strain remained similar between 
groups (Supplementary Figure S4, panel B).
Cytokine responses upon ex vivo stimulation of PBMCs with influenza-
related stimuli
There were no differences in baseline ex vivo cytokine responses between groups 
(data not shown). In both groups, the production of IFN-γ upon stimulation with 
influenza vaccine was enhanced after influenza vaccination (Figure 3, Panel A). 
Likewise, IFN-γ production upon stimulation with live influenza virus increased in 
both groups after vaccination, although this did not reach statistical significance in 
the placebo group (Figure 3, Panel B). No effect was observed on IFN-α production 
upon stimulation with influenza vaccine in both groups (Figure 3, Panel C), 
whereas production of this cytokine upon stimulation with live influenza virus was 
enhanced in both groups, although this did not reach statistical significance in 
the BCG group (Figure 3, Panel D). No significant differences between treatment 
groups were observed, apart from a trend towards enhanced and more sustained 
IFN-γ production upon stimulation with influenza vaccine in the BCG-group.
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Figure 2. HI antibody titres (left panels) and percentage seroconversion (right panels) over time 
for A/H1N1/2009, A/H3N2/2012, and B/2012 in subjects that were vaccinated with BCG or placebo 
followed by influenza vaccination. There were no baseline (day 0) differences between groups. Left 
panels: Baseline titres are plotted as 1, and subsequent time-points are plotted as fold change of 
baseline values. P-values were calculated using Mann-Whitney U tests on Area Under the Curve 
(AUC) of subjects in both groups. Right panels: Percentage of subjects that attain seroconversion 
(defined as ≥4-fold titre increase compared with baseline) over time. p-values were calculated using 
log-rank tests.
Influenza antibody titres
There were no baseline differences in antibody titres between groups for the three 
influenza strains (Table 2). In BCG-vaccinated subjects, HI antibody responses 
against the pandemic H1N1pdm09 vaccine strain was markedly enhanced 
compared with the placebo-treated group, and there is a trend towards more 
rapid seroconversion (Figure 2A). No significant differences between groups 
were observed regarding HI antibody response  again t the A/H3N2 and B 
vaccine strains (Figure 2, panels B and C). Stratified analyses according to bas line 
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in BCG-vaccinated subjects (Figure 4), while no effects were observed for the anti-
inflammatory cytokine IL-10 (data not shown). 
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Figure 4. Cytokine responses of PBMCs ex vivo stimulated with Mycobacterium tuberculosis 
(MTB). There were no baseline (day -14) differences between groups. Baseline responses are 
plotted as 1, and subsequent time-points are plotted as fold changes of baseline values. p-values 
were calculated using Mann-Whitney U tests of Area Under the Curve (AUC) of subjects in both 
groups. Changes in cytokine response between day -14 (before BCG/placebo vaccination) and day 
0 (before influenza vaccination) were calculated using Mann-Whitney U tests between two groups 
(p-values between brackets for those with p<0.05).
To investigate the effects of influenza vaccination on ex-vivo cytokine responses to 
unrelated pathogens, we assessed changes in cytokine responses within the pl o-
group between day 0 (before influenza vaccination) and day 14 (Figure 5, Panel A). 
Influenza vaccination on its own resulted in enhanced TNF-α and IL-6 production 
upon stimulation with LPS. Furthermore, upon stimulation with C. albicans, enhanced 
production of TNF-α and reduced production of IL-10 was observed. However, 
IFN-γ and IL-1β production were also decreased upon stimulation with C. albicans. 
Stimulation with S. aureus also resulted in reduced expression of IFN-γ, IL-1β, and IL-
10, which was also the case for IL-1β and IL-10 production upon stimulation with MTB.
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Figure 3. Cytokine responses of PBMCs ex vivo stimulated with live influenza virus and with 
trivalent influenza vaccine. There were no baseline (day -14 for live influenza stimulations and day 
0 for influenza vaccine stimulations) differences between groups. Baseline responses are plotted 
as 1, and subsequent time-points are plotted as fold changes of baseline values. Within-group 
differences in cytokine production over time were calculated using Friedman tests. P-values of 
differences between groups (BCG vs Placebo) were calculated using Mann-Whitney U tests of Area 
Under the Curve (AUC) of subjects in both groups.
Cytokine responses upon ex vivo stimulation of PBMCs with stimuli 
unrelated to influenza
There were no differences in baseline ex vivo cytokine responses between groups 
(data not shown). As expected, enhanced production of IFN-γ and IL-6was found 
upon stimulation with Mycobacterium tuberculosis (MTB) in BCG-vaccinated 
subjects compared with the placebo group (Figure 4). This enhanced cytokine 
production was already present at day 0 (just before influenza vaccination), 
thereby indicating that these effects are mediated by BCG. For MTB-induced 
TNF-α and IL-1β production a trend towards enhanced responses was observed 
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DISCUSSION
In the present study, we investigated the capacity of BCG vaccination to modulate 
the immune response to subsequent vaccination with a trivalent influenza vaccine. 
We demonstrate that BCG vaccination not only modulates innate immune 
responses upon ex-vivo stimulation with unrelated pathogens, as previously 
reported (15, 16), but also enhances functional antibody responses against 
the pandemic H1N1 2009 strain induced by subsequent influenza vaccination, 
reflected by a more pronounced increase in antibody titres and a trend towards a 
more rapid seroconversion. 
In addition to its effects on the severe clinical forms of tuberculosis, BCG 
vaccination also beneficially influences morbidity and mortality due to other 
infections (18). This is accompanied by non-specific stimulatory effects on the 
function of both myeloid and lymphoid cells (15, 19). These epidemiological 
and immunological data formed the basis of the hypothesis that BCG 
vaccination may also potentiate the function of antigen-presenting cells, and 
thus improve the response to other vaccines. This hypothesis is supported 
by the increase in the titres of neutralizing antibodies against the pandemic 
H1N1 2009 influenza strain, while a similar tendency was observed for the 
responses to an influenza B strain, especially in individuals with initial low 
antibody titres. A potentiating effect of BCG on the response to other vaccines 
is also supported by observational studies in infants, in which BCG increased 
heterologous responses to poliovirus vaccination (20), responses to anti-
pneumococcus, anti-Haemophilus type B and anti-tetanus toxoid vaccines 
(21), and responses to hepatitis B vaccine (22).
BCG vaccination influenced both humoral and cellular responses to influenza 
vaccination. The magnitude and quality of antigen-specific antibody titres is 
considered to be the primary correlate of protection against most pathogens/
viruses that infect the host through mucosal surfaces, such as influenza virus (23, 
24). The effects of BCG-vaccination on antibody responses to subsequent influenza 
vaccination observed in this study demonstrate that the immunological history 
Furthermore, we assessed how BCG vaccination modulates influenza 
vaccination-induced non-specific cytokine responses (Figure 5, Panel B). BCG 
vaccination potentiated the influenza vaccination-induced increase in TNF-α 
and IL-6 production upon LPS stimulation. Also, BCG enhanced production of 
IL-1β upon stimulation with LPS in the volunteers vaccinated with influenza 
vaccine. In accordance, the influenza vaccination-induced attenuation of IFN-γ 
and IL-1β production upon stimulation with C. albicans was less pronounced in 
BCG-vaccinated subjects, although the influenza vaccination-induced increase 
in TNF-α was also attenuated. Pro-inflammatory effects of BCG vaccination 
were also observed for ex-vivo stimulation with S. aureus: in BCG-vaccinated 
subjects the influenza vaccination-induced attenuation of IL-1β production 
was abrogated and production of IL-6 was enhanced. Finally, BCG vaccination 
resulted in abrogation of the influenza vaccination-induced attenuation of IL-1β 
upon stimulation with MTB, and resulted in enhanced production of TNF-α in 
response to this pathogen (Figure 5).
Figure 5. Spider plots of effects of influenza vaccination on cytokine responses of PBMCs ex vivo 
stimulated with influenza-unrelated pathogens in the placebo (panel A) and BCG (panel B) groups. 
Cytokine responses on day 0 (before influenza vaccination) are set as 0 (dashed lines) and cytokine 
responses 14 days later are plotted as fold change. Data are represented as median (solid lines) and 
interquartile range (hatched areas). * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001; 
calculated using Wilcoxon matched-pairs tests between responses at day 0 and those at day 14.
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be due to differences in cells responsible for the recall response caused by the 
different localization of the primary infection, but this remains to be demonstrated 
by future studies.
In addition to the effects of antibody titers, BCG-vaccination also modulated the 
effects on cytokine production capacity induced by the influenza vaccination. 
Interestingly, our data indicate that trivalent influenza vaccine exerts non-specific 
effects as well, although different from those observed following BCG vaccination 
(15). BCG-vaccination exerted an overall immunostimulatory effect on the cytokine 
production modulated by influenza vaccine. In contrast, influenza-vaccination 
results in enhanced responses against certain pathogens, but impaired responses 
against others. These findings are in support of the hypothesis that infectious/
vaccine history affects immune status in a clinically relevant manner. 
This study has several limitations. Firstly, the relatively small sample size could 
be a reason for a type 2 error, resulting in the fact that some of the effects 
observed did not reach statistical significance, most importantly the enhanced 
antibody production against the B/2012 strain in the BCG-vaccinated subjects 
when stratified according to baseline antibody titres. Nevertheless, the significant 
effects on antibody titres to the pandemic strain and the ex-vivo cytokine 
responses illustrate the extent to which BCG-vaccination impacts on unrelated 
adaptive and innate immune responses. Secondly, although BCG vaccination 
potentiated antibody responses, humoral immunity is not the only mechanism 
involved in the protection against influenza infection. Upon vaccination, not 
only an adequate antibody response, but also generation of specific memory 
cytotoxic T lymphocytes (CTLs) contributes to protection against influenza virus 
(29). It has even been suggested that in the elderly CTL immune responses are 
better predictors of immunity than antibody titres (30, 31). We only studied IFN-γ 
responses as a surrogate of T-cell function, and direct CTL assays could be also 
considered in future studies to understand how BCG affects the response to 
influenza vaccination. Finally, we based our 14-day interval between BCG and 
influenza vaccination on previous studies in mice, in which viral challenges were 
performed 14 to 49 days after BCG vaccination (11), and in humans, in whom non-
affects the humoral immune response to subsequent infections/vaccinations 
in a clinically relevant manner. Moreover, a trend towards enhanced and more 
sustained IFN-γ production upon ex-vivo stimulation with influenza vaccine was 
also observed in the BCG-vaccinated group. 
The percentage subjects who achieve a four-fold increase of baseline antibodies 
in this study is in line with the influenza vaccination-induced increase previously 
observed in healthy male volunteers (25). Not surprisingly, subjects with low 
baseline anti-influenza virus antibody titres displayed the strongest increase 
in antibody titres following influenza vaccination. Nevertheless, an increase in 
antibody titre was also observed in subjects with baseline antibody titres higher 
than 1:40 (26). Moreover, in these subjects, BCG-vaccination still exerted a 
potentiating effect on antibody responses. Earlier studies demonstrated that a 
progressive increase in protection is reached with increased titres, rather than that 
protection is attained above a discrete threshold that is applied to each individual 
(26). The increase in protection is particularly important for titres up to 1:160 (26), 
which applies to our study. 
The reason for the significant effects of BCG vaccination on the response to 
the pandemic H1N1 2009 influenza strain, but not to the H3N2 strain, remains 
unkown. Previous studies have reported differential effects of BCG on different 
antigens from the same vaccination as well (21), but no clear mechanism has been 
proposed. The absence of BCG-induced effects on H3N2 antibody titres (see also 
below), could be explained from an immunological point-of-view. Previous work 
has shown differences in the immunopathology caused by pandemic and seasonal 
strains, related to the strain virulence and the localization of the inflammatory 
response (27, 28). In this respect, infections with the pandemic H1N1 strain 
result in expression of viral antigens in mucosal epithelial cells of the airways 
(from the nasopharynx to the bronchioles), but also in alveolar macrophages, 
and pneumocytes (27, 28). In contrast, infections with the H3N2 strain show 
viral antigens primarily in mucosal epithelial cells of the larger airways (27, 28). 
It is tempting to hypothesize that the potentiating effects of BCG on antibody 
responses against the H1N1pdm09 strain, but not against the A/H3N2 strain, may 
172 173
8
REFERENCES
1. Stohr K. Influenza--WHO cares. The Lancet infectious diseases. 2002;2(9):517.
2. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza 
mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet. 
2006;368(9554):2211-8.
3. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus research. 
2011;162(1-2):19-30.
4. Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to 
protection. Mayo Clinic proceedings. 2010;85(3):257-73.
5. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, et al. Influenza vaccine 
immunology. Immunological reviews. 2011;239(1):167-77.
6. Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Current opinion in 
immunology. 2014;29:38-42.
7. Webster RG, Govorkova EA. Continuing challenges in influenza. Annals of the New York Academy of 
Sciences. 2014;1323:115-39.
8. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the 
prevention of tuberculosis. Meta-analysis of the published literature. JAMA : the journal of the American 
Medical Association. 1994;271(9):698-702.
9. van ‘t Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against 
systemic candidiasis in mice. Scandinavian journal of immunology. 1992;36(5):713-9.
10. Tribouley J, Tribouley-Duret J, Appriou M. [Effect of Bacillus Callmette Guerin (BCG) on the receptivity 
of nude mice to Schistosoma mansoni]. Comptes rendus des seances de la Societe de biologie et de ses 
filiales. 1978;172(5):902-4.
11. Floc’h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus 
calmette-guerin). Annales d’immunologie. 1976;127(2):173-86.
12. Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. Bacillus Calmette-Guerin vaccination and infant mortality. 
Expert review of vaccines. 2006;5(2):277-93.
13. Breiman RF, Streatfield PK, Phelan M, Shifa N, Rashid M, Yunus M. Effect of infant immunisation on 
childhood mortality in rural Bangladesh: analysis of health and demographic surveillance data. Lancet. 
2004;364(9452):2204-11.
14. Shann F, Nohynek H, Scott JA, Hesseling A, Flanagan KL, Working Group on Nonspecific Effects of V. 
Randomized trials to study the nonspecific effects of vaccines in children in low-income countries. The 
Pediatric infectious disease journal. 2010;29(5):457-61.
15. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces 
NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. 
Proceedings of the National Academy of Sciences of the United States of America. 2012;109(43):17537-
42.
16. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, et al. Long-Lasting Effects of BCG 
Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. Journal of innate 
immunity. 2013.
specific effects of BCG were demonstrated ex-vivo 14 days after vaccination (15). 
However, there is little knowledge on the optimal timing of BCG vaccinations in 
the context of influenza virus vaccination and it is possible that a different time-
interval between BCG and influenza vaccination could prove to be even more 
effective.
CONCLUSIONS
In the present study, we demonstrate that BCG vaccination followed by trivalent 
influenza vaccination significantly improves the magnitude and possibly also 
the swiftness of the antibody responses against the pandemic H1N1 2009 
influenza virus in humans in vivo. In addition, this study validates the previously 
observations that vaccination exerts non-specific effects on cytokine responses 
against unrelated pathogens. In line with this, our data indicate that modulatory 
effects on innate immunity are not restricted to BCG, but that trivalent influenza 
vaccination also exerts non-specific effects on cytokine responses elicited by 
various pathogens. Overall, our data further support the concept that trained 
immunity effects on myeloid APCs can influence the specific response to other 
vaccines, and the hypothesis that vaccination history affects immune status in a 
clinically relevant manner. This is the first randomized trial showing that BCG can 
potentiate the responses to other vaccines. As such, these results open the door 
to improve vaccination strategies in at-risk groups such as neonates or the elderly. 
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ONLINE SUPPLEMENT
Peripheral blood mononuclear cell (PBMC) isolation
Venous blood was drawn into EDTA tubes, after which peripheral blood 
mononuclear cells (PBMCs) were isolated as described previously (1). In short, blood 
was diluted in phosphate buffered saline (PBS) (1:1) and fractions were separated 
by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) density gradient 
centrifugation. Cells were washed twice with PBS and resuspended in RPMI-1640+ 
(RPMI-1640 Dutch modification supplemented with 10µg/mL gentamicin, 10mM 
L-glutamine, and 10mM pyruvate) (Gibco, Invitrogen, Breda, The Netherlands). 
PBMCs were counted using a particle counter (Beckmann Coulter, Woerden, The 
Netherlands) and were seeded in 96-well round-bottom plates (Corning, NY, USA) 
at a final concentration of 2.5x106/mL, in a total volume of 200 µL. PBMCs were 
stimulated for 24 hours (for measurement of TNF-α, IL-1β, and IL-6) and 48 hours 
(IL-10 and IFN-γ) with E. coli lipopolysaccharide (LPS; 10 ng/mL), heat-inactivated 
Candida albicans blastoconidia UC820 (1 x 106 microorganisms/mL), sonicated 
Mycobacterium tuberculosis (MTB) H37Rv (1 μg/mL), heat-killed Staphylococcus 
aureus (1 x 106 microorganisms/mL) or RPMI culture medium (medium controls). 
Furthermore, we stimulated PBMCs for 48 hours with medium alone, or medium 
containing live swine-origin influenza virus strain A/Netherlands/602/2009(H1N1) 
(2), at a multiplicity of infection (MOI) of 1 plaque forming unit (PFU) per cell. In 
separate wells, PBMCs were also stimulated with influenza vaccine (gathered from 
the same batch of trivalent influenza vaccine that was administered to the healthy 
volunteers) (1µg/ml, Batrevac; Abbot biologicals B.V., Weesp, the Netherlands). 
After incubation at 37°C and 5% CO2, cell culture supernatants were collected 
and stored at -20°C. After all samples were collected, cytokines were measured 
batch-wise using commercially available ELISAs (R&D Systems, MN, USA and 
Sanquin, Amsterdam, The Netherlands) according to the protocols supplied by 
the manufacturer.
Hemagglutination inhibition (HI) assay
HI assays were performed according to standard procedures (3). Briefly, two-fold 
serial dilutions of the serum samples, starting at a 1:20 dilution, were mixed with 
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Supplementary Figure 1. Antibody titres and percentage seroconversion over time for the 
pandemic H1N1 2009 strain, stratified by baseline antibody titre. Left panels: Geometric Mean 
Antibody Titres. To correct for baseline differences, baseline titres are plotted as 1, and subsequent 
time-points are plotted as fold changes of baseline values. Data are presented as median ± range. 
Right Panels: Percentage of subjects that attain seroconversion (defined as ≥4-fold titre increase 
compared with baseline) over time.
25 µl of a virus stock containing four hemagglutinating units of the virus strains 
present in the vaccine, and were incubated at 37°C for 30 min. Subsequently, 25 
µl of 1% turkey erythrocyte solution was added, and the mixture was incubated 
at 4°C for 1 h. The HI titre is expressed as the reciprocal value of the highest serum 
dilution that completely inhibited hemagglutination. Titres of less than 10 were 
recorded 5.
REFERENCES
1. Netea MG, Warris A, Van der Meer JW, Fenton MJ, Verver-Janssen TJ, Jacobs LE, et al. Aspergillus 
fumigatus evades immune recognition during germination through loss of toll-like receptor-4-
mediated signal transduction. The Journal of infectious diseases. 2003;188(2):320-6.
2. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, et al. 
Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science. 
2009;325(5939):481-3. Epub 2009/07/04.
3. Hirst GK. Studies of Antigenic Differences among Strains of Influenza a by Means of Red Cell 
Agglutination. The Journal of experimental medicine. 1943;78(5):407-23. Epub 1943/11/01.
Supplementary Table 1. 
Placebo P-value BCG P-value
A/California/7/2009 89.7 [-61.8-241.2] 0.15 16.2 [-8.4-40.8] 0.24
A/Texas/50/2012 -22.7 [-61.4-16.0] 0.31 93.1 [5.6-180.6] 0.01
B/Massachusetts/2/2012 18.9 [-8.6-46.4] 0.11 6.07 [-11.6-23.7] 0.11
Difference in antibody titre within groups between visit 1 (day -14, before BCG-vaccination) and visit 2 (day 0, 
before influenza vaccination) per serotype. Data are presented as median [IQR]. P-values were calculated using 
Wilcoxon matched-pairs tests
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Supplementary Figure 3. Antibody titres and percentage seroconversion over time for the B/2012 
strain, stratified by baseline antibody titre. Left panels: Geometric Mean Antibody Titres. To correct 
for baseline differences, baseline titres are plotted as 1, and subsequent time-points are plotted as 
fold changes of baseline values. Data are presented as median ± range. Right Panels: Percentage of 
subjects that attain seroconversion (defined as ≥4-fold titre increase compared with baseline) over 
time.
Supplementary Figure 2. Antibody titres and percentage seroconversion over time for the A/
H3N2/2012 strain, stratified by baseline antibody Titre. Left panels: Geometric Mean Antibody Titres. 
To correct for baseline differences, baseline titres are plotted as 1, and subsequent time-points are 
plotted as fold changes of baseline values. Data are presented as median ± range. Right Panels: 
Percentage of subjects that attain seroconversion (defined as ≥4-fold titre increase compared with 
baseline) over time.
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Supplementary Figure 4. Panels A-C. Antibody titres and percentage seroconversion over time 
for pandemic H1N1 2009, A/H3N2/2012, and B/2012 strains in subjects with relatively low baseline 
antibody titres (arbitrarily set as the Titre for which >25% of subjects in both groups attained 
seroconversion) that were vaccinated with BCG or placebo followed by influenza vaccination. Left 
panels: Geometric Mean Antibody Titres. To correct for baseline differences, baseline titres are 
plotted as 1, and subsequent time-points are plotted as fold changes of baseline values. p-values 
were calculated using Mann-Whitney U tests on Area under the curve (AUC) of subjects in both 
groups. Right Panels: Percentage of subjects that attain seroconversion (defined as ≥4-fold titre 
increase compared with baseline) over time. p-values were calculated using log-rank tests.
PloS ONE. 2014;9(9):e108794
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INTRODUCTION
Defense mechanisms against invading pathogens are of vital importance to our 
survival. Therefore, to prevent or combat infection, increasing the effectiveness 
of the immune response is highly desirable. However, immunostimulatory 
therapies are scarce, expensive, and often have unwanted side-effects [1].
“Medicinal” mushrooms are used in alternative medicine throughout the world 
for their presumed enhancing effect on the immune system [2,3]. Although 
a number of fungal components have been implicated in these properties, 
β-glucans (naturally occurring carbohydrates) have attracted the most 
attention [4]. Since the early 1900s, numerous in vitro and animal studies have 
demonstrated immunostimulatory effects of β-glucans [5]. In addition, the advent 
of molecular immunology has provided rigorous mechanistic explanations for 
how humans recognize glucans and how this may influence the immune system 
[6]. β-glucan is already applied as a food additive in animal feed to enhance the 
immune response [7] and it is also widely offered on the internet as a dietary 
supplement for humans, advertised to have beneficial immunostimulatory 
effects. Due to the fact that it is inexpensive and well tolerated, oral β-glucan 
appears as a promising candidate to enhance the immune response. However, 
there are no studies to substantiate the putative immunostimulatory effects of 
orally administered β-glucan in humans. The only evidence of immunological 
effects of oral β-glucan in humans to date is derived from a study in patients 
with advanced breast cancer, in which oral β-glucans enhanced expression of 
surface molecules associated with macrophage proliferation and activation in 
peripheral blood mononuclear cells (PBMCs) [8]. 
In the present study we investigated the effects of a commercially available 
orally administered water-insoluble β-glucan on immune responses of ex vivo-
stimulated leukocytes in healthy volunteers.
ABSTRACT
Rationale: To prevent or combat infection, increasing the effectiveness of the 
immune response is highly desirable, especially in case of compromised immune 
system function. However, immunostimulatory therapies are scarce, expensive, 
and often have unwanted side-effects. β-glucans have been shown to exert 
immunostimulatory effects in vitro and in vivo in experimental animal models. 
Oral -glucan is inexpensive and well-tolerated, and therefore may represent a 
promising immunostimulatory compound for human use. 
Methods: We performed a randomized open-label intervention pilot-study in 15 
healthy male volunteers. Subjects were randomized to either the β-glucan (n=10) 
or the control group (n=5). Subjects in the β-glucan group ingested β-glucan 1000 
mg once daily for 7 days. Blood was sampled at various time-points to determine 
β-glucan serum levels, perform ex vivo stimulation of leukocytes, and analyze 
microbicidal activity. 
Results: β-glucan was barely detectable in serum of volunteers at all time-points. 
Furthermore, neither cytokine production nor microbicidal activity of leukocytes 
were affected by orally administered β-glucan. 
Conclusion: The present study does not support the use of oral β-glucan to enhance 
innate immune responses in humans. This study was registered at ClinicalTrials.
gov as NCT01727895.
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Study design 
We performed an open-label, intervention pilot-study in 15 healthy human 
volunteers. The study design is depicted in Figure 2. Briefly, subjects were 
randomized to either the β-glucan group (n=10) or the control group (n=5) using 
the sealed envelope method. Subjects in the β-glucan group ingested β-glucan 
(water-insoluble β-glucan derived from bakers yeast [S. cerevisiae] sold as a 
dietary supplement [Glucan #300, BG; Biothera, Eagan, Minnesota, USA, for 
Transferpoint, Columbia, USA, hereafter designated as BG]) 1000 mg once daily 
as recommended by the manufacturer, for 7 days. This preparation, has a purity of 
at least 83% guaranteed by the manufacturer. Before the first BG ingestion (on day 
0) as well as 3, 6, and 24 hours afterwards, subjects came to the hospital for blood 
sampling and reporting of side-effects. This sampling schedule was repeated on 
day 6 (before and after the seventh BG ingestion). A final single sampling time-
point took place on day 20. The subjects in the control group (n=5) did not take BG, 
but the sampling schedule was otherwise identical.
Figure 2. Experimental design of the study 
The primary outcome measure was the TNF-α secretion by ex vivo lipopolysaccharide (LPS)-
stimulated peripheral blood mononuclear cells (PBMC’s). Secondary endpoints were the production 
of other cytokines (TNF-α, IL-6, IL-10, IL-1β, IL-17, IL-22, Interferon (IFN)-γ) by leukocytes ex vivo 
stimulated with various stimuli, β-glucan plasma levels, and Microbicidal activity of PBMC’s.
Cytokine measurements
Venous blood was drawn into EDTA tubes, after which peripheral blood 
mononuclear cells (PBMCs) were isolated as described previously [9]. In short, 
blood was diluted in phosphate buffered saline (PBS) (1:1) and fractions were 
separated by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) 
density gradient centrifugation. Cells were washed twice with PBS and 
METHODS 
Subjects
This study was registered at ClinicalTrials.gov as NCT01727895. After approval 
from the local Ethics Committee of the Radboud University Nijmegen Medical 
Centre, 15 healthy male volunteers gave written informed consent to participate 
in the experiments which took place from May 2013 until July 2013 (Figure 1). All 
experiments were in accordance with the declaration of Helsinki. Subjects were 
screened before the start of the experiment. Subjects with febrile illness during 
the two weeks before the experiment were excluded, and subjects were not 
allowed to take any prescription drugs. Throughout the study period, subjects 
documented their consumption of β-glucan-containing foods in a “food-diary”, 
and the amount of consumed β-glucan-containing foods was limited in order to 
minimize the inter-individual variability.
Figure 1. CONSORT flowchart
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(1→3)-β-D-glucan detection in serum samples
β-glucan levels were determined for all subjects on several time points using 
the Fungitell kit (Associates of Cape Cod, Inc., Cape Cod, MA), according to the 
manufacturer’s instructions [11]. Lower and upper detection limits were 31.25 and 
500 pg/ml, respectively. 
Calculations and statistical analysis
Distribution of data was determined using Kolmogorov-Smirnov tests. Demographic 
data were analyzed using Mann-Whitney U tests. Comparisons between the two 
groups over time were made using repeated measures two-way analysis of variance 
(ANOVA, interaction term). Ex vivo stimulation cytokine data were log-transformed 
to obtain a normal distribution. A p-value of <0.05 was considered statistically 
significant. Calculations and statistical analyses were performed using Graphpad 
Prism version 5.0 (Graphpad Software, San Diego, CA, USA).
RESULTS
Demographic characteristics
Demographic characteristics of the study population are listed in Table 1. There 
were no significant differences in baseline characteristics between the two study 
groups. No serious adverse events occurred during the trial. BG intake was well 
tolerated, with no side effects reported besides one subject who reported a flare 
of acne one week after discontinuation of BG for which he contacted his general 
practitioner.
Table 1. Demographic characteristics
β-glucan (n=10) Control (n=5) P-value
Age (years) 20 [19-22] 20 [19-24] 1.00
Hight (cm) 182 [179-188] 183 [177-196] 0.78
Weight (kg) 81 [74-87] 80 [74-87] 0.90
BMI (kg/m²) 24.1 [22.9-26.5] 23.9 [23.6-25.1] 0.95
BMI: body mass index. Data are presented as median and interquartile range. p-values calculated using Mann-
Whitney U-tests.
resuspended in RPMI-1640+ (RPMI-1640 Dutch modification supplemented 
with 10µg/mL gentamicin, 10mM L-glutamine, and 10mM pyruvate) (Gibco, 
Invitrogen, Breda, The Netherlands). PBMCs were counted using a particle 
counter (Beckmann Coulter, Woerden, The Netherlands) and were plated 
in 96 well round-bottom plates (Corning, NY, USA) at a final concentration 
of 2.5x106/mL, in a total volume of 200 µL. The PBMCs were stimulated for 
24 hours, 48 hours, and 7 days with medium alone, or medium containing E. 
coli lipopolysaccharide (LPS; 10 ng/mL), heat-inactivated Candida albicans 
blastoconidia UC820 (1 x 106 microorgansims/mL), Pam3Cys 10μg/mL (EMC 
Microcollections), sonicated mycobacterium tuberculosis (MTB) H37Rv (1 μg/
mL), poly(I:C) 50 μg/mL (Invivogen), S. aureus (1 x 107 microorgansims/mL), 
antiCD3/antiCD28 2,5x105 beads/well (Miltenyi Biotec). After stimulation, cell 
culture supernatant was collected and stored at -20°C. When all samples were 
collected, cytokines were measured using commercially available ELISAs (R&D 
Systems, MN, USA and Sanquin, Amsterdam, The Netherlands) according to 
the protocols supplied by the manufacturer. 
Microbicidal activity assay
Microbicidal activity assay was performed as previously described, using the 
fungal microorganism Candida albicans as a model pathogen [10]. Briefly, C. 
albicans UC820 yeast suspension was incubated with PBMCs isolated from the 
volunteers at day 0 (t=0) and day 6 (t=0) at a MOI of 1:5 or 1:50 in RPMI in a 96 
wells plate. C. albicans UC820 suspension was obtained from an overnight culture 
in 25ml liquid Sabouraud at 29°C. The C. albicans solution was washed three times 
with PBS, and the number of yeast cells counted in a hemacytometer. C. albicans 
were then incubated with PBMCs or no cells (control well) for 5 hours at 37°C. The 
amount of C. albicans added to the wells was determined by plating serial dilutions 
on Sabouraud plates in duplo. After a 5–hour incubation, the content of each well 
was recovered in sterile water and serially diluted. Serial dilutions were plated on 
Sabouraud plates in duplo. After 24 hours at 29°C, the CFU were counted. The 
candidacidal activity was calculated as a ratio of Candida growth with PBMCs vs. 
control wells (Candida alone, no cells).
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Figure 3. Effect of oral β-glucan on ex vivo TNF-α production by PBMCs stimulated for 24 hours 
with lipopolysaccharide (LPS), Pam3Cys, Poly(I:C), S. aureus, C. albicans, or M. tuberculosis (MTB). 
To correct for possible baseline differences between groups, concentrations at day 0 are set at 1, and 
concentrations at subsequent time-points are plotted as ratios (median and interquartile range). 
Baseline (day 0) TNF-α concentrations in pg/ml [interquartile range] of subjects in the β-glucan 
and control groups were: LPS: 691 [276-2649] and 749 [287-1160]), Pam3Cys: 855 [590-1727] and 
1242 [622-3567], Poly(I:C): 107 [78-399] and 125 [78-250], S. aureus: 21948 [14347-41751] and 19424 
[12140-31722], C. albicans: 10875 [5860-14159] and 6208 [3924-14943], and MTB: 424 [285-1980] 
and 1153 [218-2461]. P values between groups were calculated using repeated measures two-way 
analysis of variance (ANOVA, interaction term) on log transformed data.
(1→3)-β-D-glucan serum levels
Following oral administration, β-glucan was barely detectable in serum of 
volunteers at all time-points, and this was not significantly different from the 
β-glucan levels observed in the placebo group (data not shown). 
Cytokine production by ex vivo-stimulated PBMCs
The production of the archetypal proinflammatory cytokine tumor necrosis factor 
(TNF)-α after incubation with various stimuli at different time points showed 
considerable interindividual variation, but it was not affected by β-glucan intake 
(Figure 3). Furthermore, no relevant differences in TNF-α production compared 
with the control group were observed. Likewise, no effects of BG intake within 
the β-glucan group or between the β-glucan group and the control group were 
observed with regard to the production of interleukin (IL)-6, IL-1β, IL-10, Interferon 
(IFN)-γ, IL-17 and IL-22 (Figure S1, Panel A-D, in the online supplement). 
Microbicidal activity
We assessed the candidacidal properties of PBMCs isolated from volunteers 
before and 6 days after the administration of β-glucan, and at the same time-
points in the control group. No significant differences could be observed in 
candidacidal activity in both groups, using multiplicity of infection (MOI) of 
either 1:50 or 1:5 (Figure 4).
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the class of most active β-glucans. In addition, in an evaluation of four different 
orally administered commercially available β-glucans in mice, BG was shown to be 
the most potent in increasing phagocytosis capacity of peripheral blood cells and 
IL-2 production of splenic cells [10]. Based on these data, and because BG is rated 
‘GRAS’ (Generally Recognized As Safe) by the Food and Drug Administration 
(FDA) as a dietary food additive supplement [14], and safe and non-toxic by the 
Dutch Medicines Evaluation Board (MEB) [15], we deemed this preparation of BG 
representative of commercially available oral β-glucans. Because of the complete 
absence of any effect on cytokine production or microbicidal activity, although 
investigated in a small number of subjects for only a limited period, we conclude 
that BG or similar glucan products do not appear to be viable approaches for 
immunostimulation in humans. 
 
The lack of immunostimulatory effects of β-glucan in our study could have several 
reasons. First, it could be due to the absence of adequate absorption of β-glucans 
from the intestinal tract in healthy volunteers, which is in agreement with the 
undetectable serum levels found in various other studies showing that enteral 
administration of insoluble β-glucans from different sources result in low systemic 
blood levels (less than 0.5%) in mice [16], and weaned pigs [17]. Nevertheless, 
despite these low systemic blood levels, significant systemic immunomodulating 
effects in terms of humoral and cellular immune responses were demonstrated. 
It was speculated that these effects are exerted by enterocytes that facilitate the 
transportation of β-glucans and similar compounds across the intestinal cell wall 
into the lymph fluid, where they interact with macrophages and thereby activate 
the immune system despite low serum levels [18]. Given the lack of effects of BG 
in our study, it is unlikely that these local effects also take place to a significant 
degree in humans. 
 A second explanation might be related to the water solubility of β-glucans, 
because previous studies have demonstrated that water soluble β-glucans interact 
with the immune system differently compared with their insoluble counterparts. 
Soluble β-glucans activate the immune system in a complement mediated 
manner, depending on specific antibodies[19], while insoluble β-glucans, like BG 
used in this study, activate both the innate and the adaptive immune responses 
Figure 4. Microbicidal activity of PBMCs isolated from the volunteers at day 0 (before β-glucans 
intake), or at day 6 (after six days of β-glucan intake ) from β-glucan (white) or from control (grey) 
volunteers. The microbicidal activity was calculated as a ratio of Candida growth with PBMCs vs. 
control wells (Candida alone, no cells). Data are presented as mean ± SEM. P values between groups 
were calculated using repeated measures two-way analysis of variance (ANOVA, interaction term).
DISCUSSION
In the present study, we show that daily intake of 1000 mg commercially available 
oral β-glucan for 7 days does not result in detectable serum β-glucan levels in 
healthy human volunteers, and that it does not modulate the innate immune 
response, as reflected by leukocyte-derived cytokine production upon ex vivo 
stimulation and microbicidal activity.
Because of increasing evidence for immunomodulatory properties of β-glucans 
[5,10], and because commercially available oral β-glucans are widely advertised as 
having beneficial immunostimulatory effects, we wanted to assess their biological 
effects in humans. β-glucans are glucose polymers which can be isolated from cell 
walls of yeasts and mushrooms, but also from cell walls of other fungi, bacteria, 
algae, and cereal grains [5]. Their activity has been shown to be influenced by 
their degree of branching, size, molecular structure [12,13], and the purity of the 
administered β-glucan [12]. The most active β-glucans reportedly share a common 
structure: a main chain consisting of (l-3)-linked β-D glucopyranosyl units, along 
which are randomly dispersed single β-D-glucopyranosyl units attached by l-6 or 
1-4 linkages [5]. The BG used in this study is a polymer of β-(1-3)-D-glycopyranosyl 
units with branching at β-(1-6)-D-glycopyranosyl units, therefore belonging to 
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CONCLUSION
Despite promising results obtained in in vitro and animal studies, our study 
demonstrates that the use of oral β-glucan does not enhance the responsiveness 
of the immune system in humans. Future efforts should concentrate on assessing 
the immunological and clinical effects of intravenous β-glucan preparations.
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via the dectin-1 receptor pathway [19,20]. As such, it has been suggested that 
soluble β-glucans possess less biological activity than their insoluble counterparts. 
Therefore, although we did not investigate a soluble formula, it is unlikely that 
orally administered water soluble β-glucans will have a more pronounced 
immunostimulatory effect in humans than the BG used in this study. However, 
future studies are warranted to assess this aspect.
 Third, the lack of effects might be related to the fact we used a commercially 
available β-glucan preparation sold as a dietary supplement, with a relatively 
modest purity of at least 83%. It is possible that a highly purified pharmaceutical 
preparation optimized for oral delivery could have immunostimulatory effects 
in humans. 
 Finally, we only investigated one dose of BG, based on the recommendation 
of the manufacturer, which is not supported by empirical data. Nevertheless, this 
dose is similar to that used in two previous studies, where it was demonstrated 
that oral ingestion of 900 mg water-insoluble β-glucan daily for 16 or 26 weeks 
reduced the incidence in common cold episodes during the cold season [21,22]. Of 
note, endpoints in both studies were based on questionaires, no immunological 
endpoints were assessed. Also, the dose used in the present study is higher than 
the dose rated ‘GRAS’ by the FDA and MEB (375 mg per day) [14] [15], which was 
based on the mean background intake of β-glucans from other dietary sources. 
While our study does not support use of oral β-glucan to enhance the immune 
response, it does not exclude that parental administration of β-glucan, as currently 
performed in clinical trials (e.g. NCT01269385, NCT00002099), could represent a 
valuable immunostimulatory therapy. It has been reported that β-glucan from 
S. cerevisiae administered intravenously to high-risk surgical patients resulted in 
decreased infection incidence, reduced need for antibiotics, shortened intensive 
care unit length stay, and ultimately improved survival compared with placebo [23]. 
In addition, several clinical trials in East Asia have proposed immunomodulatory 
and antioncogenic effects of β-glucan in cancer patients [24-26]. Larger studies 
are warranted to confirm these data, investigate the biological mechanisms 
though which effects are induced, and to fully explore the therapeutic potential 
of β-glucans.
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Supplementary Figure 1B. Effect of oral β-glucan on ex vivo IL-β production by PBMCs stimulated 
for 24 hours with lipopolysaccharide (LPS), Pam3Cys, Poly(I:C), S. aureus, C. albicans, or M. 
tuberculosis (MTB).
To correct for possible baseline differences between groups, concentrations at day 0 are set at 1, 
and concentrations at subsequent time-points are plotted as ratios (median and interquartile range). 
Baseline (day 0) IL-β concentrations in pg/ml [interquartile range] of subjects in the β-glucan and 
control groups were: LPS: 5600 [2604-12624] and 4061 [2322-10436], Pam3Cys: 9295 [3688-11162] 
and 5189 [3303-6686], Poly(I:C): 233 [39-412] and 142 [39-266], S. Aureus: 24141 [20536-29528] and 
15456 [14697-24582], C. Albicans: 6975 [5327-8954] and 6187 [3832-8224], and MTB: 2574 [1680-
7120] and 3313 [1211-6465]. P values between groups were calculated using repeated measures two-
way analysis of variance (ANOVA, interaction term) on log transformed data.
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Supplementary Figure 1A. Effect of oral β-glucan on ex vivo IL-6 production by PBMCs 
stimulated for 24 hours with lipopolysaccharide (LPS), Pam3Cys, Poly(I:C), S. aureus, C. 
albicans, or M. tuberculosis (MTB). 
To correct for possible baseline differences between groups, concentrations at day 0 are set at 1, and 
concentrations at subsequent time-points are plotted as ratios (median and interquartile range). 
Baseline (day 0) IL-6 concentrations in pg/ml [interquartile range] of subjects in the β-glucan and 
control groups were: LPS: 22862 [37588-11284] and 14516 [13980-17357], Pam3Cys: 33293 [15632-
40949] and 12258 [9957-22041], Poly(I:C): 5308 [1618-8228] and 937 [468-2964], S. Aureus: 19277 
[12123-24092] and 11585 [8093-15266] , C. Albicans: 11130 [8899-15794] and 8924 [5168-10147], and 
MTB: 21997 [10416-35469] and 12470 [12232-15365]. P values between groups were calculated using 
repeated measures two-way analysis of variance (ANOVA, interaction term) on log transformed data. 
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Supplementary Figure 1D. Effect of oral β-glucan on ex vivo Interleukin-17 and -22 production by 
PBMCs stimulated for 7 days with S. aureus, C. albicans, or anti-CD3CD28. To correct for possible 
baseline differences between groups, concentrations at day 0 are set at 1, and concentrations at 
subsequent time-points are plotted as ratios (median and interquartile range). Baseline (day 0) 
IL-10 concentrations in pg/ml [interquartile range] of subjects in the β-glucan and control groups 
were: S. Aureus: 245 [116-470] and 200 [70-563], C. Albicans: 885 [606-1621] and 940 [720-1365], and 
anti-CD3CD28: 488 [219-580] and 360 [235-1268]. Baseline (day 0) IL-22 concentrations in pg/ml 
[interquartile range] of subjects in the β-glucan and control groups were: S. Aureus: 2620 [1089-12670] 
and 6145 [2140-9165], C. Albicans: 2730 [1694-9335] and 6875 [5588-10440], and anti-CD3CD28: 250 
[147-1623] and 1175 [363-1225]. P values between groups were calculated using repeated measures 
two-way analysis of variance (ANOVA, interaction term) on log transformed data. 
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Supplementary Figure 1C. Effect of oral β-glucan on ex vivo Interleukin-10 and Interferon-gamma 
(IFN) production by PBMCs stimulated for 48 hours with S. aureus, C. albicans, or anti-CD3CD28.
To correct for possible baseline differences between groups, concentrations at day 0 are set at 1, 
and concentrations at subsequent time-points are plotted as ratios (median and interquartile range). 
Baseline (day 0) IFN concentrations in pg/ml [interquartile range] of subjects in the β-glucan and 
control groups were: S. Aureus:24950 [10491-48275] and 21100 [5633-37350], C. Albicans: 22100 
[13450-37225] and 26400 [14563-40550], and anti-CD3CD28: 35900 [12628-50000] and 27300 
[15800-65075]. Baseline (day 0) IL-10 concentrations in pg/ml [interquartile range] of subjects in the 
β-glucan and control groups were: S. Aureus: 405 [158-503] and 140 [59-267], C. Albicans: 83 [44-189] 
and 39 [25-93], and anti-CD3CD28: 160 [102-229] and 129 [77-362]. P values between groups were 
calculated using repeated measures two-way analysis of variance (ANOVA, interaction term) on log 
transformed data.
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SUMMARY
In this thesis, preclinical, translational and clinical studies investigating 
immunomodulatory therapies for the adjunctive treatment of life-threatening 
infectious diseases are described. We focused on the effects of the well-
known immunostimulatory compounds Interferon-γ (IFN−γ) and Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF) as adjunctive treatment of 
sepsis, and IFN−γ as adjunctive treatment of invasive opportunistic infections. 
In addition, the effects of new immunomodulatory approaches based on the 
recently discovered concept of “trained innate immunity” (memory of the innate 
immune system), were explored in humans.
In chapter 1 a short introduction on the innate immune system with focus on 
the pathophysiology of infectious disease-specific immune dysfunction is given. 
First, opportunistic infections in patients with a pre-existing suppressed immune 
system are discussed, followed by an introduction in secondary infections in 
patients with sepsis-induced “immunoparalysis”. Finally, the rationale behind the 
immune stimulatory compounds used in this thesis is provided. 
PART ONE: IMMUNOMODULATION AS ADJUNCTIVE TREATMENT 
FOR SEPSIS
Chapter 2 provides an overview of the pathophysiology of sepsis, with a focus 
on recent insights in immunosuppressive mechanisms that play an important 
role. Despite advances in medical care, sepsis remains a major cause of death 
worldwide. In recent years it has become clear that most septic patients do 
not die from an overwhelming initial pro-inflammatory immune response, 
but in the subsequent immunosuppressive phase, called “immunoparalysis”, 
which is characterized by a compromised ability to clear the initial infection, 
and increased susceptibility to secondary and opportunistic infections. 
Although infection control and supportive therapies, especially in the early 
phase of sepsis, will remain the cornerstone of sepsis treatment, the discovery 
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PART TWO: IMMUNOMODULATION AS ADJUNCTIVE TREATMENT FOR 
OPPORTUNISTIC INFECTIONS
Because most patients suffering from opportunistic infections have an impaired 
immune system, albeit to varying degrees, adjunctive immunotherapy to improve 
host defence is theoretically an attractive strategy to improve patient’s outcome. 
In chapter 4 we describe a case series of patients with invasive fungal infections 
in which we demonstrate that adjunctive immunotherapy with IFN-γ improves 
leukocyte immune responses ex vivo in these patients. This was reflected by 
increased production of innate pro-inflammatory cytokines, such as IL-1β or 
TNF−α, as well as increased production of T-cell cytokines IL-17 and IL-22, which 
are known to play an important role in the anti-fungal host defence. Furthermore, 
IFN-γ treatment increased mHLA-DR expression in a subset of severely 
immunosuppressed patients with very low baseline mHLA-DR expression. These 
data indicate that adjunctive immunotherapy with IFN-γ in patients with invasive 
fungal infections partially restores cell-mediated immunity, and suggest that 
IFN−γ treatment can enhance anti-fungal immunity and thereby may improve 
outcome of these patients.
Chapters 5 and 6 describe the effects of adjunctive last-resort immunotherapy 
with IFN-γ in a pediatric patient with progressive invasive Candida infection 
after remission-induction chemotherapy for Acute Lymphoblastic Leukemia, 
and in a patient with cerebral Nocardiosis. Both patients deteriorated despite 
optimal antimicrobial treatment. IFN-γ therapy resulted in augmentation of 
the innate immune response in both patients, and was associated with clinical 
and radiographic recovery. In the absence of randomized clinical trials, these 
case reports suggest that in patients with invasive opportunistic infections, who 
deteriorate despite optimal antimicrobial treatment, immunotherapy with IFN−γ 
could be considered as adjuvant salvage therapy.
of immunoparalysis and its detrimental consequences is currently causing 
a profound shift in the sepsis research field. Hitherto, research related to 
treatment for sepsis predominantly focused on suppression of the immune 
system (for example with anti-cytokine and anti-Toll-like receptor therapies), 
but more recently, sepsis research increasingly focuses on immunostimulatory 
treatment options. In this chapter an overview of mechanisms behind sepsis-
induced immunoparalysis and possible markers to identify immunoparalyzed 
patients is provided (including the most studied markers HLA-DR expression 
on monocytes (mHLA-DR), and ex vivo leukocyte responses). In addition, the 
few studies that have evaluated immunostimulatory therapies in sepsis are 
discussed, and new compounds that seem promising candidates to reverse 
sepsis-induced immunoparalysis are proposed.
In chapter 3 the effects of IFN−γ and GM-CSF on immunoparalysis in vivo 
in humans are described. Repeated administration of endotoxin to healthy 
volunteers was used to mimic sepsis-induced immunoparalysis and it was 
demonstrated that a second endotoxin administration a week after the first 
results in a profoundly suppressed innate immune response. This indicates that 
this approach represents a suitable model for sepsis-induced immunoparalysis 
and, importantly, provides a timeframe to administer immunostimulatory 
therapy in between endotoxin administrations. In a few small studies it was 
already demonstrated that both IFN−γ and GM-CSF are able to enhance ex 
vivo immune responses of septic patients. However, using the repeated human 
endotoxin model it was already demonstrated that ex vivo measurements do not 
necessarily reflect the in vivo immune status. We demonstrated that, compared 
with placebo, treatment with IFN−γ in between endotoxin administrations not 
only increased expression of the well-known immunoparalysis marker mHLA-
DR, but indeed also restored in vivo production of the proinflammatory cytokine 
TNF−α, while further attenuating the production of the anti-inflammatory 
cytokine IL-10 upon the second endotoxin administration. Similar, but less 
pronounced, effects were found in subjects treated with GM-CSF, thereby 
demonstrating that immunoparalysis in vivo in humans can be partially reversed 
by IFN−γ and, to a lesser extent, by GM-CSF. 
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the immune system. However, its immunostimulatory effects in humans 
have never been investigated. In chapter 9 we describe that daily intake of 
1000 mg commercially available oral Beta-glucan for 7 days does not result in 
detectable serum Beta-glucan levels in healthy human volunteers, and that 
it does not modulate the innate immune response, as reflected by leukocyte-
derived cytokine production upon ex vivo stimulation with various pathogenic 
stimuli and microbicidal activity. We therefore cannot substantiate the putative 
immunostimulatory effects of commercially available orally administered Beta-
glucan.
PART THREE: NEW IMMUNOMODULATORY APPROACHES
Non-specific effects of BCG-vaccination were long ignored, and only in the last 
decade interest in these nonspecific effects revitalized. Several randomized studies 
demonstrated reduced mortality in early BCG-vaccinated neonates (which could not 
be explained by TBC prevention, as TBC is a rare cause of death in neonates) (1-5). 
Additionally, it was demonstrated in vitro and ex vivo that BCG provides protection 
against unrelated infections later on. Moreover, experimental studies suggested 
that these unrelated beneficial effects were independent of B- and T-cells, and 
consequently based on “training” of the innate immune responses. However, the 
immune modulating effects of BCG vaccination in humans have hitherto only been 
shown ex vivo using stimuli of bacterial and fungal origin. In chapter 7 we describe 
that prior vaccination with live attenuated BCG leads results in a more swift and 
pronounced induction of antibodies following administration of trivalent influenza 
vaccine in healthy volunteers. In addition, we confirmed the non-specific effects of 
BCG on cytokine production upon ex vivo stimulation of PBMC’s with non-related 
pathogens, and demonstrated that trivalent influenza vaccination also exerts non-
specific effects on cytokine responses elicited by various pathogens. Overall, our 
data further support the hypothesis that vaccination history of the host affects the 
immune status in a clinically relevant manner, and as such, it opens up new avenues 
towards improved vaccination strategies. Because live attenuated BCG is not a 
treatment option in patients with impaired immune functions due to the associated 
risk of dissemination, we investigated the trained-immunity effects of gamma-
irradiated (and thus inactivated) BCG. However, in chapter 8 we demonstrate that 
gamma-irradiated BCG does not induce trained immunity ex vivo. Furthermore, it 
does not potentiate the innate immune response in vivo during immunoparalysis 
induced by repeated human entotoxemia. This is likely due to the inactivation of 
the vaccine. Therefore, Gamma-irradiated BCG is unlikely to represent a possible 
treatment option for the reversal of sepsis-induced immunoparalysis. 
In addition to BCG, Beta-glucan has also been demonstrated to induce trained 
immunity in vitro and in vivo in animals. Furthermore, oral Beta-glucan is widely 
offered on the internet as a dietary supplement for humans claiming to improve 
CHAPTER11
General discussion and 
future perspectives
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
The backbone of infectious disease management consists of source control, 
through administration of antimicrobial/antifungal/antiviral therapy and surgical 
removal of infected tissue if necessary. However, despite advances in medical care, 
infectious diseases still account for unacceptably high mortality worldwide (6), and 
the ever increasing resistance to the currently available antimicrobial therapies 
emphasizes the need for novel approaches to treat infectious diseases. Because 
a well functioning immune system is of primordial importance for the adequate 
eradication of invading pathogens (7), increasing the effectiveness of the immune 
response is a very attractive strategy to improve outcome. This is especially true 
for patients with a compromised immune system, such as those suffering from 
opportunistic infections and sepsis-induced immunoparalysis. However, immune 
stimulation as adjunctive treatment for infectious diseases is only in its infancy. 
As evidenced in this thesis, the currently available immunostimulatory therapies 
IFN−γ and GM-CSF appear promising strategies to potentiate the immune system 
of these patients. However, these therapies are expensive, have potentially serious 
side effects, and might not always be effective. Furthermore, new molecular and 
transcriptional pathways in the context of disease pathogenesis are constantly 
being discovered. Therefore, novel immunomodulatory therapies are highly 
warranted.
In this final chapter, we discuss the findings described in this thesis, also in light 
of recent studies in the field that were performed during the conduct of our own 
research, present future perspectives, and draw conclusions. 
Immunoparalysis in sepsis
In the first part of this thesis, we presented an overview of recent insights in the 
pathophysiology of sepsis with a focus on sepsis-induced immunoparalysis, 
which plays an important role in the outcome of these patients. Furthermore, 
we demonstrated that IFN−γ is able to partially restore immunocompetence in a 
model for sepsis-induced immunoparalysis in humans in vivo.
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The clinical relevance of sepsis-induced immunoparalysis is illustrated by an 
observational study in surgical patients who died from sepsis or septic shock (10). 
In 63 of 71 patients (89%) who were treated with antibiotics for more than 7 days a 
continuous septic focus was found, illustrating that these patients were unable to 
eradicate their infection (10). Furthermore, other reports have shown that during 
the late phase of sepsis, infections due to opportunistic bacteria increase from 9 to 
18%, and Candida-infections from 13 to 30% (11). Also, many pathogens responsible 
for nosocomial sepsis in ICUs are weakly virulent opportunistic pathogens usually 
isolated only from severely immunodepressed patients (12). Further evidence for 
a severely immunosuppressed state is derived from a recent study that reported 
reactivation of latent viruses in 43% of 560 sepsis patients (13). Of note, Epstein Barr 
virus (EBV) and cytomegalovirus (CMV) detection in sepsis patients was similar to 
those reported in stem cell and organ transplant patients (13). However, there is 
still much debate about the clinical relevance of immunoparalysis in septic patients 
(14-16), and many clinicians argue that they do not recognize it to be a relevant 
problem in their septic patient population. These doubts are further substantiated 
by the fact that a causative link or mechanism between immunoparalysis and the 
development of organ damage and lethality has not yet been established. 
Of interest, very recent studies provide the first evidence that could link 
immunoparalysis and cell dysfunction leading to multi-organ failure in sepsis. It was 
demonstrated that impaired bioenergetics and mitochondrial dysfunction, leading 
to ATP depletion, may be an important feature of sepsis-induced immunoparalysis 
(17-21), that could also contribute to organ dysfunction (19). A decrease in metabolic 
activity reduces energy requirements and result in a new hibernating steady-
state in which the cell does not longer perform its specialized function but at the 
same time does not allow ATP to decrease to levels that trigger cell death. Such 
a decrease in cell functionality, if sufficiently severe, will be manifest as decreased 
functionality of organs, which may represent a mechanism to cope with a severe 
and/or prolonged inflammatory insult, but will eventually lead to the death of 
the patient (22). Interestingly, every hallmark of failed cellular homeostasis (e.g. 
inadequate contraction of myocardial cells [myocardial depression]; impaired 
constriction of vascular smooth muscle cells [hypotension]; failure of the cell-cell 
A major problem in sepsis research is the fact that sepsis patients are a very 
heterogeneous group. This heterogeneity is caused by the definition of sepsis (Table 
1), which uses broad clinical and/or laboratory criteria (8) resulting in a group of 
patients who differ in causative agent, site of infection, and severity and differences 
in the phase of disease. The heterogeneity of the patients that fit the sepsis criteria 
makes it likely that numerous different (immuno)pathological mechanisms are 
involved, rendering targeting of any single mechanism unlikely to be effective. In 
accordance, as described in chapter 2 of this thesis, both pro-inflammatory and anti-
inflammatory processes are active simultaneously, and depending on a number 
of individual factors, a pro- or anti-inflammatory predominance will affect the 
chances of survival of the individual patient. Due to aging of the population which is 
associated with senescence of the immune system (so-called immunosenescence), 
and advances in supportive care which can mitigate the detrimental effects of 
a pronounced pro-inflammatory response, immunoparalysis, rather than an 
overwhelming pro-inflammatory immune response, will increasingly constitute 
the overriding immune pathology in septic patients. As described in chapter 2 of 
this thesis, this is likely to be the main reason behind the failure of all clinical trials 
to date, including a very recent one (9), that have attempted to improve clinical 
outcome by suppressing the pro-inflammatory immune response.
Table 1. SIRS, sepsis, severe sepsis or septic shock criteria
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Independent of the impaired bioenergetics hypothesis proposed above, the initial 
excessive degree of inflammation in response to the infectious insult remains the 
obvious trigger for these and other downstream pathways, and, in selected cases, is 
responsible for distinct collateral damage (e.g. in meningococcal sepsis or infectious 
diseases causing macrophage activation syndromes such as dengue (25), severe 
influenza infections (26), malaria (27)). In addition, the impaired immune signaling 
and effector functions described in chapter 2 of this thesis are a clear hallmark 
of sepsis. Therefore, finding ways to orchestrate the inflammatory response in a 
tailored fashion could be of great therapeutic value: potentiation when necessary 
to eliminate microorganisms, dampening in case of potential collateral tissue 
damage. Hence, accurate biomarkers that can identify a patient’s immune status 
are of primordial importance for the future of immunotherapy in sepsis. Biomarkers 
may serve both as a means to select patients eligible for immunomodulatory 
therapies, as well as for monitoring the response to treatment. Furthermore, 
biomarkers may identify high risk patients that are potentially eligible for therapies 
associated with higher risks, or to exclude patients who are anticipated to have 
a good clinical outcome with standard therapy. The goal of stratification would 
thus be to target a distinct biological process, while at the same time maximizing 
the benefit-risk ratio. In order to achieve routine clinical applicability, an accurate 
biomarker should provide reliable and reproducible results within a short time-
frame and at low costs. HLA-DR expression on monocytes measured by flow 
cytometry, and ex vivo leukocyte responses to LPS, both discussed in chapter 2 of 
this thesis, currently represent the most widely used markers for immunoparalysis 
(28-30). However, they reflect only the immune status of the blood compartment, 
and pre-analytical and analytical issues inherent to these markers limit their use 
in large multicentered clinical studies and/or on a routine basis. There is hope that 
improved molecular diagnostics and prognostics based on a systems biology 
approach (combining genomic, transcriptomic, metabolomic, proteomic, and/or 
epigenetic data), will eventually result in new diagnostic tools, although up till now, 
these are largely unstudied in the context of sepsis research (31-34). 
Until then, clinical trials investigating immune modulatory therapies should 
stratify sepsis patients according to their immune status using the tools currently 
junctions [capillary leak]) represents a characteristic pathophysiological feature of 
severe sepsis and/or septic shock (8). Moreover, these findings of mitochondrial 
dysfunction are consistent with autopsy findings that sepsis is not associated 
with extensive cell death (19, 23). Cell death is more prominent in the lymphocyte 
compartment (23, 24), which may be more sensitive to ATP depletion. This may 
explain the fact that septic patients recover function of most organs/tissues within 
days to weeks after resolution of sepsis, although this is not the case for the lymphoid 
compartment, thereby causing persistent immunoparalysis. Depending on the 
degree of lymphoid cell death (responsible for the extent of immunoparalysis), the 
patient will have impaired clearance of his/her initial or a secondary infection which 
is accompanied by ongoing inflammation, resulting in persistent mitochondrial 
dysfunction. This vicious circle leads to failed cellular homeostasis and ultimately 
to organ failure (Figure 1). 
Figure 1. Simplified representation of the impaired bioenergetics hypothesis. 
This is in accordance with the general clinical picture of those septic patients 
who survive the initial infectious hit, but die at a later time point. They more or 
less fade away. 
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Immunomodulation in opportunistic infections
In the second part of this thesis we demonstrated that IFN-γ immunotherapy is 
able to enhance mHLA-DR expression and/or ex vivo leukocyte responses, and 
very likely contributed to clinical and radiographic recovery, in patients with 
invasive opportunistic infections. 
In contrast with the earlier described sepsis patients who can either suffer from 
a too pronounced immune response or a severely suppressed one, non-septic 
patients suffering from non-resolving opportunistic infections represent a are 
more uniform group in terms of their immune response as these infections are 
virtually always related to impaired host defense mechanisms. Nevertheless, 
although most patients are likely to benefit of adjunctive therapy, similar to 
sepsis, there is no established marker that can be used to identify patients 
who would benefit or not of adjunctive therapy, or that can be used to monitor 
treatment responses. In chapter 4 and 5 of this thesis we described for the first 
time that mHLA-DR may serve this purpose as mHLA-DR expression levels 
inversely correlated with disease severity. In these patients, immunoparalysis was 
illustrated by very low expression of mHLA-DR at baseline, while this significantly 
increased after initiation of IFN-γ therapy. Although these results from case series/
studies are promising, larger clinical trials are warranted to confirm our results. 
Also, the pitfalls of these markers described before should also be taken into 
account in this patient group. Nevertheless, in both patients described in chapter 5 
and 6 of this thesis, monitoring of the immune responses by mHLA-DR expression 
and/or ex-vivo cytokine responses proved to be of great value in the guidance of 
immunomodulatory treatment. Similar to sepsis, this biomarker-guided approach 
should be applied in future larger (multicentre) clinical trials powered on both 
hard clinical endpoints and immunological effects to substantiate the future of 
adjunctive immunotherapy in invasive opportunistic infections. National and 
international collaboration between infectious-disease specialists, intensivists, 
oncologists and translational immunologists will be required, as studies in these 
patients are clearly challenging.
available. Because these are suboptimal, a panel of markers should be used. 
For instance, in case of immunoparalysis, reduced mHLA-DR expression and/
or impaired production of cytokines by leukocytes ex vivo stimulated with LPS 
in combination with clinical data such as a pronounced reduction in vasopressor 
need, and no signs of macrophage activation syndrome as surrogate markers 
of reduced pro-inflammation could be of value, although this remains to be 
determined. This biomarker-guided stratification will hopefully improve the 
chances to demonstrate a beneficial effect in intervention trials and facilitate large 
clinical trials adequately powered to evaluate the effects on hard clinical endpoints 
(e.g. mortality, hospital length of stay) that are required to substantiate the value 
of adjunctive immunotherapy in sepsis.
As described in chapter 2 and 3 of this thesis, IFN-γ and GM-CSF are the two most 
frequently studied immunostimulatory compounds in sepsis. In addition, based 
on the promising results of IFN-γ described in chapter 3, a phase 3 clinical trial in 
which IFN-γ is administered to immunoparalyzed septic patients in a randomized 
double-blind manner is currently ongoing. Unfortunately enrollment rates are lower 
than anticipated, probably due to very strict exclusion criteria in this very ill patient 
population. Next to IFN-γ and GM-CSF, other new immunostimulatory therapies 
may be effective in restoring immunity. Parallels between sepsis-induced immune 
dysfunction and alterations in immune function in patients with cancer (35, 36) 
or chronic viral infections (37), have guided immunomodulatory sepsis research 
towards lymphocyte function restoration using anti-PD-1 and IL-7 treatment (38). 
Both compounds are readily available for human use and safety and kinetics have 
been studied in (pre-)clinical studies in cancer and HIV patients (36, 37, 39). Pre-clinical 
studies show very promising results of both compounds in restoring sepsis-induced 
immune dysfunction (38), however, this has yet to be confirmed in clinical trials. In 
this respect it is noteworthy that a revolution in immunotherapy is currently under 
way in oncology (35), with a recently announced and unprecedented collaboration 
among four major pharmaceutical companies in developing combination 
immunotherapeutic drugs for cancer, underscoring the perceived importance of 
immunotherapy (40). As such, new immunotherapeutic agents are likely to be 
discovered in the near future and the sepsis field could benefit from this.
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The results described in chapter 7 are the first non-observational data that show 
that BCG-vaccination has immune modulating effects against unrelated pathogens 
in vivo in humans. Moreover, the fact that trivalent influenza vaccination also 
exerts non-specific effects on cytokine responses against several other pathogens 
indicates that modulation of innate immune parameters is not restricted to BCG. 
This makes sense from an evolutionary perspective, but also underscores that 
trained immunity completely changes the dogma of innate immunity lacking 
any form of adaptation. These data implicate that all vaccinations (and probably 
also all infectious diseases encountered during lifetime) will affect the immune 
status in a non-specific manner. However, the concept of trained immunity has 
only recently been proposed, and as such, the underlying mechanisms remain 
to be fully elucidated. Recently, it has been demonstrated that epigenetic 
reprogramming plays a central role not only in the induction of trained immunity 
resulting in an enhanced immunological phenotype, but also in the induction of 
LPS-tolerance, which can be regarded as the opposite (33). As described in chapter 
2 of this thesis, epigenetic regulation of gene transcription occurs through several 
mechanisms but can be regarded as the regulated organization of gene loci into 
transcriptionally active or silent states in which H3K4 methylation and H3K27 
acetylation play an important role (Figure 2). 
Figure 2. Schematic overview of epigenetic reprogramming underlying trained immunity. BCG, 
Bacille Calmette-Guérin; H3-K4me3, .H3K4 trimethylation. Copyright by Siroon Bekkering.
Of interest, for patients with invasive fungal infections, improvements in the field 
of molecular diagnostics and prognostics based on a systems biology approach 
already resulted in important discoveries. For instance, the type I IFN pathway 
was identified as the most prominent Candida-specific transcriptional response, 
and Candida-induced type I IFN induction modulates Th1/Th17 responses in vitro, 
resulting in increased IFN-γ production while IL-17 production is suppressed (41). 
Moreover, in the first genome-wide association study (GWAS) assessing genetic 
susceptibility to candidaemia (42), three novel risk factors for susceptibility 
to candidaemia were identified. Carrying two or more risk alleles from these 
loci increases the risk for candidaemia by 19-fold. In addition, the unexpected 
identification of CD58 as an important risk factor for candidaemia resulted in 
the discovery of its role in inhibiting Candida germination at the level of the 
phagosome and involvement of Candida-induced TNF-α production (42). These 
findings illustrate the importance of systems biology approaches, even in smaller 
patient groups. Using this approach, screening strategies based on SNPs to identify 
patients at risk who could benefit from prophylactic treatment can be developed,. 
Furthermore, it will provide more insight into immunological pathways and 
identify new pathways that can contribute to a better understanding of host 
defenses (including the mechanism of action of IFN-γ). Taken together, a systems 
biology approach represents a powerful tool for the discovery of more accurate 
immune status biomarkers as well as for the design of future immunotherapeutic 
strategies. 
New immunomodulatory approaches
In the final part of this thesis we demonstrated that live attenuated BCG 
vaccination resulted in enhanced antibody responses induced by administration 
of trivalent influenza vaccine, and that trivalent influenza vaccine itself also exerts 
non-specific effects on cytokine responses against several other pathogens. 
Furthermore, we demonstrated that vaccination with gamma-irradiated (and 
thus inactivated) BCG, and oral administration of commercially available Beta-
glucan, did not induce training of the innate immune system. 
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The lack of any effects of orally administered commercially available Beta-glucan 
on ex vivo leukocyte innate immune responses in chapter 9 emphasize the need 
for thorough clinical research of claimed health food effects, especially because 
these oral Beta-glucan formulations are sold all over the world as a health food 
supplement claiming to enhance the immune system. Despite the absence of 
effects in our study, immunological training effects of Beta-glucan are clearly 
demonstrated in vitro (17, 33, 46). A very recent study, using a systems biology 
approach, demonstrated that Beta-glucan training of monocytes results in a 
long-lasting exclusive epigenetic signature, revealing a complex network of 
promoters and enhancers linked to genomic coordinates (33). Furthermore, 
again by a systems biology approach, it was demonstrated that cAMP mediated 
molecular signal transduction is important for Beta-glucan-induced training. 
This study further highlights the importance of these combined approaches and 
provides a resource to further understand the biological mechanisms through 
which Beta-glucan-induced training effects are mediated. Together with this 
growing basic knowledge, clinical studies are warranted to confirm the beneficial 
immunostimulatory effects of Beta-glucan in-vivo. However, future studies should 
not use commercially available orally administered compounds, but rather focus 
on formulas of which it is demonstrated that they are absorbed and/or penetrate 
target tissues, e.g. compounds approved for parental administration.
CONCLUSION
The past few years of research have dramatically changed our perspective 
of infection-related immune responses. The identification of sepsis-induced 
immunoparalysis, probably an important determinant of mortality, has resulted in 
a real paradigm shift in the general thinking and experimental immunomodulatory 
treatment of sepsis. Trained immunity challenged our perspective of the innate 
immune system lacking immunological memory, because it provides innate 
protection against re-infection by related as well as unrelated pathogens. 
The results of the studies described in this thesis endorse these theories. We 
demonstrated that immunoparalyis can be reversed by IFN-γ in a model for 
In addition, it has recently been demonstrated that autophagy plays a central role in 
BCG-induced trained immunity (43). However, signalling and molecular mechanisms 
responsible for the induction of trained immunity remain subject of future studies, and 
molecular mechanisms through which autophagy is related to epigenetic changes 
remain subject of future studies. Moreover, the extent to which trained immunity 
affects immune responses (e.g. the nature of effects of a given vaccine against 
specific pathogens) and the optimal timing for therapeutic use (the timeframe, but 
also the sequence of vaccine administration could be important in order to achieve 
the intended effect), are unknown. In addition, in addition to the age-specific aspects 
regarding the immunological response to vaccines discussed in chapter 7, there are 
studies indicating that non-specific effects of vaccines are also gender-specific (44, 
45). All these aspects have to be unravelled before we can fully understand to which 
extent trained immunity will affect daily clinical practice. The proof-of-principle data 
discussed in chapter 7 of this thesis suggest that (the cost-effictiveness of) vaccination 
strategies could be greatly improved, and that vaccination therapy could also be used 
for the prevention of non-related infectious diseases. 
As such, this concept could have a major impact on public health. For instance, the 
combination of BCG and influenza vaccination could reduce the dose influenza 
vaccine needed to mount adequate antibody responses, which could save many 
lives in case of a new influenza pandemic, as the amount of influenza vaccine 
available is limited. Larger randomized clinical trials are warranted to investigate 
these BCG-influenza specific effects in which the aforementioned age- and gender-
specific differences should also be taken into account. Thereto, (non-specific) 
trained immunity effects could also be employed for the adjunctive treatment of 
diseases associated with primary or secondary immunodeficiencies. However, in 
these patients only compounds that are not associated with risk of dissemination 
(as is the case for live attenuated BCG) can be used. The lack of effects of gamma 
irradiated (thus inactivated) BCG vaccination concerning the induction of trained 
immunity in vivo or ex vivo indicates that both live attenuated and inactivated BCG 
vaccination do not represent viable treatment options for the reversal of sepsis-
induced immunoparalysis. For this patient group, future studies should focus on 
other immunostimulatory compounds. 
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Het aspecifieke, aangeboren, “innate“ afweersysteem is verantwoordelijk voor 
de initiële herkenning van, en verdediging tegen, pathogene micro-organismen 
die door de fysieke barrières van de gastheer heen zijn gedrongen. De activatie 
van het aangeboren afweersysteem wordt gekarakteriseerd door secretie van 
onder andere pro-inflammatoire cytokines, chemokines, en vaso-actieve stoffen. 
Dit leidt ondermeer tot koorts, T-cel activatie (met als gevolg activatie van het 
specifieke immuunsysteem), activering van pijnreceptoren, en vasodilatatie (1, 2). 
In een vroeg stadium zijn deze pro-inflammatoire mediatoren verantwoordelijk 
voor de typische symptomen waarmee een patiënt met bloedvergiftiging (ook 
sepsis genoemd) zich zal presenteren (koorts, hemodynamische instabiliteit, 
stollingsstoornissen, eind-orgaan dysfunctie, etc.). Gelijktijdig met deze pro-
inflammatoire respons wordt er ook een anti-inflammatoire reactie opgestart, 
waarin anti-inflammatoire cytokines een belangrijke rol spelen die ervoor 
moet zorgen dat de pro-inflammatoire afweerrespons niet uit de hand loopt 
(3). Een adequate pro- en anti-inflammatoire afweerrespons zal pathogene 
micro-organsimen elimineren zonder dat het lichaam van de gastheer schade 
wordt berokkend. Levensbedreigende situaties kunnen ontstaan wanneer een 
inadequate afweerrespons ervoor zorgt dat organen van de gastheer worden 
aangetast (zoals het geval is bij een uit de hand gelopen pro-inflammatoire 
afweerrespons), maar ook dat de pathogeen niet uit het lichaam verwijderd wordt 
(zoals het geval is bij zeer pathogene microorganismen zoals het griepvirus, maar 
ook bij patiënten met een onderdrukte pro-inflammatoire afweerrespons of een 
te uitgesproken anti-inflammatoire afweerrespons). In de laatste jaren is duidelijk 
geworden dat onderdrukking van de afweerrespons bij septische patiënten in 
de dagen tot weken na de eerste sepsis symptomen zeer vaak voor problemen 
zorgt. Deze zogenaamde “immuunparalyse” zorgt er namelijk voor dat deze 
patiënten minder goed hun primaire infectie kunnen klaren en bovendien zijn ze 
veel vatbaarder voor secundaire infecties. 
Dit proefschrift bevat preklinische, translationele en klinische studies gericht op 
modulatie van de afweerrespons voor de aanvullende behandeling van ernstige 
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lag op onderdrukken van het immuunsysteem met bijvoorbeeld anti-cytokine 
therapieën of corticosteroïden, ligt de nadruk nu meer en meer op het stimuleren 
van het immuunsysteem. In dit hoofdstuk geven we dan ook een overzicht 
van de mechanismen die ten grondslag liggen aan immuunparalyse en van 
mogelijke markers die patiënten met immuunparalyse kunnen identificeren. 
Verder bespreken we het kleine aantal klinische studies die stimulatie van 
de afweerrespons hebben onderzocht bij septische patiënten, en bespreken 
we nieuwe immuunstimulerende middelen die veelbelovend lijken voor het 
behandelen van immuunparalyse.
In hoofdstuk 3 beschrijven we de effecten van IFN-γ en GM-CSF op 
immuunparalyse in vivo bij de mens. In deze studie werd gebruik gemaakt van 
het experimentele humane endotoxinemie-model, een humaan preklinische 
model dat gebruikt kan worden om de reactie van het immuunsysteem te 
onderzoeken. In dit model wordt endotoxine (een stukje van de celwand van 
een Gram-negatieve bacterie) toegediend aan gezonde vrijwilligers waardoor 
een systemische immuunreactie ontstaat die veel overeenkomsten vertoond 
met de immuunreactie tijdens sepsis. Wanneer endotoxine na een week 
voor een 2e keer wordt toegediend aan dezelfde proefpersoon, is de reactie 
van het aspecifieke immuunsysteem veel minder uitgesproken dan na de 
eerste endotoxine-toediening. Deze zogenaamde “endotoxine-tolerantie” 
vertoont veel overeenkomsten met sepsis-geïnduceerde immuunparalyse. 
Gebruikmakend van dit model werd aangetoond dat behandeling met IFN-γ 
niet alleen de cytokineproductie van witte bloedcellen in het laboratorium, maar 
ook de in vivo secretie van het pro-inflammatoire cytokine TNF-α stimuleerde, 
terwijl het de productie van het anti-inflammatoire cytokine IL-10 onderdrukte 
na herhaalde toediening van endotoxine. IFN-γ veroorzaakt dus een duidelijke 
verschuiving van de immuunrespons richting een meer uitgesproken pro-
inflammatoire reactie. Ook verhoogde IFN-γ de expressie van HLA-DR op 
monocyten (mHLA-DR; een belangrijke marker van immuunparalyse). In 
een derde groep proefpersonen die behandeld werd met GM-CSF werden 
vergelijkbare, maar minder uitgesproken effecten gevonden.
 
infecties. We hebben ons gefocust op de effecten van Interferon-gamma (IFN-γ) en 
Granulocyt Macrofaag-kolonie Stimulerende Factor (GM-CSF) (middelen bekend 
om hun stimulerende effect op de afweerrespons) als aanvullende behandeling van 
sepsis, en op de effecten van IFN-γ als aanvullende behandeling van infecties die 
alleen voorkomen in patiënten met een onderdrukt afweersysteem (de zogenaamde 
“opportunistische infecties”). Daarnaast hebben we nieuwe immuunmodulerende 
methoden onderzocht die gebaseerd zijn op de recente ontdekking dat het 
aangeboren immuunsysteem, net als het specifieke immuunsysteem, ook getraind 
kan worden.
Hoofdstuk 1 is een korte inleiding over het aangeboren immuunsysteem maar richt 
zich vooral op de afwijkingen in de afweerrespons die verantwoordelijk zijn voor 
een ernstiger beloop van bepaalde infecties. Als eerste worden opportunistische 
infecties besproken die alleen voorkomen bij patiënten met een onderdrukte 
afweerrespons, waarna een korte introductie volgt over infecties die voorkomen 
bij patiënten met sepsis-geïnduceerde immuunparalyse. Al laatste wordt uitgelegd 
waarom we voor de immuunstimulerende middelen hebben gekozen die we 
hebben gebruikt in de studies die in dit proefschrift beschreven zijn.
DEEL 1: MODULATIE VAN DE AFWEERRESPONS ALS AANVULLENDE 
BEHANDELING VOOR SEPSIS
Hoofdstuk 2 geeft een overzicht van de pathofysiologie van sepsis en focust met 
name op de recente ontdekking dat niet de pro-inflammatoire afweerrespons, 
maar juist de anti-inflammatoire afweerrespons belangrijk is voor het ziektebeloop 
van septische patiënten. Deze zogenaamde “immuunparalyse” zorgt er namelijk 
voor dat patiënten minder goed hun primaire infectie kunnen klaren en dat zij 
bovendien veel vatbaarder zijn voor secundaire infecties. Hoewel broncontrole 
en orgaan-ondersteunende behandelingen, zeker in de vroege fase van sepsis, de 
hoeksteen van de behandeling van septische patiënten zal blijven, is de ontdekking 
van deze immuunparalyse de reden dat er momenteel een verschuiving optreedt 
in onderzoek naar de adjuvante behandeling van sepsis. Waar de nadruk voorheen 
234 235
12
DEEL 3: NIEUWE IMMUUNMODULERENDE STRATEGIEËN
Bacille Calmette Guérin (BCG) is een vaccin tegen tuberculose dat gemaakt 
wordt van de bij runderen voorkomende tuberculosebacterie, Mycobacterium 
bovis. In grote epidemiologische studies werd jaren geleden al aangetoond dat 
BCG niet alleen beschermd tegen tuberculose, maar ook tegen andere niet 
verwante infecties. Lange tijd zijn deze aspecifieke effecten van BCG vaccinatie 
genegeerd, pas in de laatste 10 jaar is hier belangstelling voor gekomen. Recent 
werd in vitro en ex vivo aangetoond dat blootstelling aan BCG niet alleen 
bescherming biedt tegen tuberculose, maar ook tegen ander (niet-verwante) 
pathogenen. Bovendien werd aangetoond dat deze niet–tuberculose-
gerelateerde gunstige effecten onafhankelijk waren van B- en T-cellen, en 
daarom veroorzaakt lijken te worden door “training” van het aangeboren 
afweersysteem. Desalniettemin zijn tot op heden deze aspecifieke effecten van 
BCG bij de mens enkel ex vivo aangetoond. In hoofdstuk 7 beschrijven we dat bij 
gezonde vrijwilligers, vaccinatie met levend afgezwakte BCG leidt tot snellere 
en meer uitgesproken antistofvorming uitgelokt door een daaropvolgende 
toediening van trivalent griep vaccin. Verder werden de aspecifieke effecten 
van BCG op cytokine productie van ’witte bloedcellen die ex vivo gestimuleerd 
werden met niet verwante pathogenen bevestigd, en hebben we bovendien 
aangetoond dat het griepvaccin zelf ook niet-specifieke effecten heeft op 
cytokine productie uitgelokt door verschillende pathogenen. In het geheel 
ondersteunen deze resultaten de hypothese dat de afweerstatus op een klinisch 
relevante manier wordt beïnvloed door de vaccinatievoorgeschiedenis, en door 
de mogelijkheid de immuunrespons op vaccinaties te verbeteren kan deze 
kennis bijvoorbeeld gebruikt worden om vaccinatiestrategieën te verbeteren. 
In hoofdstuk 8 tonen we aan dat toediening van gamma-bestraald (en dus 
geïnactiveerd) BCG niet tot training van witte bloedcellen leidt. Bovendien 
stimuleert het ook niet de in vivo afweerrespons tijdens endotoxinemie. Dit is 
waarschijnlijk te wijten aan de inactivatie van het vaccin en daardoor is gamma-
bestraald BCG geen geschikte behandeloptie voor het behandelen van sepsis-
geïnduceerde immuunparalyse. 
DEEL 2: IMMUUNMODULATIE ALS AANVULLENDE BEHANDELING 
VOOR OPPORTUNISTISCHE INFECTIES
 
Alle patiënten met opportunistische infecties hebben in meer of mindere 
mate een onderdrukt afweersysteem. Vandaar dat aanvullende therapie 
om het afweersysteem van de gastheer te verbeteren een aantrekkelijke 
manier is om de prognose van deze patiënten te verbeteren. In  hoofdstuk 4 
beschrijven we een reeks patiënten met invasieve schimmelinfecties, bij wie 
we laten zien dat aanvullende behandeling met IFN-γ leidt tot verbeterde 
immunologische functie van witte bloedcellen. Dit is gebaseerd op zowel de 
verhoogde ex vivo pro-inflammatoire cytokine productie door cellen van het 
aangeboren afweersysteem (zoals IL-1β of TNF-α), als de verhoogde productie 
van typische T-cel cytokines die erom bekend staan een belangrijke rol te spelen 
bij de afweer tegen schimmels (IL-17 en IL-22). Bovendien vonden we een 
door IFN-γ veroorzaakte verhoging expressie van mHLA-DR in die patiënten 
die vanaf het begin een lage mHLA-DR waarde hadden (als maat voor het 
minder goed functioneren van hun afweersysteem). Deze resultaten wijzen 
erop dat aanvullende behandeling met IFN-γ het aangeboren afweersysteem 
van patiënten met invasieve schimmelinfecties (gedeeltelijk) verbetert, wat 
suggereert dat aanvullende behandeling met IFN-γ ook de afweer tegen 
schimmels zou kunnen verbeteren. 
In hoofdstuk 5 en 6 beschrijven we dat aanvullende behandeling met IFN-γ, 
ingezet als laatste redmiddel bij een patiëntje met progressieve invasieve 
Candida infectie na remissie-inductie chemotherapie voor acute lymfoblastische 
leukemie, en bij een patiënt met progressieve cerebrale Nocardiosis, leidde 
tot verhoging van hun aangeboren afweerrespons, en zeer waarschijnlijk 
ook bijdroeg aan radiografische en klinische verbetering. Dit wijst erop dat 
aanvullende behandeling van het afweersysteem met IFN-γ gebruikt kan worden 
als laatste redmiddel bij patiënten met opportunistische infecties die achteruit 
gaan ondanks optimale antimicrobiële therapie.
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veroorzakende pathogenen, plaats van infectie of ernst van de ziekte (4). Deze 
heterogeniteit maakt het dan ook waarschijnlijk dat per patiënt verschillende 
afweermechanismen betrokken kunnen zijn, waardoor evaluatie van een enkel 
mechanisme ernstig bemoeilijkt wordt. Zoals beschreven in hoofdstuk 2 van 
dit proefschrift vinden inderdaad zowel pro- als anti-inflammatoire processen 
tegelijkertijd plaats, en afhankelijk van verschillende individuele factoren zal een pro- 
of anti-inflammatoir overwicht de overleving van de individuele patiënt in gevaar 
brengen. Door de vooruitgang in orgaanondersteunende therapieën en doordat 
patiënten steeds ouder worden zal immuunparalyse waarschijnlijk in het merendeel 
van de patiënten de overleving bedreigen, en niet de primaire pro-inflammatie. 
Dit laatste is dan ook zeer waarschijnlijk een van de belangrijkste redenen van het 
mislukken van alle voorgaande studies die geprobeerd hebben om de overleving van 
septische patiënten te verbeteren door het onderdrukken van de afweerrespons. 
Tabel 1. Definities voor SIRS, sepsis, ernstige sepsis en septische shock
Temperatuur <36˚C of >38.3˚C
Hartfrequentie > 90 min-1
Ademhalingsfrequentie >20 min-1 of een PaCO2 <32 mmHg (4.3 kPa)
WBC < 4000 μL-1 of >12000 μL-1 of normaal WBC met > 10%
immature vormen
SIRS +  bewezen of waarschijnlijke infectie
Sepsis + orgaandysfunctie
Sepsis + hypotensie of verminderde weefselperfusie, ondanks 
adequate volume resuscitatie
SIRS
Sepsis
Severe sepsis
Septic shock
SIRS, systemisch inflammatie-respons syndroom; WBC, witte bloed cel; adequate volume resuscitatie: 
≥20 ml/kg per ideaal lichaamsgewicht isotoon crystalloid vocht, of een centraal veneuze druk ≥8 
mmHg of een pulmonale capillaire wiggedruk van ≥12 mmHg.
Tabel 1. Definities voor SIRS, sepsis, ernstige sepsis en septische shock
Hoewel het in verschillende observationele studies al werd aangetoond dat 
immuunparalyse klinische relevant is, zeggen veel clinici dat zij immmuunparalyse 
niet herkennen als een relevant probleem bij hun septische patiënten. Deze 
twijfels worden verder ondersteund door het feit dat er nog geen directe relatie 
tussen immuunparalyse en orgaanfalen/mortaliteit is aangetoond. Recente 
studies hebben hier echter verandering in gebracht: inzichten in de verminderde 
bio-energetica en mitochondriële dysfunctie die leiden tot ATP-depletie zorgt 
BCG is niet de enige stimulus waarvan werd aangetoond dat het aangeboren 
afweersysteem hierdoor getraind kan worden, ook van Beta-glucan werd dit in vitro 
en in vivo bij dieren aangetoond. Beta-glucanen zijn natuurlijke koolhydraten die wijd 
verspreid voorkomen, waarvan geclaimd wordt dat ze een versterkende werking op 
het afweersysteem hebben, en die daarom wereldwijd op het internet aangeboden 
worden als voedingsupplement. Omdat oraal Beta-glucan bovendien goedkoop is en 
zeer goed verdragen wordt, is het een veelbelovende kandidaat om het afweersysteem 
te versterken, alhoewel dit nog niet bij mensen werd onderzocht. In hoofdstuk 9 
beschrijven we dat dagelijkse inname van 1000mg commercieel verkrijgbaar oraal 
Beta-glucan gedurende 7 dagen bij gezonde vrijwilligers niet leidt tot aantoonbare 
serum spiegels van Beta-glucan, en dat het aangeboren afweersysteem er ook niet 
door beïnvloed wordt; we vonden namelijk onveranderde microbicide activiteit en 
ook de cytokineproductie van witte bloedcellen die ex vivo gestimuleerd werden 
met verschillende pathogenen was niet anders na behandeling met Beta_glucan. De 
geclaimde afweersysteem-stimulerende effecten van commercieel verkrijgbare en 
oraal toegediende Beta-glucan kunnen wij dan ook niet bevestigen.
ALGEHELE CONCLUSIE EN TOEKOMSTPERSPECTIEVEN
In het eerste deel van dit proefschrift hebben we een overzicht gegeven van recente 
inzichten in de pathofysiologie van sepsis. Hierbij hebben we de nadruk gelegd op 
sepsis-geïnduceerde immuunparalyse omdat dit een belangrijke rol speelt in de 
prognose van septische patiënten. Verder hebben we aangetoond dat IFN-γ in 
staat is om immuunparalyse gedeeltelijk op te heffen in een onderzoeksmodel voor 
sepsis-geïnduceerde immuunparalyse bij de mens.
Een groot probleem binnen het sepsisonderzoek is het feit dat sepsispatiënten een 
zeer heterogene groep vormen. Dit wordt op de eerste plaats verklaard door de 
definitie van sepsis (Tabel 1), die zeer ruime klinische en laboratorium parameters 
(zoals verandering in hartslag, temperatuur, ademhaling, of aantal witte bloedcellen 
in aanwezigheid van een infectie) gebruikt, waardoor vrijwel alle patiënten met 
een ontstekingsreactie hieraan voldoen, zonder onderscheid te maken tussen 
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voor de eerste link tussen immuunparalyse en cel dysfunctie die resulteert in multi-
orgaanfalen (5-9). Een afname in metabole activiteit zal ervoor zorgen dat een cel 
minder energie nodig heeft. Hierdoor zal de cel minder goed functioneren, maar zal 
de cel ook kunnen overleven door een kritische daling in ATP. Elk van de kenmerken 
van deze maladaptieve cellulaire homeostase zorgt voor een kenmerkende 
eigenschap van sepsis (bijvoorbeeld het niet goed contraheren van myocardcellen 
zorgt voor myocarddepressie, het niet goed contraheren van spiercellen in de 
vaatwand leidt tot hypotensie, enz.) (10). Dit is bovendien volledig in lijn met autopsie 
studies waarbij gevonden werd dat bij overleden septische patiënten nagenoeg 
geen apoptose (geprogrammeerde celdood) gevonden kan worden, behalve in de 
lymfocyten compartimenten (11, 12). Hiermee wordt dan ook meteen de link met 
immuunparalyse verklaard: cellen in de lymfocyten compartimenten die in apoptose 
zijn gegaan zullen leiden tot immuunparalyse. Dit zal tot gevolg hebben dat septische 
patiënten hun initiële infectie minder makkelijk kunnen klaren, en dat zij vatbaarder 
zijn voor secundaire infecties wat dan weer gepaard kan gaan met voortgaande 
inflammatie die leidt tot mitochondriële dysfunctie en een vicieuze cirkel zal ervoor 
zorgen dat cellen niet in staat zijn om te herstellen (Figuur 1).
Figuur 1. Vereenvoudigde weergave van de de verminderde bio-energetica hypothese. 
Onafhankelijk van deze bio-energetische hypothese zal de buitensporige pro-
inflammatoire reactie op een binnendringende pathogeen de uitlokkende factor 
zijn van een cascade van gebeurtenissen. De overmatige pro-inflammatie kan 
in bepaalde gevallen zelf ook voor veel bijkomende schade en zelfs overlijden 
zorgen (zoals het geval is bij bijvoorbeeld meningokokkensepsis of infecties 
die voor een macrofaag activatie syndroom zorgen (bijvoorbeeld ernstige 
influenza infecties, dengue of malaria)). Daarnaast zijn de in hoofdstuk 2 van dit 
proefschrift beschreven onderdrukte afweerfuncties ook duidelijk aangetoond bij 
septische patiënten in het algemeen. Vandaar dat het van grote therapeutische 
waarde zal zijn als we manieren vinden om de afweerrespons “op maat” aan te 
pakken: de afweerrespons verhogen als deze niet in staat is om binnendringende 
micro-organismen te elimineren en deze onderdrukken als deze zo overmatig 
is dat het voor veel bijkomende schade zal zorgen. Accurate biomarkers die 
de afweerstatus van een patiënt kunnen identificeren zijn daarom bijzonder 
belangrijk voor de toekomst van immuuntherapie bij sepsis. Biomarkers kunnen 
zowel patiënten identificeren die baat zouden kunnen hebben van stimulatie van 
het afweersysteem, maar ze zouden ook gebruikt kunnen worden om de respons 
op therapie te monitoren. Op dit moment worden mHLA-DR en de respons van 
witte bloedcellen op ex vivo stimulatie met lipopolysaccharide (LPS), hiervoor 
het meest gebruikt. Zij geven echter alleen de immuun status van het bloed, en 
niet van de weefsels, weer en bovendien zorgen pre-analytische en analytische 
kwesties die inherent zijn aan hun analyse ervoor dat zij slechts beperkt bruikbaar 
zijn in grote internationale studies of routinematig in de kliniek zoals besproken in 
hoofdstuk 2 van dit proefschrift. Er is hoop dat verbeterde moleculaire methodes 
gebaseerd op een “systeembiologie” aanpak (een combinatie van genomische, 
transcriptomische, metabolomische, proteomische en/of epigenetische 
gegevens) uiteindelijk zal leiden tot nieuwe diagnostische instrumenten, hoewel 
dit wat betreft sepsis nog in de kinderschoenen staat (13-16). Omdat de huidig 
beschikbare biomarkers suboptimaal zijn, moeten toekomstige klinische studies 
een panel van markers gebruiken om hun patiënten te stratificeren waarbij gebruik 
gemaakt kan worden van mHLA-DR en witte bloedcel responsen in combinatie 
met klinische data (zoals een duidelijke afname van vasopressiebehoefte als 
surrogaat marker van pro-inflammatie). Hopelijk voorkomt deze biomarker-
240 241
12
gestuurde stratificatie nog meer mislukte klinische studies bij septische patiënten, 
en zal hierdoor het uitvoeren van grote klinische studies vergemakkelijkt worden.
 
IFN-γ en GM-CSF zijn, zoals beschreven in hoofdstuk 2 en 3 van dit proefschrift, 
de best onderzochte immuunstimulerende middelen bij septische patiënten. Op 
basis van de in hoofdstuk 3 beschreven resultaten, wordt er momenteel een fase 
3 klinische studie uitgevoerd bij septische patiënten met immuunparalyse die we 
IFN-γ toedienen op een dubbel-blinde gerandomiseerde wijze. Helaas verloopt 
de inclusie trager dan verwacht, mogelijk doordat we zeer strenge in- en exclusie 
criteria hanteren bij deze ernstig zieke patiënten. Buiten IFN-γ en GM-CSF zouden 
ook andere afweersysteem-stimulerende middelen effectief kunnen zijn in het 
herstellen van de afweer. Parallellen tussen sepsis-geïnduceerde immuundysfunctie 
en veranderingen in het immuunsysteem bij patiënten met kanker of chronische 
virale infecties hebben onderzoek naar immuunstimulerende middelen bij septische 
patiënten in de richting van lymfocyt-herstellende therapieën geleid, zoals anti-
PD(L)1 en IL-7 therapie . Beide middelen zijn direct beschikbaar voor patiënten 
omdat zij al onderzocht zijn in preklinische en klinische studies bij patiënten met 
kanker (17-19) of HIV (20). In pre-klinische studies werd al gevonden dat beide 
middelen in staat zijn om sepsis-geinduceerde immuunparalyse om te keren (21), 
hoewel dit wel nog bevestigd moet worden in klinische studies . 
In het tweede deel van dit proefschrift hebben we aangetoond dat immuunstimulatie 
met IFN-γ bij een reeks patiënten met invasieve schimmelinfecties leidde tot 
verhoogde productie van cytokines door witte bloedcellen die ex vivo gestimuleerd 
werden met verwante stimuli, en dat het mHLA-DR expressie duidelijk verhoogde 
bij patiënten met lage baseline mHLA-DR waarden. Daarnaast beschreven we 
dat aanvullende behandeling met IFN-γ bij een patiëntje met refractaire invasieve 
Candida infectie en een patiënt met refractaire cerebrale Nocardiose leidde tot 
verbetering van de aangeboren immuun respons en zeer waarschijnlijk heeft 
bijgedragen aan radiografische en klinische verbetering.
Ook bij patiënten met opportunistische infecties ontbreekt een adequate 
biomarker die patiënten kan identificeren die baat zouden kunnen hebben 
bij immuunstimulerende therapie of die de respons op behandeling kan 
monitoren. In hoofdstuk 4 en 5 van dit proefschrift hebben we voor de eerste 
keer beschreven dat naast ex vivo cytokineresponsen ook mHLA-DR bij deze 
patiënten als marker voor hun immuunstatus zou kunnen dienen: mHLA-DR 
expressie was omgekeerd gecorreleerd met ziekte ernst en bij patiënten met 
lage baseline waarden kon de mHLA-DRexpressie duidelijk verhoogd worden 
door toediening van IFN-γ. Ondanks dat deze resultaten veelbelovend zijn zullen 
zij eerst bevestigd moeten worden in grote klinische studies waarbij bovendien 
rekening gehouden moet worden met de beperkingen van mHLA-DRmetingen 
die al beschreven werden bij septische patiënten. Desalniettemin was monitoring 
van de immuunrespons met ex vivo cytokine responses en/of mHLA-DR expressie 
bij de in hoofdstuk 5 en 6 beschreven patiënten van grote meerwaarde in het 
sturen van de immuunmodulerende behandeling. Deze biomarker-gestuurde 
benadering zal ook toegepast moeten worden bij toekomstige grotere (multi-
center) klinische studies bij patiënten met invasieve opportunistische infecties 
om immunotherapie bij deze patiënten te onderbouwen door het bevestigen 
van gunstige immunologische maar ook klinische effecten. Dit zal nationale 
en internationale samenwerking vereisen tussen infectiologien, intensivisten, 
oncologen en immunologen, aangezien onderzoek bij deze patiënten zeer 
uitdagend is vanwege de lage incidentie. 
In het laatste deel van dit proefschrift hebben we onderzocht of het aangeboren 
immuunsysteem ook in vivo bij mensen getraind kan worden en of deze nieuwe 
benadering kan leiden tot nieuwe immuunmodulerende strategieën. In hoofdstuk 
7 van dit proefschrift tonen we aan dat vaccinatie met levend afgezwakte BCG leidt 
tot snellere en meer uitgesproken antistofvorming uitgelokt door daaropvolgende 
toediening van een trivalent griep vaccin aan gezonde vrijwilligers, en dat niet 
alleen BCG maar ook het griepvaccin zelf niet-specifieke effecten heeft op 
cytokineresponsen van witte bloedcellen die ex vivo gestimuleerd werden met 
niet verwante stimuli. Dit is niet alleen logisch vanuit een evolutionair perspectief, 
maar het onderstreept ook hoe totaal het dogma van het niet-specifiek zijn van het 
aangeboren immuunsysteem verandert door de ontdekking dat het dit systeem 
toch getraind kan worden: alle vaccinaties (en waarschijnlijk ook alle doorgemaakte 
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infecties) zullen het immuunsysteem beïnvloeden op een niet-specifieke en klinisch 
relevante wijze. Nochtans staat dit onderzoek nog in de kinderschoenen en het 
ontrafelen van de onderliggende mechanismen is pas net begonnen. Onlangs 
werd aangetoond dat epigenetische veranderingen niet alleen ten grondslag 
liggen aan de training van het aangeboren immuunsysteem, maar ook aan de 
tolerantie die ontstaat na blootstelling aan LPS (15). Zoals beschreven in hoofdstuk 
2 van dit proefschrift, is epigenetische regulatie van gentranscriptie door talrijke 
mechanismen gemedieerd, maar in het algemeen kan het beschouwd worden 
als de gereguleerde organisatie van genloci in transcriptioneel actief of inactieve 
toestand waarin H3K4 methylering en H3K27 acetylering een rol spelen (Figuur 2). 
Daarenboven werd recent aangetoond dat autofagie ook een belangrijke rol speelt 
bij het trainen van het aangeboren immuunsysteem door BCG (22). Desalniettemin 
zijn de moleculaire mechanismen die ten grondslag liggen aan het trainen van 
het aangeboren immuunsysteem nog verre van ontrafeld. Ook de mechanismen 
waardoor autofagie epigenetische veranderingen zou kunnen medieren is nog 
niet bekend. De mate waarin het trainen van het aangeboren immuunsysteem 
het immuunsysteem beïnvloed (bijvoorbeeld welk effect welk vaccin heeft tegen 
welke pathogenen), en wat de optimale timing is voor behandeling (niet alleen het 
Figuur 2. Schematisch overzicht van epigenetische reprogrammering die ten grondslag ligt aan het 
geheugen van het aangeboren immuunsysteem. BCG, Bacille Calmette-Guérin; H3-K4me3, .H3K4 
trimethylatie. Copyright bij Siroon Bekkering.
tijdsbestek maar ook de volgorde van toediening kan van belang zijn) is bovendien 
ook nog steeds niet bekend. Al deze aspecten moeten eerst ontrafeld worden 
voordat we volledig kunnen begrijpen in welke mate de klinische praktijk beïnvloed 
zal worden door de ontdekking dat het aangeboren immuunsysteem getraind 
kan worden. De data die in hoofdstuk 7 van dit proefschrift beschreven worden 
geven een eerste hint dat vaccinatie strategieën veel efficiënter gemaakt zouden 
kunnen worden en dat vaccinaties ook gebruikt zouden kunnen worden in het 
voorkomen van niet-gerelateerde infecties. Zo zou BCG vaccinatie er bijvoorbeeld 
voor kunnen zorgen dat maar de helft van de dosis van het griepvaccin nodig zou 
zijn om mensen tegen de griep te beschermen.
In het geval van een grieppandemie zou dit veel levens kunnen redden 
aangezien de beschikbare hoeveelheid griepvaccin beperkt is. Voor het zover is 
zullen er echter veel grotere studies uitgevoerd moeten worden om deze BCG-
griep effecten te bevestigen.
 Training van het aangeboren afweersysteem zou bovendien niet alleen 
gebruikt kunnen worden in het voorkomen van infecties maar ook voor de 
behandeling van infecties bij mensen met een onderdrukt afweersysteem. Bij 
deze patiënten zullen echter alleen middelen gebruikt kunnen worden die niet het 
risico hebben om zelf ernstige en verspreide infecties te veroorzaken (zoals wel het 
geval is bij levend afgezwakt BCG). In hoofdstuk 8 van dit proefschrift beschrijven 
we echter dat gamma-bestraald (en dus geïnactiveerd) BCG niet in staat is om 
in of ex vivo training van het aangeboren afweersysteem te veroorzaken bij het 
eerder beschreven humaan endotoxinemie model. Daarom zijn zowel levend 
afgezwakt als gamma-bestraald BCG geen goede opties om sepsis-geinduceerde 
immuunparalyse te behandelen. Onderzoek bij deze patiënten zal zich moeten 
focussen op andere immuunstimulerende middelen. 
 Tenslotte hebben we in hoofdstuk 8 van dit proefschrift aangetoond dat 
oraal toegediend commercieel verkrijgbaar Beta-glucan geen effect heeft 
op de functie van witte bloedcellen bij mensen. Deze gegevens benadrukken 
de behoefte aan gedegen klinisch onderzoek en bevestigen dat de 
gezondheidsclaims die bij dit soort middelen vaak gedaan worden niet altijd 
voor waarheid moeten worden aangenomen.
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dat het congres in Rhodos zeker op de jaarlijkse agenda wordt gezet. Met trots kan 
ik zeggen dat ik één van jouw eerste promovendi was en dat ik hoop dat ik mijn 
toekomstige PhD-student(en) net zo kan begeleiden als jij mij begeleid hebt. 
Dan mijn paranimfen, Rebecca en Lieve, fijn dat jullie vandaag aan mijn zijde 
staan! Rebecca, lieve Becs, ik kon me geen betere “roomie” wensen. Dank voor 
je student-zijn bij mijn eerste studie, je gezelligheid, je hilarische opmerkingen/
uitspraken, de klassieke muziek momentjes, het vele thee drinken, je attentheid, 
de gedachtewisselingen over werk-gerelateerde zaken, maar zeker ook niet-werk-
gerelateerde zaken, en ook voor alle regeldingetjes rondom de promotie. Binnen 
niet al te lange tijd hoop ik op jouw promotie aanwezig te mogen zijn en daarnaast 
hoop ik dat we nog vaak gaan borrelen.
 Lieve Lieve, dank je wel voor alle (vaak telefonische) gesprekken over het 
werk maar vaak ook over “ons leven in het algemeen”. Ik hoop dat er voor jou 
snel duidelijkheid komt over hoe je jouw wetenschappelijke carrière verder vorm 
gaat geven, ik heb er alle vertrouwen in dat het goed komt want je bent een van 
de slimste personen die ik ken! Hierbij ook een dikke dank-je-wel voor mijn andere 
vriendinnen uit Leuven (Eveline, Margot, Anne-Sophie, Sophie en Karen). Jullie 
vriendschap is mij heel dierbaar en ondanks de drukte van werk en gezin van ons 
allemaal hoop ik dat wij onze vriendinnenavondjes/weekendjes nog lang zullen 
kunnen voortzetten.
Jelle Gerretsen, “monster Jelle”, PBMC-isolatie-god, dank voor al je hulp! Zonder 
jou waren de Beta-glucan en de BCG-influenza studie nooit gelukt en ik amuseerde 
me kostelijk tijdens de lange dagen in het lab door alle verhalen over van-alles-en-
nog-wat. Je verloving met Ka Man zat er al lang aan te komen, veel geluk samen! 
Collega’s van de IC-research, beste Esther, Kim, Lucas, Mark, Bart, Mirrin, 
Benno, Paul, Lex, Annelies, Lisanne, Eline, Roger, Dorien, Jelle, Jonne en 
Linda, dank voor alle gezelligheid, kletspraatjes, ondersteuning, goede raad en 
collegialiteit. Dank ook voor de erg leuke congressen die ik met een aantal van jullie 
heb meegemaakt en hoewel ik niet altijd van de partij kon zijn hoop ik toch dat ik 
de stapavondjes tijdens bijvoorbeeld de vierdaagse feesten nog regelmatig mag 
DANKWOORD
Dit laatste (én meest gelezen) stuk van mijn proefschrift vormt de afsluiting van 3 
jaar promotieonderzoek. Gelukkig vielen de voorspelde dalen erg mee en kan ik 
terugkijken op een zeer leuke, leerzame en inspirerende tijd. Ondanks het risico 
dat ik iemand vergeet wil ik een aantal mensen hiervoor in het bijzonder bedanken.
Professor Pickkers, beste Peter, heel graag wil ik je bedanken voor je 
vertrouwen in mij en voor de vrijheid en mogelijkheden die ik gaandeweg 
mijn promotietraject heb gekregen. Dit, in combinatie met je humor en je 
onovertroffen enthousiasme zorgden niet alleen voor veel plezier in mijn werk 
maar ook voor een werkomgeving waarin ik heb kunnen floreren. Je manier van 
to-the-point analyseren en jouw commerciële instelling maken je bovendien 
tot een uniek onderzoeker waar ik veel van heb kunnen leren. Hoewel ik geen 
intensivist word hoop ik toch dat ik ook bij de vasculaire geneeskunde nog af en 
toe met je kan blijven samenwerken. 
Professor Netea, beste Mihai, ook jou wil ik bedanken voor je vertrouwen in mij 
en voor de vrijheid en mogelijkheden die ik van jou en Peter heb gekregen. Je bent 
een zeer inspirerende wetenschapper en ondanks je drukke agenda was er altijd 
tijd voor laagdrempelig overleg waarbij ik het beste uit mezelf heb kunnen halen. 
Daarnaast heb je samen met Leo de basis gelegd die er mede voor gezorgd heeft 
dat ik internist-vasculair geneeskundige zal worden in plaats van nefroloog. Het is 
een eer dat ik deel mag blijven uitmaken van het grote team dat je om je heen 
verzameld hebt! 
Dr. Kox, beste Matthijs, dank! Dank voor alle constructieve (en soms minder 
constructieve:-) commentaren. Jij leerde mij de praktijk, niet alleen de basis 
labvaardigheden, maar bijvoorbeeld ook wat er allemaal bij een CMO-aanvraag 
komt kijken en hoe je een goed artikel moet schrijven. Ik heb mogen profiteren van 
je nog niet zo overvolle agenda en ik hoop voor alle volgende promovendi dat je 
ook voor hen laagdrempelig beschikbaar kunt blijven voor overleg. Daarnaast hoop 
ik ook voor hen dat je ze meeneemt naar alle congressen waar wij zijn geweest en 
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Dr. Netten, beste Paetrick, jij zag als eerste een onderzoeker in me en initieerde 
de gesprekken die ervoor gezorgd hebben dat ik nu hier sta. Daarnaast ben je ook 
een fantastische opleider en een inspirerend mens, ik ben heel blij dat ik de eerste 
jaren van mijn opleiding tot internist onder jouw hoede heb mogen doorbrengen. 
Lieve Kees en Jose, dank voor jullie gastvrijheid, het altijd voor ons klaarstaan en 
het zo fijn opa-en-oma zijn voor de kinderen. Dank ook dat jullie altijd oprecht 
geïnteresseerd zijn in alles waar ik mee bezig ben ondanks dat jullie enigszins 
sceptisch tegen de medische wetenschap en zeker ook tegen medicijnen/vaccins 
aankijken. Lieve Paul en Suzanne, dank voor de gezellige familie bijeenkomsten 
en wat fijn dat onze kinderen het zo goed met elkaar kunnen vinden.
Lieve mam, dank voor alle liefde en onvoorwaardelijke steun. Ik heb ongelofelijk 
veel bewondering voor jou, voor het feit dat je ons na het overlijden van pap alleen 
hebt moeten opvoeden en dat je zo volop in het leven staat ook nu we allemaal 
het huis uit zijn. Pap en jij hebben ervoor gezorgd dat ik terug kan kijken op een 
hele fijne jeugd, jij zorgt nog steeds voor een heel warm thuis. Lieve pap, er zijn 
een aantal momenten waarop ik je nog steeds verschrikkelijk mis, dit is er een van. 
Dank dat je altijd trots op me bent geweest. 
Lieve broers en zus, Tim, Bas(je) en Elke, dank voor alle gezelligheid en zeer hechte 
band die we als broers en zussen hebben. Jullie hebben inderdaad mijn karakter 
gevormd en daar heb ik nog altijd profijt van:-). Lieve Emmy, een betere schoonzus 
kan ik niet wensen, je past echt in onze familie en dat op zich is al een hele prestatie.
Lieve Finne en Nout, jullie zijn mijn allergrootste schatten! Jullie aanwezigheid 
maakt mijn leven veel meer waard en ik ben heel erg trots op jullie! Mochten jullie 
geïnteresseerd zijn dan leg ik het later allemaal graag uit. 
Lieve Bas, je weet niet hoe belangrijk jij bent geweest voor mijn promoveren. Waar alles 
als vanzelf lijkt te gaan zorg jij voor mijn rust, relativeringsvermogen en vertrouwen in 
mezelf. Jij zorgt ervoor dat ik meer-dan-het-beste uit mezelf kan halen. Ik hou van jou!
meemaken! Esther en Lucas, speciale dank ook voor alle oefenpartijtjes om mijn 
tafeltennis skills te verbeteren: ideale momenten om de boog te ontspannen (“want 
die kan niet altijd gespannen staan”:-).
Veel dank ook voor de research verpleegkundigen van de IC, beste Marieke, 
Chantal en Hellen, dank voor al jullie ondersteuning, voor het randomiseren en 
klaarmaken van de studiemedicatie, de inclusie van de septische patiënten en 
nog veel meer; jullie tillen de kwaliteit van het IC-onderzoek naar een nog hoger 
niveau. Yvonne, steun en toeverlaat van ons allen, dank voor je attentheid, 
zorgzaamheid en secretariële ondersteuning. Tijn, dank voor alle ondersteuning 
de eerste jaren en vooral ook voor alle praktische hulp bij het werken volgens de 
GCP-richtlijnen.
Alle medewerkers van het laboratorium experimentele interne geneeskunde, 
bedankt voor jullie gastvrijheid, hulp en gezelligheid. Een aantal mensen wil ik in 
het bijzonder bedanken. Professor Joosten, beste Leo, bedankt dat ik al mijn ex 
vivo experimenten mocht doen op “jouw” lab. Dr. Gresnigt, beste Mark, dank voor 
alle PBMC stimulaties die je (vaak ook buiten normale werktijden) voor de klinische 
studies hebt gedaan. Beste Trees en Liesbeth, dank jullie wel voor de cytokine 
analyses die jullie voor de Beta-glucan en BCG-influenza studie hebben gedaan. 
Beste Cor, dank je wel voor het wegwijs maken op het lab en het telkens toch weer 
kunnen regelen van vriezerruimte. Bas en Rob, dank jullie wel voor al het werk dat 
jullie gedaan hebben voor de BCG-LPS studie.
Dr. Diavotopoulos, beste Dimitri, dank voor alle uitleg en adviezen over influenza 
virus infecties/vaccinaties en dank dat wij de stimulaties met levend influenza virus 
op jullie ML-II lab mochten doen.
Stafleden Interne Geneeskunde en collega’s internisten in opleiding, hartelijk 
dank voor de samenwerking en steun bij het afronden van mijn boekje. Dankzij jullie 
ga ik dagelijks met veel plezier naar mijn werk. Anne en Anne-Els, al sinds de JBZ-
tijd dank voor de gezellige lunches en de interesse in mijn onderzoek. 
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